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Abstract 
Purpose/Objectives: A drawback of tandem and ovoid (T&O) ICBT is exposure of the posterior bladder 
and anterior rectal walls to relatively high isodoses. To mitigate this effect, intra-ovoid shielding may be 
used to reduce dose to these OARs.  However, metal artifacts present in images acquired via kVCT make 
anatomy segmentation and catheter localization difficult for the purpose of 3D treatment planning.  We 
present a method that combines MVCT-based imaging and applicator modeling to increase the quality 
of 3D treatment plans for shielded T&O ICBT. 
Materials/Methods:  Using Oncentra’s TPS, 9 participants from multiple institutions performed organ 
segmentation and catheter reconstruction for KVCT and MVCT data sets acquired of a water phantom 
containing bladder and rectum surrogates and various HDR T&O applicators: Nucletron’s CT/MR 
compatible (CTMR), Nucletron’s shielded Fletcher Williamson (FW) and (3) Varian’s shielded Fletcher-
Suit-Delclos style (FSD). The dimensions of OAR structures were determined using in-air kVCT and 
physical measurements.  By comparing the 3D volumes and centroid-to-perimeter (C2P) measurements 
of individual OAR contours, segmentation accuracy was assessed in regions exhibiting artifact under 
kVCT (1cm superior and inferior to shielding). Comparing the TPS-defined coordinate of the most distal 
dwell position to that of the true position (determined using radiographs of a fiducial affixed to the 
applicators), assessed catheter reconstruction accuracy. For Nucletron devices, this metric was also 
quantified using an applicator-model for localization. 
Results:   The percentage of points for C2P measurements that differ (greater than 2mm) from the true 
contour extents decreased under MVCT for the shielded T&Os (78.4 vs. 71.3%), while the converse is 
observed for the CTMR. Similarly, the volume of the OAR surrogates follows the same trend. This is 
attributed to the lack of metal artifacts as well as the decrease in the contrast of low Z materials 
observed when utilizing MVCT.  Catheter reconstruction accuracy improved by 26% under MVCT for 
xvi 
 
shielded T&Os, was invariant for the CTMR and within 2.29mm of the true position using applicator 
modeling.  
Conclusions:  The quality of MVCT 3D ICBT treatment plans of shielded T&O is comparable to MVCT 
CTMR treatment plans.  Further improvements were observed when using an applicator model for 
catheter reconstruction.  
 1 
 
Chapter 1  Introduction 
1.1 Brachytherapy for the Treatment of Cervical Cancer 
It is estimated that in 2012 in the United States 12,200 women will be diagnosed with cervical 
cancer of which 4,210 will result in death (National Cancer Institute, 2011). For early or non-bulky 
disease (typically FIGO stages IB-IVA), the current standard of care is a combination of external beam 
radiotherapy (EBRT) and intracavitary brachytherapy (ICBT). EBRT is administered first to sterilize 
regional and local pelvic disease as well as decrease the volume of the primary tumor. ICBT is then used 
to boost dose delivered to the diseased area with minimal dose to surrounding normal tissue 
(Viswanathan, et al., 2007). High-dose rate (HDR) brachytherapy (i.e. >12 Gy/hr) is a common form of 
ICBT for the treatment of cervical cancer and has a typical fractionation scheme of 5.5-7 Gy per fraction 
for 4-5 fractions (Viswanathan, et al., 2011). Through the combination of these two radiotherapy 
delivery methods, local control of cervical cancer for a large patient population has been achieved 
(Saibishkumar, et al., 2005). 
Brachytherapy is ideally suited for the treatment of cervical cancer for several reasons. 
Radiation is emitted from brachytherapy sources isotropically, falling off inversely with the square of the 
distance. This makes it possible to deliver therapeutic doses to diseased tissue while minimizing dose to 
surrounding normal tissues. Additionally, while localization of the vagina and uterus is of concern when 
utilizing EBRT, placing the source in vivo aids in accurate dose delivery to the desired tissues 
(Viswanathan, et al., 2007). A distinct disadvantage of ICBT is the inevitable dose delivered to the 
bladder and rectum. As such, the delivery of therapeutic levels of radiation via ICBT is often limited by 
these two organs. Common complications due to overdosing of the bladder and rectum include 
proctitis, fistulas, cystitis and bladder and rectal ulceration (Kapp, et al., 1997). 
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1.2 Administration of Intracavitary Brachytherapy via Tandem and Ovoid Applicators 
A variety of applicators have been developed to administer ICBT. One of the most common 
applicators utilized in the administration of ICBT is the tandem and ovoid (T&O) applicator (see Figure 
1-1). 
 
Figure 1-1: Nucletron’s CT/MR compatible applicator. This is the current, clinical tandem and ovoid 
applicator used at Mary Bird Perkins Cancer Center in Baton Rouge, LA where this study was performed. 
The tandem is a hollow stainless steel or plastic rod that extends through the cervix into the 
uterus. To accommodate variations in patient anatomy, tandems are available in multiple angles of 
anteversion. In addition, the applicator has two catheter tubes that are positioned laterally to the 
tandem. These channels are capped with ovoids, plastic oval ellipsoids that are seated in the vaginal 
fornices. The purpose of the ovoids is to broaden the dose distribution into the paracervical regions, 
while the tandem delivers dose to the cervical, endometrial and uterine tissues (Bentel, 1996). 
1.3 Shielded Ovoids for the Tandem and Ovoid Applicator 
Ovoids containing shields at their posterior and anterior ends may be used to mitigate dose to 
the bladder and rectum, minimizing the aforementioned late sequelae (see Figure 1.2). Intra-ovoid 
shields are commonly constructed of tungsten, titanium or stainless steel. The implementation of intra-
ovoid shielding has been demonstrated to substantially reduce dose to the bladder and rectum when 
compared to equivalent treatments delivered utilizing unshielded ovoids (Yorke, et al., 1987) 
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(Williamson, 1990) (Verellen, et al., 1994) (Williamson, et al., 2002). Of the shielded applicators 
developed, tungsten shielded ovoids have proven most effective, reducing dose to the bladder and 
rectum by up to 48% compared to equivalent treatments delivered using unshielded ovoids (Williamson, 
1990). 
 
Figure 1-2: Nucletron's shielded Fletcher-Williamson applicator. (A) External image showing the anterior 
bladder shields. (B) Ovoid tube with ovoid cap removed showing the bladder (anterior) and rectum 
(posterior) shields. 
1.3.1 Shielded Ovoid-Induced Image Artifact 
The main disadvantage associated with shielded ovoids is the introduction of image obscuring 
metal artifacts in treatment planning CT data sets. High Z shields scatter significant portions of the 
imaging beam. The inability of CT filtered backprojection algorithms to compensate for these 
heterogeneities is manifest in severe, anatomy-obscuring metal artifact, which in turn limits the ability 
of physicians and physicists to accurately locate source dwell positions and contour the organs at risk 
(OAR) within the treatment planning system (TPS). A comparison of CT scans obtained of a Varian 
unshielded CT/MR compatible applicator and a Nucletron shielded Fletcher (tungsten shields) applicator 
can be seen in Figure 1-3 (A) and (B), respectively. Extensive metal artifact is observed in the case of the 
tungsten shielded applicator, severely limiting accurate OAR segmentation and applicator localization. 
For this reason, many clinics choose to use CT/MR-compatible applicators for ICBT. 
A B 
Bladder Shield 
Rectum Shield 
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Figure 1-3: A transverse pelvic CT scan of typical patient anatomy with (A) an unshielded, CT/MR 
Fletcher applicators and (B) a tungsten shielded Fletcher applicator. For the CT/MR compatible 
applicator, minimal metal artifact can be seen from the source position markers within the ovoids when 
compared with the metal artifact present in the CT slice of the shielded Fletcher applicator. (Roeske, et 
al., 2003) 
1.3.2 Image Artifact Reduction Methods 
Attempts to reduce the presence of high Z metal artifact in CT image sets have met with limited 
success. Multiple methods of CT artifact reduction are considered in this section.  
Roeske et al. explored the use of CT projection-interpolation algorithms to mitigate metal 
artifacts due to the Fletcher-Suit applicator (2003). Linear or higher order CT projection-interpolation 
algorithms have previously proven effective in reducing metal artifact due to high Z objects with minimal 
structural integrity (surgical clips, dental fillings, etc.) yielding near artifact-free CT data sets  (Glover & 
Pelc, 1981) (Hsieh, 1998) (Kalendar, et al., 1987). These same methods were applied for phantom and 
patient CT data sets obtained of the stainless steel, unshielded Fletcher-Suit applicator. While this 
technique offered the benefits of ease of use and short computational time, results met with limited 
success (see Figure 1-4). Clinical implementation of this technique remains limited to smaller, high Z 
objects as it has not yet yielded sufficient metal artifact reduction to warrant clinical implementation.  
A                                                                            B 
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Figure 1-4: CT scan showing the top of the ovoids, tandem and contrast in the Foley catheter (A) before 
and (B) after CT projection-interpolation algorithm artifact reduction (Roeske, et al., 2003). 
 
Another approach to reduce CT artifact is iterative statistical CT image-reconstruction which 
more accurately model CT detector response and the physical process of signal acquisition (Williamson, 
et al., 2002). This method is capable of yielding nearly artifact-free CT imaging of soft tissues near high Z 
metal objects (see Figure 1-5). This method is limited however in that it relies on an accurate a priori 
model of the metal object, including its pose (position and orientation), shape and a well-defined 
attenuation map. The inability to correctly determine 3D applicator pose has limited the iterative 
statistical CT image-reconstruction approach (Williamson, et al., 2002) (Yazdia, et al., 2005). Attempts 
have been made to improve these methods using generalized iterative forward projection matching 
(gIFPM) reliant on three 2D x-ray projections. It was reported that pose localization errors were less than 
1.5 mm and 2o for orientation angles (Pokhrel, et al., 2011). This method of mitigating metal artifact is 
not yet clinically availably nor have its capabilities been proven for CT acquisition of shielded ovoids. 
 
Figure 1-5: A transverse pelvic CT slice through a patient’s hip prostheses (A) before and (B) after metal 
artifact reduction (Yazdia, et al., 2005). 
 
A                                    B   
 
 
 
 
 
A                                                                               
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Several attempts have been made to develop clinically viable, CT-compatible shielded ICBT T&O 
applicators. The first of these, the “Weeks” applicator, utilized tungsten-shielded source carriers that are 
loaded post-CT acquisition (Weeks & Montana, 1997). This applicator was based off the shielded 
Fletcher-Suit-Delclos applicator with mini-colpostats (both systems are shown in Figure 1-6 and Figure 
1-7). The affixed Fletcher shields were replaced with manually loaded tungsten shields that are inserted 
in conjunction with 137Cs source loading (see Figure 1-7(left)) (Weeks & Montana, 1997). The main 
disadvantage of the Weeks applicator, preventing clinical implementation, is the inability for remote 
afterloading resulting in increased exposure to clinical staff for low dose rate (LDR) procedures and no 
possible treatment for HDR or pulsed-dose-rate (PDR) applications.  
 
Figure 1-6: Side-by-side comparison of the second generation Weeks ovoids (left) and the Fletcher-Suit-
Delclos ovoids (right) showing their similarity. The second generation Weeks ovoids were composed of 
Aluminum. The change from plastic ovoid tubing to aluminum improved the rigidity of the applicator 
(Weeks & Montana, 1997). 
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Figure 1-7: Schematic of the Weeks ovoids with the catheter tube (top), a lateral view of the post-CT 
added shielded source carrier (middle) and an anterior view of the post-CT added shielded source carrier 
(bottom). (Weeks & Montana, 1997) 
A prototype CT/MR compatible Fletcher Williamson applicator with moveable interovoid shields 
(the Anatomically Adaptive Applicator or A3) has also been developed in an attempt to reduce metal 
artifact in CT data sets (see Figure 1-8). It has been shown that this applicator yields artifact-free images 
of patient anatomy with metal artifact limited to a region contained within the ovoid (see Figure 1-9 ) 
(Price, et al., 2009). A step-and-shoot method of CT acquisition is used to acquire artifact-free CT 
images. MR compatibility is achieved through the use of carefully selected MR-compliant materials. 
Although several centers are initiating clinical trials utilizing the A3 applicator, it is not available for 
clinical use at this time. 
 
Figure 1-8: Price’s CT/MR compatible shielded A3 applicator. The external appearance of the applicator 
(A) and interovoid shields (B). (Price, 2008) 
A                                                                                 B 
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Figure 1-9: Comparison of reconstructed axial CT slices through the bladders shields of the shielded 
Fletcher-Suit-Delclos applicator (A), the shielded Fletcher Williamson applicator (B) and Price’s A3 
applicator (C) 
1.4 Megavoltage Computed Tomography for Planning Shielded Ovoid ICBT 
Treatments 
Alternatively, the use of megavoltage CT (MVCT) may pose a viable solution for artifact-free 
imaging of shielded tandem and ovoid applicators. An MVCT imaging beam is more penetrating than a 
Kilovoltage CT (kVCT) beam; as energy increases, linear attenuation decreases with relatively more 
radiation arriving at the CT detector panels. For example, at 60 keV (typical kVCT scan mean energy), the 
linear attenuation coefficient () of tungsten is 71 cm-1 whereas at 3.5 MV (average energy of 0.75 
MeV),  is equal to 1.71 cm-1, a decrease by a factor of 40. An increase in energy also results in an 
increase in penetration through CT detectors yielding a decrease in image contrast and resolution. 
However, it has been demonstrated that helical tomotherapy yields CT data sets acceptable for patient 
alignment and delineation of many soft tissue structures (Meeks, et al., 2005). Also, multiple studies 
have demonstrated that MVCT data sets continue to display sufficient contrast to facilitate critical 
structure segmentation even when high Z objects, such as hip prosthesis, spinal stabilization rods and 
dental appliances are present (see Figure 1-10) (Hansen, et al., 2006), (Aubin, 2006), (Yank, et al., 2010), 
(Korol, et al., 2010). One study has explored the feasibility to utilizing MVCT for the treatment planning 
A                                                            B                                                             C 
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of a shielded Fletcher-Suit-Delclos applicator, concluding that MVCT images for clinical LDR 
gynecological brachytherapy are acceptable for 3D, MVCT-based dose planning (Wagner, et al., 2009). 
 
Figure 1-10: CT scans of a cervical ICBT T&O patient with hip prostheses with (A) a MVCT scanner and (B) 
a kVCT scanner. It is noted that in image (A), MV energy, the scan quality was sufficient for physician 
organ segmentation of the rectum (R), small bowl/sigmoid colon (SB) and the bladder (B). (Korol, et al., 
2010)  
MVCT imaging of patients containing metallic objects often results in negligible metal artifacts 
when compared to equivalent scans acquired via kVCT. It is not yet known if MVCT scans of a patient 
containing shielded HDR tandem and ovoid applicators are of sufficient quality to allow 3D treatment 
planning of a gynecologic ICBT treatment, to localize source dwell positions and to segment OARs 
(bladder, rectum and sigmoid colon). The purpose of this work is to investigate the use of MVCT imaging 
to acquire artifact-free or nearly-artifact-free imaging data sets of a shielded applicator in a patient-
surrogate phantom for ICBT organ segmentation and catheter reconstruction.  
1.5 Hypothesis and Specific Aims 
Metrics1 quantifying the accuracy of (a) organ segmentation and (b) intracavitary brachytherapy 
catheter reconstruction will agree within ±2 mm/±15 cc and ±2 mm, respectively, of known values for 
                                                          
1
Organ segmentation two- and three-dimensional metrics: centroid-to-perimeter (CTP) measures (2D) as well as 
volume comparisons (3D). The three-dimensional dwell position metric is a comparison of the distal-most origin of 
catheter reconstruction relative to applicator reference markers. The two-dimensional organ segmentation metric 
was chosen to be 2mm as this was within 1mm of the systematic error. The three-dimensional organ segmentation 
metric was chosen to be 15cc, a volume representing 5%-12% of surrogate organ structure volumes. For three-
A                                                                               
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image sets acquired via mega-voltage computed tomography (MVCT) for shielded tandem and ovoid 
(T&O) brachytherapy applicators imaged in a water phantom containing surrogate organ structures. 
1.5.1 Aim 1. Water Phantom Development and Image Acquisition 
First, a water phantom containing structures acting as surrogates for patient rectums and 
bladders will be constructed. Second, kVCT and MVCT image sets will be acquired for three (3) HDR 
T&O-type ICBT applicators: a Nucletron unshielded, CT/MR compatible Fletcher applicator, a Nucletron 
shielded Fletcher-Williamson applicator and a Varian shielded Fletcher-Suit-Delclos-style applicator. 
1.5.2 Aim 2. Organ Segmentation and Catheter Reconstruction 
Medical physicists and physicians from multiple institutions will segment the bladder and 
rectum on both kVCT and MVCT data sets for all applicator types and perform catheter reconstruction 
for kVCT and MVCT image sets. In the case of the Nucletron applicators, an additional catheter 
reconstruction will be performed with the assistance of the Oncentra Brachy applicator modeling TPS 
plugin. 
1.5.3 Aim 3. Determination of Organ Segmentation and Catheter Reconstruction Accuracy 
The quality of the resulting treatment plans will be evaluated based on the accuracy of the 
participant organ segmentation and catheter reconstruction. Organ segmentation accuracy will be 
determined via two-dimensional centroid-to-perimeter (CTP) measurements and three-dimensional 
volume comparison. CTP values will be compared with bladder and rectum structure scans in air to 
obtain values which will be designated as CTP-diff. Overall structure volumes will be compared with 
volumes measured via water displacement to obtain values designated as VOL-diff. Catheter 
reconstruction accuracy will be determined for each applicator tube by comparing the location of the 
distal-most, participant-defined dwell positions relative to applicator reference markers, with control 
values measured via radiograph; this measure will be referred to as MD-diff. 
                                                                                                                                                                                           
dimensional dwell position metric, 2mm was chosen because this is outside the specifications of the mechanical 
accuracy of the afterloader (+/-1mm). 
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Chapter 2  Methods and Materials 
2.1 Aim 1: Water Phantom Development and Image Acquisition 
To achieve the aims of this study, a water phantom was constructed to provide participants with 
image sets containing surrogate bladder and rectum structures as well as clinically viable applicator 
positioning relative to these structures. The water phantom consisted of a water tank, structure 
immobilization devices, bladder and rectum surrogates, and various T&O applicators.  
2.1.1 Tandem and Ovoid Applicators 
The imaging properties of three different HDR T&O applicators were investigated in this study: 
the Nucletron CT/MR compatible Fletcher applicator (CTMR), the Nucletron shielded Fletcher-
Williamson applicator (FW) and the Varian shielded Fletcher-Suit-Delclos-style applicator (FSDs) (see 
Figure 2-1). 
 
Figure 2-1: HDR T&O applicators used in this study. (A) Nucletron's CT/MR compatible applicator. (B) 
Nucletron's Fletcher-Williamson applicator. (C) Varian's Fletcher-Suit-Delclos-style applicator. 
The CTMR applicator is the current, clinical applicator used at Mary Bird Perkins Cancer Center 
(MBPCC) in Baton Rouge, LA where this study was conducted. It is composed of special composite, low Z 
plastics which mitigate artifact in CT and MR images, facilitating 3D ICBT treatment planning and dose 
analysis. 
The FW applicator catheters are constructed of stainless steel and the ovoids consist of 
polysulfone caps surrounding Densimet-17 (tungsten alloy, Z=74, ρ = 17g/cm3) bladder and rectal shields 
A B C 
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(Horton, et al., 2005). The bladder and rectum shields are 2.0 and 2.1 mm thick, respectively, and are 
welded to the applicator tubes in an orientation that optimizes shielding to the posterior bladder and 
anterior rectal walls for ideal insertions (see Figure 2-2). For ideal insertions, these shields yield a dose 
reduction in the bladder and rectum greater than 40% for ideal anatomy positioning relative to the 
ovoid shields. 
 
 
Figure 2-2: (A) The exterior of the FW ovoid (rectal shield not visible) and (B) a schematic of the interior 
of the FW ovoid, mainly the bladder and rectum shields. (Price, 2008) 
The Varian Fletcher-Suit-Delclos-style applicator catheters and inter-colpostatic shields are 
constructed of stainless steel (ρ  8 g/cm3, Z27 (exact composition proprietary)) and the ovoid caps are 
acetal (Naydenov & Ryzhikov, 2005). The manufacturer reports that the stainless steel shields are 
capable of reducing dose in the bladder and rectum by up to 20% (Varian Medical Systems, 2009). While 
this is less than half the dose reduction achieved with FW ovoid shields, the intent is to provide an 
applicator capable of shielding the bladder and rectum while yielding CT data sets with sufficient 
visibility to facilitate organ segmentation and catheter reconstruction. 
For all applicators investigated, a tandem tube angle of 30 degrees and an ovoid diameter of 25 
mm were chosen because all applicator sets include components of these specifications and these sizes 
FW rectum shields 
FW bladder shields 
A                                                      B 
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are commonly utilized clinically. Clinical source position markers were used for investigations of the 
CTMR applicators (see Figure 2-3). Source position markers are made of a thin metal strand with larger 
metallic markers placed periodically along the strand. These markers are used clinically in patient CT 
scans to represent actual source paths during treatment and to aid physicists and physicians in 
accurately choosing dwell positions within the TPS. Source position markers were not used for the 
Nucletron Fletcher-Williamson or the Varian Fletcher-Suit Delclos-style applicators because image 
artifacts inhibit visualization of source position markers. Clinical treatment planning for shielded 
applicators typically involves localizing the catheter tube tip end, measuring a fixed distance (which is 
institution dependent) inferior to the tip end and placing the source in the middle of the catheter tube. 
 
Figure 2-3: CTMR applicator source position markers. (A) Metallic markers along wire strand (a single 
marker pointed out by black arrow) representing various source positions within the catheter. (B) 
Sagittal CT slice showing the source position markers (white marks) and planned TPS dwell positions (red 
dots along green reconstructed catheter). 
For each applicator catheter tube (the tandem and both ovoids), applicator reference markers 
were attached to facilitate Aim 3 of the study (see Figure 2.4). These markers were 1.2 mm in length 
A                                                                          B 
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and 1 mm in diameter and made of stainless steel. To determine the correct applicator reference 
marker size, various sizes were imaged on kVCT and MVCT scanners until the markers were visually 
present for both kV and MV image sets with default window (=500) and level (=1) settings while 
minimizing metal artifact. For the ovoid catheters, applicator reference markers were placed directly 
behind the ovoids. In the case of the shielded ovoids, a 5 mm wooden spacer was placed between the 
ovoid tube and the marker so as to limit artifact interference from the stainless steel tubes. For the 
tandem tubes, the markers were placed 3 cm inferior from the tip. Again, a wooden spacer (1 mm thick) 
was utilized for tandem tubes from the shielded applicators. 
 
Figure 2-4: Attachment of fiducial markers to the tandem and ovoids for (A) the CT/MR compatible 
applicator (markers attached with duct tape), (B) the Fletcher-Williamson applicator and (C) the 
Fletcher-Suit-Delclos-style applicator. The spacers can be seen on both the FW and FSDs applicators 
moving the markers outside of the regions containing image obscuring artifact. Arrows designate ovoid 
catheter markers with wooden spacers.  
2.1.2 Water Phantom Constituents: Bladder and Rectum Surrogate Structures 
Surrogate anatomic structures were developed with realistic size (diameter and volume), shape 
and positioning relative to the T&O applicator. Multiple patient CT scans were gleaned from the MBPCC 
database and analyzed to develop the general geometry typical of OARs (bladder, rectum and sigmoid 
colon) encountered clinically. 
2.1.2.1 Development of Bladder and Rectum Surrogate Structures 
First-generation surrogate patient rectums and bladders were composed of iodinated 
contrast/saline filled latex material deformed into irregular shapes using duct tape (see Figure 2.5). 
These structures could be filled to known volumes facilitating the comparison between actual and TPS-
A                                                            B                                                               C 
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generated volumes. To secure the structures within the phantom water tank, the rectum structures 
were attached via duct tape and the bladder was mounted on a rod suspended superior to the 
assembled applicator and surrogate rectum. The lack of rigidity of these structures proved problematic 
as motion of water within the tank during scanning induced surrogate structure motion, hindering the 
acquisition of reproducible image sets. Further details regarding the development of the first generation 
phantom are included in Appendix A. 
 
Figure 2-5:  Initial attempts at constructing surrogate patient bladder (A) and rectum (B) 
2.1.2.2 Aquaplast Bladder and Rectum Surrogates 
A rigid substitute with a physical density similar to bladder and rectal tissue was needed to 
overcome the problem of surrogate structure motion. Aquaplast was chosen for two main reasons: 
rigidity at room temperature and a physical density (ρ=1.08 g/cm3) (RPD, 2011) similar to bladder and 
rectal tissues (1.04 g/cm3) (Awschalom, 1983). Typically, aquaplast is used as surface bolus in the clinic 
for areas of irregular surfaces due to its (a) malleability and (b) rigidity at room temperature. Bladder 
and rectum surrogate structures were made by molding heated aquaplast around the first generation 
structures described in Section 2.1.2.1 (see Figure 2-6 and Figure 2-7).  
The process of molding the aquaplast resulted in variations of wall thickness, typical of 
variations seen in patient anatomy. The minimum wall thickness was about 0.5 mm. A re-sealable cap 
was fitted to each structure to allow for partial filling with water and air to mimic expected organ 
content. Four rectums and two bladders were constructed. A pseudo urethra was added to the bladder 
A                                                                                       B            
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in order to secure the bladder structure to the water tank via a mounted rod and thereby prevent 
motion of the bladder structure during CT scans. For each structure, laser/ovoid alignment markings 
were placed on the structure to ensure a reproducible setup for 3D image acquisition (see Figure 2-8).  
 
Figure 2-6: Second-generation aquaplast rectum surrogate structures. (A) Test surrogate rectum, (B) 
surrogate rectum-1, (C) surrogate rectum-2 and (D) surrogate rectum-3. 
 
Figure 2-7: Second-generation aquaplast bladder surrogate structures. (A) Test surrogate bladder and 
(B) surrogate bladder used for all image sets containing a T&O applicator. 
 
Figure 2-8: Laser/ovoid alignment markings added to the bladder and rectum surrogate structure. (A) 
The applicator in the water phantom aligned to the bladder and rectum surrogate structures (bladder 
and rectum ovoid alignment markings outlined in red), (B) Bladder ovoid marking and (C) Rectum ovoid 
markings (outlined in red) with green marks for shielded applicators and black for the CTMR applicator. 
A                                                  B                                               C                                    D 
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One bladder and one rectum were used solely as “pre-test” structures to validate the ability of 
participants to use the Oncentra TPS organ segmentation tools. The three remaining rectum surrogate 
structures and bladder, combined with the three different applicators, yielded nine different image sets 
for organ segmentation and catheter reconstruction for each imaging modality.  
The physical volume of each structure was measured via water displacement to facilitate 
volume comparisons between measured and segmented volumes. Volumes were measured via 
displacing a structure in a large, water-filled beaker and, upon removing the structure, re-filling the 
beaker to the same water level using a graduated cylinder with +/-0.4 ml accuracy (see Figure 2-9). The 
measured values are included in Table 2-1. The volumes of the test rectum and bladder structures are 
189 ±0.8 ml and 300 ±1 ml respectively. The measured volumes of rectum-1, rectum-2, rectum-3, and 
the main phantom bladder are 160 ±0.8 ml, 125 ±0.7 ml, 184 ±0.8 ml and 265 ±1 ml, respectively. 
 
Figure 2-9:  Organ surrogate volume measurements via water displacement. (A) Submersion of 
surrogate rectum structure, water level is recorded from a ruler. (B) Water is added using the graduate 
cylinder to the same level displaced by the surrogate rectum structure. 
Table 2-1: Bladder and rectum surrogate structure control volumes determined via water displacement.  
Bladder and Rectum Surrogate Structure Measured Volumes 
Test Structures   Main Structures     
Bladder Rectum Bladder Rectum-1 Rectum-2 Rectum-3 
300 ±1 ml 189 ±0.8 ml 265 ±1 ml 160 ±0.8 ml 125 ±0.7 ml 184 ±0.8 ml 
2.1.2.3 Bladder and Rectum Surrogate Structure Fiducial Markers 
To facilitate the 2D organ segmentation stated in aim 3, fiducial markers were added to all 
surrogate bladder and rectum structures except for the test set. Fiducial markers facilitate the 
A                                                                 
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determination of an axial cross section of each surrogate organ capable of being localized for kV and MV 
image sets. Three sets of three fiducial markers were embedded in each rectal structure wall: (1) 
superior to the ovoid region, (2) directly posterior to the ovoids (same axial CT slice) and (3) inferior to 
the ovoids. Similarly, for the bladder, there were also three sets of three fiducial markers embedded into 
each bladder structure wall: (1) to the left lateral of the ovoids, (2) directly anterior to the ovoids and (3) 
to the right lateral of the ovoids.  
Fiducial markers capable of being visually present on both kV and MV image sets without 
introducing metal artifact into kVCT data sets were needed. Clinical fiducial markers used with kVCT 
were nearly indiscernible on MV image sets. A variety of high Z objects with various sizes were tested 
(different paper clips and pushpins mainly) and it was determined that suitable fiducial markers could be 
obtained by cutting a typical pushpin (diameter =1 mm) into 1.25 mm lengths. To improve their 
visibility on MVCT scans, a second marker was placed superior to previously attached markers. The end 
product yielded sufficient visibility on both kVCT and MVCT data sets (see Figure 2-10). 
 
Figure 2-10: Examples of the surrogate structure fiducial markers. (A) Fiducial markers attached to the 
outer surface of the bladder surrogate structure (encircled in red). The blue line represents the plane 
from which images (B) and (C) were acquired. KVCT (B) and MVCT (C) scans in the ECS view of the 
bladder for the sets of markers depicted by the blue line in (A). 
A                                                            B                                                            C 
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It was assured that one set of fiducial markers for each structure lay within the artifact region. 
The artifact region is defined as the region of slices containing metal artifact due to ovoid shielding (see 
Figure 2-11). The fiducial markers were placed on each rectum such that one set of markers would be 
located in the artifact region.  
 
Figure 2-11: Sagittal kVCT slice of the FW applicator demonstrating the “artifact region” of each 
applicator. 
2.1.3 Phantom Alignment 
Reproducible phantom alignment was critical for accurate comparisons of kVCT and MVCT 
image sets for each bladder/rectum arrangement. The process for phantom alignment was: 
1. First, the water tank was aligned with the CT coordinate system. To accomplish this, the 
water tank was squared with the CT patient table using a rigid table attachment utilized for 
patient immobilization. Two slabs of SolidWater® (Gammex RMI, Middleton, WI) were then 
placed within the phantom water tank and immobilized in the right superior corner using 
plastic spacers (see Figure 2-12). Using markings on the SolidWater®, the phantom was 
aligned laterally with the overhead CT lasers (see Figure 2-12). Water was then filled to 
markings on the tank that placed the water level 2cm above the anterior portion of the 
phantom bladder.  
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Figure 2-12: Overhead view of the Solidwater®/CT laser alignment. A black, plastic spacer (in red box) 
was used to immobilize the SolidWater® within the water tank.  
2. Next, the rectum was immobilized atop the solid water using rubber bands and aligned 
laterally with the overhead CT lasers (see Figure 2-13). Alignment in the superior/ inferior 
direction was accomplished in the following step. 
 
Figure 2-13: Surrogate rectum structure alignment. The structure was attached to the Solidwater® using 
rubber bands and then aligned laterally with the overhead CT lasers. 
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3. One of the three T&O applicators investigated was then attached to the clinical applicator 
mount and aligned with the rectum via the ovoid alignment marks in the posterior ovoid 
caps touching the rectum (see Figure 2-15). The tandem tube was aligned with the overhead 
CT lasers (see Figure 2-14). This alignment procedure also facilitated the superior/inferior 
rectum alignment within the water tank, being based off of the T&O applicator positioning 
within the water tank. 
 
Figure 2-14: Overhead view of T&O applicator alignment with surrogate rectum structure. The T&O 
applicator was aligned with the overhead CT laser.  
4. The bladder was then immobilized in the water tank via a rod and mount, and aligned via 
ovoid alignment markings that resulted in the anterior portion of the ovoid caps touching 
the bladder (see Figure 2-8and Figure 2-15). The anterior side of the bladder was 
simultaneously aligned with the overhead CT lasers (see Figure 2-16).  
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Figure 2-15: Ovoid contact with the bladder and rectum ovoid alignment markings. 
 
Figure 2-16: Surrogate bladder structure alignment with the overhead CT lasers. Note: a difference in 
the internal and external overhead CT lasers is seen in this figure. To avoid problems with alignment 
mismatch between the internal and external CT lasers, all parts of the phantom were aligned to the 
internal CT lasers. 
A lateral view of the completed phantom can be seen in Figure 2-17. It is worth noting that the 
relative spatial locations of the bladder, rectum and applicator are not typically this close in patients. 
However, this setup resembles a “worst case scenario” encountered clinically when poor or lack of 
vaginal packing provides insufficient bladder and rectal wall displacement. It also aids in achieving a 
reproducible setup via ovoid/structure alignment markings. The setup also should result in the largest 
adverse effects to the results of organ segmentation and catheter reconstruction due to metal artifacts. 
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Figure 2-17: Water phantom assembled for scanning on the TomoTherapy Hi-Art II MVCT scanner. This 
image also shows the bladder attachment arm and the applicator mount. 
2.1.4 Image Acquisition: kVCT versus MVCT 
kVCT image sets were acquired using a GE Lightspeed RT 16 CT scanner (General Electric 
Medical Systems, Fairfield, CT). The MBPCC gynecological ICBT HDR treatment imaging protocol was 
followed. The MVCT image sets acquired using the TomoTherapy Hi-Art II MVCT scanner (TomoTherapy, 
Madison, WI) with parameters set as close to the kVCT parameters as allowed by the Hi-Art system 
other than energy. The imaging parameters used in this study are tabulated in Table 2-2. 
Table 2-2: Imaging parameters for both the kV and MV imaging modalities used in this study. 
Kilovoltage CT Megavoltage CT 
(GE Lightspeed 16RT) (TomoTherapy Hi-Art) 
kVp 120 E(MV) 3.5 
Slice Thickness (mm) 1.25 Slice Thickness (mm) 2 (minimum) 
SFOV (cm) 50 SFOV (cm) 40 
Pixel Size (mm2) 
0.976 x 
0.976 
Pixel Size (mm2) 0.76 x 0.76 
Voxel Size (mm3) 1.19 Voxel Size (mm3) 1.16 
Image Size 512 x 512 Image Size 512 x 512 
 
 24 
 
2.2 Aim 2. Participant Organ Segmentation and Catheter Reconstruction  
2.2.1 Physicist and Physician Participation 
Seven physicists and two physicians from multiple institutions participated in this study. 
Institutions included MBPCC (Baton Rouge, LA), the University of Texas MD Anderson Cancer Center 
(Houston, TX), the University of Texas Medical Branch at Galveston (Galveston, TX), and the University of 
North Carolina School of Medicine (Chapel Hill, NC). Each participant was proficient with the Oncentra 
Brachy TPS for planning cervical ICBT T&O treatments. A variety of questions were asked of the 
participants to ascertain their skill with organ segmentation and catheter reconstruction. As shown in 
Table 2-3, there were no specific qualifications for participating in the study other than (a) working 
currently as a clinical medical physicist/physician and (b) familiarity with the Oncentra Brachy TPS. 
Experience as a medical physicist/physician ranged from 1-17 years (this does not indicate an equivalent 
number of years of experience with ICBT). It was not clinical practice for all participants to segment the 
bladder and rectum structures; some clinics rely on dose calculations using the ICRU 38-defined bladder 
and rectum points. Regarding experience with planning of patient cases with shielded T&O applicators, 
“infrequent” refers to any time period longer than three months between shielded T&O insertion plans. 
Each participant was provided with seven image sets, including one pre-test image set, which 
was the same for all participants. The primary purpose of the pre-test image set was to confirm the 
familiarity of the participant to perform organ segmentation using Oncentra Brachy’s TPS. All resulting 
reconstructed volumes were within ±17.5cc of known volumes. The remaining six image sets were 
comprised of kV and MV image sets for each applicator with various combinations of rectum structures 
with the bladder structure. Image set assignments were made randomly to prevent participant bias 
towards a given modality or method of segmentation/catheter reconstruction. The image set 
assignments are shown in Table 2-4. 
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Table 2-3: Participant experience prior to participation in the study.  
Participant Experience         
  Physicist 1 Physicist 2 Physicist 3 Physicist 4 Physicist 5 Physicist 6 Physicist 7 Physician 1 Physician 2 
Years in Clinic? 17 4 12 9 3 8 8.5 2 2 
Board Certified? (Y/N) yes yes yes yes no, 1&2 yes yes no no 
# of ICBT Insertions 
Planned (6 months) 
4 10 24 5 1 1 2 5 10 
Clinical Practice to 
Segment 
Bladder/Rectum? 
no yes yes yes yes yes yes yes yes 
Experience Planning 
Shielded T&O Insertions? 
yes no yes no no yes yes yes yes 
If so, with what 
frequency? 
infrequent N/A infrequent N/A N/A infrequent infrequent infrequent infrequent 
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Table 2-4: Participant image set assignment. Every third participant has the same image sets however each participant’s image sets were 
individually randomized to help eliminate bias towards certain applicators or imaging modalities. 
Physicist 1 Physicist 2 Physicist 3 Physicist 4 Physicist 5 Physicist 6 Physicist 7 Physician 1 Physician 2 
Test Test Test Test Test Test Test Test Test  
CTMR kV 2 FSDs kV 1 FSDs kV 2 FSDs MV 1 CTMR MV 3 FW kV 1 FSDs MV 1 CTMR kV 1 CTMR MV 1 
CTMR MV 3 CTMR kV 2 FW kV 1 CTMR MV 2 FW kV 3 FW MV 2 FW kV 2 FSDs kV 3 FW MV 2 
FW MV 1 FSDs MV 2 FW MV 2 CTMR kV 1 FSDs MV 2 FSDs MV 3 FW MV 3 FW kV 2 FW kV 1 
FSDs MV 2 FW MV 1 FSDs MV 3 FSDs kV 3 CTMR kV 2 FSDs kV 2 FSDs kV 3 FSDs MV 1 CTMR kV 3 
FSDs kV 1 CTMR MV 3 CTMR MV 1 FW kV 2 FSDs kV 1 CTMR kV 3 CTMR kV 1 FW MV 3 FSDs MV 3 
FW kV 3 FW kV 3 CTMR kV 3 FW MV 3 FW MV 1 CTMR MV 1 CTMR MV 2 CTMR MV 2 FSDs kV 2 
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2.2.2 Participant Instructions 
Participants were provided with detailed instructions serving four main purposes: 1) provide 
each participant with a general overview of the study and their role therein, 2) give basic TPS setup 
guidelines (Lanczos Window smoothing, region of interest (ROI) voxel size, etc.), 3) provide clarification 
regarding organ segmentation and catheter reconstruction for phantom structures (how to contour the 
bladder with the attachment arm present in multiple slices) and 4) give detailed DICOM export 
instructions. A copy of the instruction is included in Appendix B. 
2.2.3 Organ Segmentation 
Participants were asked to perform organ segmentation for both the bladder and rectum 
surrogate structures in each of the seven image sets assigned. Instructions were provided regarding 
caveats due to phantom construction such as the surrogate structure mounting hardware as well as the 
extents to which the surrogate structures should be segmented. Participants were instructed to use 
their best judgment to contour as if fiducial markers were not present.  
2.2.4 Catheter Reconstruction 
Following clinical protocol, the participant performed catheter reconstruction on the six image 
sets containing a T&O applicator. For the CTMR compatible applicator, participants choose source dwell 
positions utilizing source position markers for guidance, as these markers are used clinically to simulate 
the location of the source dwell positions during treatment.  
For the shielded applicators, participants were instructed to define the distal-most source dwell 
position 7 mm inferior to the applicator tube tip. This method is used due to the inability to visualize 
source position markers on CT data sets acquired of shielded T&O applicators. As mentioned previously 
(see Section 1.3.1), the stainless steel catheter tubes and tungsten/stainless steel ovoid shields 
introduce image obscuring artifact into CT data sets, preventing the physicists or physicians from 
visualizing source position markers. 
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2.2.5 Catheter Reconstruction with Nucletron’s Applicator Modeling 
Catheter reconstruction was performed by the investigator utilizing Nucletron’s Applicator 
Modeling plugin (AMp) for both of the Nucletron applicators: the CTMR and the FW. The AMp utilizes a 
3D digital reconstruction of an applicator, with correct dimensions and shape, to aid in catheter 
reconstruction for cases where applicator localization cannot otherwise be determined (see Figure 
2-18).  
 
Figure 2-18: Visual example of AMp catheter reconstruction in the presence of CT metal artifact in (A) 
kVCT and (B) MVCT data sets. 
The AMp digital model position and orientation can be adjusted via rigid translation and rotation 
as well as non-rigid deformation (see Figure 2-19). However, in this study only rigid transformations 
were utilized. Twelve treatment plans were generated using the AMp—six for the CTMR applicator and 
six for the FW applicator which included a plan for each bladder/rectum combination. 
The accuracy of the AMp was determined by comparing the distance between the applicator 
reference marker and the AMp-defined distal-most dwell position with the same measure obtained via 
radiograph—the control measures (discussed in further detail in Section 2.3.2).  
A                                                                                 B 
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Figure 2-19: Application of the Applicator Modeling plugin (AMp). (A) Catheter manipulation of the 
tandem tube as it is being manipulated while the ovoid tubes remain in place. (B) Manipulation of the 
entire applicator. All tubes are being rotated around a central pivot point (red circle is pivot point). (C) A 
completed model in place within the water phantom (yellow is the bladder structure and green is the 
rectum structure). 
2.3 Aim 3. Organ Segmentation and Catheter Reconstruction Analysis 
2.3.1 Organ Segmentation Comparison: Two- and Three-dimensional Methods 
Two-dimensional CTP measurements and three-dimensional volume comparisons were used to 
quantify the accuracy of organ segmentation. The methods discussed in the following sections were 
derived from methodologies presented in the literature and have been shown to be reliable for 
assessing and quantifying the quality of organ segmentation (Jameson, et al., 2010). 
2.3.1.1 Two-dimensional CTP Analysis 
The following procedure was followed for two-dimensional analysis of the organ segmentation 
accuracy: 
1. The centroid was found for each set of fiducial markers on each rectum and bladder structure 
(three sets of three markers per structure). For rectum structures, this produced one centroid 
point superior to the artifact region, one within the artifact region and one inferior to the 
artifact region. For the bladder structure, due to the plane within which measurements were 
made (coronal, sagittal or extra coordinate system (ECS)), all slices used for measurement had at 
least one measure for which artifact could be an influencing factor.  
A                                                     B                                                              C 
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The process for finding the centroid is as follows: 
a. Using the ECS within Oncentra, a reconstructed CT slice was dervied in which all three 
fiducial markers of a given set were visible (see Section 2.1.2.3). This was accomplished 
by centering the ECS coordinate system on a fiducial marker (see Figure 2-20 A) and 
then manipulating the other two planes until the axes were visually centered through 
each of the other two markers in all three planes. (see Figure 2-20 B). 
b. With all three markers present in the derived slice, Oncentra Brachy’s “distance” tool 
was used to construct lines between each fiducial marker creating a triangle. The 
geometric center or centroid was then found by marking the intersection of the 
triangles medians, which are the lines joining each vertex (fiducial marker) with the 
midpoint of the opposite side (see Figure 2-20 C). 
 
Figure 2-20: Method for determining the centroid of each set of fiducial markers. (A) Find a CT slice with 
one of the markers and center the ECS coordinate system in that point. (B) Manipulate the ECS 
coordinate system until the centers of all points are visible in the same slice. (C) Draw the medians of 
the triangle. The point where the three medians intersect is the centroid. 
c. Using the “point” tool, a point was placed at the intersection of the medians, which is, 
by definition, the centroid of the three fiducial markers. 
d. The process was repeated for each set of three fiducial markers (three sets of three 
markers on each bladder and rectum structure) in each image set. 
2. To perform distance measurements, the “Distance and Angle” tool was used. The Distance 
and Angle tool reports the lengths of two lines with a common endpoint and calculates the 
A                                                                    B                                                                 C 
 31 
 
angle between those two lines (see Figure 2-21). To use the “Distance and Angle” tool, a line 
is extended to a point (in this case the centroid), the point is selected by clicking the mouse 
and then another line may be extended from that point. The “Distance and Angle” tool then 
displays the length of each line, the angle between the two lines and the total length of both 
lines. Clinical testing of the beta version of the Distance and Angle tool by Dr. Michael Price 
at MD Anderson Cancer Center showed the tool to have an accuracy of ±0.5 mm (Price, 
2007). 
 
Figure 2-21: Example of use of Oncentra’s “Distance and Angle” tool on an axial CT slice of a surrogate 
rectum structure. 
 
a. First, a slice was found containing the centroid (see Figure 2-22). For all rectum 
structures, all but one centroid was found in the axial slice. The other slice was found in 
the ECS coordinate system. For the bladder structure, the right lateral point was found 
in the coronal plane, the midpoint was found in the sagittal plane, and the left lateral 
point was found in the ECS view. The ECS view was only utilized when the three 
standard views failed to provide consistent images. (see Figure 2-23). When utilizing 
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the ECS, prior to each measurement, the coordinate system was squared with the 
water tank to minimize errors in using a non-rigid coordinate system. 
 
Figure 2-22: Axial CT slice of a surrogate rectum containing the centroid. This is an example of the slices 
used for two-dimensional CTP distances discussed in this section. 
 
Figure 2-23: Comparison of CTP distance measurements for the surrogate bladder structure in (A) the 
coronal view and (B) the ECS view. Zoom settings were the same for each image. 
 
b. In a slice containing the centroid, a horizontal line was drawn from the left 
extending to the centroid and then another line was extended from the centroid 
back out to the participant-defined segmentation perimeter. Distances were 
recorded for angles of 0, 40, 80, 120, 160, 200, 240, 280 and 320 degrees as shown 
A                                                                                                            B 
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in Figure 2-24 A and B. Measurements were recorded and compared to control 
values obtained via from scans of the surrogates in air. The differences were called 
CTP-diff. Phantom scans in air, rather than in water, were used to determine control 
values because of the sharp air/aquaplast border (see Figure 2-24) 
 
Figure 2-24: Images showing the method for making 2D organ segmentation measurements for (A) the 
phantom scans in air and (B) the participant-defined organ segmentation. The small box seen in (A) 
shows how the “distance and angle” tool reports angle. The window and level values for both images 
are 500 and 1, respectively. 
For two-dimensional CTP analysis, the systematic error was dependent upon the ROI pixel size 
of 2.0 x 2.0 mm2 defined within the TPS. Because the pixel size was larger than the kV and MV pixels, the 
uncertainty for such measurements is independent of imaging modality. For any point chosen within 
Oncentra, whether OAR contours or prescription points, the TPS treats those points as if they were 
placed in the center of the corresponding ROI. This yields a maximum deviance from the true value of ½ 
the diagonal of the pixel or in the case of a 2.0 x 2.0 mm2 pixel size, ±1.4 mm. This difference must be 
accounted for both at the centroid and at the perimeter. Incorporating the uncertainty of the “Distance 
and Angle” tool (±0.5 mm) results in an overall systematic uncertainty of±2.0 mm. Because both the 
control values and measured values were determined within the TPS, the systematic uncertainty is the 
same for both. 
A                                                             B 
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2.3.1.2 Three-dimensional Reconstructed Volume Analysis 
The accuracy of participant organ segmentation was also quantified by the difference between 
the control and TPS-reconstructed volumes (VOL-diff) (see Figure 2-25). The control volumes were 
determined by displacement (see 2.1.2.1). Within the treatment planning system, each participant 
segmented the bladder and rectum for each image set following the participant instructions (see Section 
2.2.2) as well as clinical practice. Upon completing the organ segmentation, the TPS displays the volume 
(in cc) of the reconstructed volume which was used for comparison against the control volumes. 
 
Figure 2-25: (A) Rectum surrogate structure control volume and (B) participant-TPS generated rectum 
surrogate structure based on participant segmentation 
The supposed manufacturer-reported systematic uncertainty of the treatment planning system 
is ±1 voxel for segmented OARs. This appeared questionable due to the variations in structure volumes 
(125 ml-265 ml) and the dependence of structure volume on the voxels it contains (if ½ or more of a 
voxel is within a contour line, the voxel is counted towards the entire structure volume). A method was 
devised to determine the expected variation between control volumes (determined via water 
displacement) and TPS reconstructed volumes. Utilizing the Oncentra “Magic Wand” tool which 
generates OAR contours based on pixel value rather than user approximation, the bladder and rectum 
structures were segmented on the kVCT phantom scans in air (with a high-contrast aquaplast/air 
border). The uncertainty in measurements was then determined by comparing the volumes of the 
phantom scans in air with the actual structure volumes, yielding a difference which we used as the 
A                                                                                         B 
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systematic uncertainty. Each structure volume was measured three times for both control volumes and 
air volumes. The results of these measurements can be seen in Table 2-5. 
Table 2-5: Comparison of control volumes determined via phantom scans in air as well as via water 
displacement. These results were used to determine the systematic uncertainty of the treatment 
planning system. 
VOL-diff Comparisons: Systematic Error Analysis –Phantom Scan in Air vs. 
Control Volumes 
    Volume (cc) Difference   
Bladder air 245.8 ± 0.2 Absolute 17.7 
  control 263.5 ± 2.7 Percent 7% 
Rectum 1 air 139.3 ± 0.5 Absolute 21.0 
  control 160.3 ± 0.5 Percent 14% 
Rectum 2 air 109.2 ± 0.2 Absolute 16.1 
  control 125.3 ± 0.5 Percent 14% 
Rectum 3 air 154.7 ± 0.4 Absolute 29.6 
  control 184.3 ± 0.5 Percent 17% 
 
Within Table 2-5, a marked difference between the bladder and rectum structures percent 
difference is observed. The rectum structures had a mean percent difference of 15% whereas the 
bladder percent difference was only 7%. It is proposed by the investigator that this is due to the 
difference in the overall segmented perimeters for axial slices of the bladder and rectum structures. 
Whereas the rectum structures had a smaller diameter (2-5cm) and extended over a larger range of 
slices (100-121 slices), the bladder had a larger volume for a smaller range of slices (volume of 263 cc for 
only 60 slices). To illustrate the effect this could have an example is given. For any given slice, you can 
have two structures with the same area—one similar to a square (bladder) and one similar to a 
rectangle (rectum). The square-like shape will have a smaller perimeter than the rectangular-shaped 
object, meaning it has fewer pixels around its border, resulting in less overall systematic error 
represented in the rectangular-shaped object (bladder). It seems this would explain the reason for a 7% 
difference between the air and control volumes for the bladder structure when the rectum structures 
 36 
 
averaged a 15% difference. Due to these differences, it is proposed that the systematic uncertainty for 
each individual structure should be reported and a mean value not be taken. 
2.3.2 Three Dimensional Catheter Reconstruction Analysis 
Each participant in this study performed catheter reconstruction for the six image sets 
containing T&O applicators. For the CTMR applicator, dwell positions were based off source dwell 
position markers, which represent actual source dwell locations. For the shielded FW and FSDs 
applicators, the participants were instructed to define the distal-most source dwell position 7 mm 
inferior to the applicator tube tip. This method is used due to the applicator tubes being constructed of 
stainless steel which inhibits source position marker visualization, most notably in regions of strong 
artifacts caused by the ovoid shields.  
To determine the accuracy of catheter reconstruction, a distance measurement from the distal-
most dwell position to the applicator reference marker—marker-to-dwell difference or MD-diff, was 
used for comparison. Control values were obtained by radiographing each applicator ovoid and tandem 
tube separately and measuring the distance between the center of the distal-most, procedurally-defined 
dwell position and the closest point of the applicator reference marker (see Figure 2-26). Distances were 
measured 10 times with IP65 SPi digital calipers with reported ±0.02 mm accuracy. Measured values are 
reported in Table 2-6.  
Table 2-6: Distances from the distal dwell position to applicator fiducial markers for the respective 
applicators. 
Distal Dwell-to-Applicator 
Reference Marker Distance CTMR FW FSDs 
Tandem (mm) 23.03±0.20 23.57±0.23 23.70±0.17 
Right Ovoid (mm) 23.47±0.18 21.66±0.25 25.11±0.23 
Left Ovoid (mm) 20.71±0.19 21.88±0.17 24.44±0.18 
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To perform distance measurements within the TPS, x, y and z coordinates for the distal dwell 
positions and applicator reference markers were utilized. To localize the applicator reference marker, a 
TPS point was placed in the general region of the marker. Then, utilizing axial, coronal and sagittal views, 
the point was moved to the part of the reference marker closest to the dwell position in each view (see 
Figure 2-26).  
The systematic uncertainty for the control measures was based off the uncertainty of the IP65 SPi 
calipers used (±0.02 mm) (see Figure 2-26(A)). To determine the uncertainty in TPS measured values, 
voxel size must be accounted for. As mentioned in Section 2.3.1.1, Oncentra’s TPS measurements are 
based off the center of pixels and voxels. For a comparison of 3D points, the furthest a point could differ 
and still be associated with a given voxel is half the diagonal from the center of the voxel, which is 0.9 
mm for kV and 1.1 mm for MV. This error must be accounted for in both the dwell position and the 
applicator reference marker point yielding a final systematic uncertainty of ±1.3 mm and ±1.6 mm for kV 
and MV imaging, respectively.  
 
Figure 2-26: Method of determining the accuracy of the participant-defined source dwell position. (A) 
Scan of the radiograph from which control distances were measured. (B) kVCT and (C) MVCT of the left 
ovoid for the FSDs applicator.  
A                                         B                                                             C 
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2.4 Statistical Tests 
A number of statistical tests were conducted to determine if the variables CTP-diff, VOL-diff, and 
MD-diff obtained from MV imaging differed significantly from the same variables obtained from kV 
imaging. A two-proportion t-test was used to determine if the percent of observations meeting the 
hypothesis criteria within MVCT data sets differed significantly from the percent of observations 
meeting the hypothesis criteria within kVCT data sets. A paired t-test was used to determine if mean 
values differed significantly between MV and kV imaging for two- and three-dimensional organ 
segmentation comparisons. An unpaired t-test was used to determine if participant-defined catheter 
reconstruction differed significantly between CTMR kVCT data sets and shielded applicator MVCT data 
sets. A paired, t-test was used to validate the Nucletron AMp (compared with results obtained following 
current, clinical procedure). 
Though no Gaussian curve fitting was performed for this data it was determined that results 
sufficiently represented a normal distribution and that the number of degrees of freedom would be 
sufficient to determine statistical significance. Results with a p-value less than 0.05 were determined to 
be statistically significant. Microsoft Excel was used for all statistical analysis. Inherent capabilities for 
comparing means were utilized for the student t-tests.  
Two-proportion t-test results were calculated as follows: 
1. The pooled sample proportion was calculated, 
  
         
     
 
where p is the pooled sample proportion, p1 is the proportion of points meeting the 
specified criteria from data set 1, p2 is the proportion of points meeting the specified 
criteria from data set 2, n1 is the sample size for data set 1 and n2 is the sample size for 
data set 2. 
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2. Next, the standard error (SE) was calculated using the pooled sample proportion and 
sample sizes:  
   √  (   )  [
 
  
 
 
  
] 
3. Utilizing the standard error and proportion results for data sets 1 and 2, a t-value was 
obtained which was used as input for a t-distribution table to obtain a probability or p-
value: 
  (      )    
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Chapter 3   Results and Discussion 
3.1 Aim 1: Water Phantom Development 
 
Figure 3-1: Completed water phantom setup for scanning on GE’s Lightspeed RT kVCT scanner. 
KV and MV image sets were acquired of all three T&O applicators in the water phantom shown 
in Figure 3-1. The CTMR kV and MV image sets exhibited no gross, anatomy-obscuring artifacts. 
Conversely, for the shielded FW and FSDs applicators, extensive metal artifacts were observed for all 
axial slices containing ovoid shields when imaged with kVCT. Qualitatively comparing shielded ovoid CT 
data sets, kV images acquired of the FW ovoids demonstrated much more severe artifacts compared to 
its FSDs ovoids. This was expected due to the composition of the ovoid shielding—FW Densimet-17 
shields (ρ = 17g/cm3) (Horton, et al., 2005) compared with the FSDs applicator stainless steel shields 
(ρ8g/cm3) (Elert, et al., 2004). 
The average image acquisition time for the kVCT scanner was 15-20 seconds whereas 
TomoTherapy’s MV scanner averaged 10 minutes per phantom scan. The kVCT scanner was capable of 
much shorter scan times due to its 16 slice detector array (giving a pitch of 11.25 mm/rotation vs. 2 
mm/rotation for MV) as well as faster gantry rotation (60 rpm for kV vs. 10 rpm for MV). Select slices for 
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each imaging modality for each applicator for a given bladder/rectum arrangement are shown in Figure 
3-4. The same slice was chosen for each transverse and sagittal slice showing the reproducibility of the 
phantom setup. The window and level values were 500 and 1, respectively. 
 
Figure 3-2: Corresponding axial and sagittal CT slices of kV and MV acquisitions for Nucletron’s 
unshielded CT/MR compatible Fletcher applicator. Images (A) and (C) are the transverse and sagittal 
slices, respectively, acquired via kV imaging. Images (B) and (D) are the transverse and sagittal slices, 
respectively, acquired via MV imaging. Also, using fiducial markers, the same slice was chosen for both 
kV and MV images for both transverse and sagittal slices. Window and level values were 500 and 1, 
respectively. 
A                                                                               B 
C                                                                                D 
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Figure 3-3: Corresponding axial and sagittal CT slices of kV and MV acquisitions for Varian stainless steel 
shielded Fletcher-Suit-Delclos-style applicator. Images (A) and (C) are the transverse and sagittal slices, 
respectively, acquired via kV imaging. Images (B) and (D) are the transverse and sagittal slices, 
respectively, acquired via MV imaging. Also, using fiducial markers, the same slice was chosen for both 
kV and MV images for both transverse and sagittal slices. Window and level values were 500 and 1, 
respectively. 
 
A                                                                            B 
C                                                                             D 
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Figure 3-4: Corresponding axial and sagittal CT slices of kV and MV acquisitions for Nucletron tungsten 
shielded Fletcher-Williamson applicator. Images (A) and (C) are the transverse and sagittal slices, 
respectively, acquired via kV imaging. Images (B) and (D) are the transverse and sagittal slices, 
respectively, acquired via MV imaging. Also, using fiducial markers, the same slice was chosen for both 
kV and MV images for both transverse and sagittal slices. Window and level values were 500 and 1, 
respectively. 
 
3.2 Aim 2: Participant Organ Segmentation and Catheter Reconstruction  
3.2.1 Physicist and Physician Organ Segmentation and Catheter Reconstruction 
The reported time required for physicists and physicians to complete organ segmentation and 
catheter reconstruction ranged from four to five hours. Participant-determined window and level values 
varied greatly for both kV and MV imaging modalities (see Table 3-1). The maximum and minimum 
A                                                                             B 
C                                                                             D 
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window and level values suggest that window and level settings are not determined by imaging modality 
but by user preference. In the pre-test image set, bladder and rectum structures, the reconstructed pre-
test volumes were within ±17.5 cc of the control volumes for all participants verifying participant 
familiarity with Oncentra Brachy’s TPS (see Section 2.2.1). The accuracy of organ segmentation and 
catheter reconstruction is reported in Section 3.3. 
Table 3-1: Minimum and maximum window and level values reported for participant’s organ 
segmentation and catheter reconstruction. 
Reported Window and Level Values 
 kVCT MVCT 
 Minimum Maximum Minimum Maximum 
Window 172 2879 250 2000 
Level -6 1982 -51 489 
3.2.2 Investigator Catheter Reconstruction via Oncentra  Applicator Modeling Plugin 
Catheter reconstruction was performed for all image sets utilizing the Nucletron Oncentra 
Applicator Modeling plugin. The primary AMp tools utilized for catheter reconstruction were “Anchor 
Points” and “Catheter Manipulation.” The average time to perform catheter reconstruction was 4-5 
minutes. Results are presented in Section 3.3.3.1.  
3.3 Organ Segmentation and Catheter Reconstruction Results 
All participant results for organ segmentation and catheter reconstruction measurements are 
included in Appendix C. The following subsections present the analysis and discussion of organ 
segmentation and catheter reconstruction results. In the tables and figures, applicators are listed in 
order of increasing atomic number—CTMR (no shielding, Z6), FSDs (stainless steel shields, Z27), and 
FW (tungsten shields, Z74). 
3.3.1 Organ Segmentation: CTP Comparisons 
Two-dimensional organ segmentation accuracy was based on measurements from the centroid 
of a given CT slice to the participant-segmented perimeter (CTP) using the Oncentra “Distance and 
 45 
 
Angle” tool. As the positioning of the surrogate bladder and rectum structures differed from one 
another as well as variations in physical characteristics (shape, wall thickness, etc.), results for bladder 
and rectum structures were analyzed separately. 
3.3.1.1 Results and Analysis for Bladder Segmentation  
For 2D organ segmentation analyses of the surrogate bladder, fewer CTP measurements met 
the ±2 mm criteria on MVCT data sets than on kVCT data sets. As reported in Table 3-2, kVCT data sets 
of the CTMR, FSDs and FW applicators resulted in 79%, 80% and 77% of points meeting the ±2 mm 
criteria, respectively; whereas on MVCT data sets, these percentages decreased to 65%, 65% and 67%, 
respectively. A two-proportion t-test determined that the percentage of CTPs meeting the 2 mm criteria 
in FSDs MVCT data sets was significantly less than the percentage of CTPs meeting the 2 mm criteria in 
CTMR kV data sets (65% vs. 79%, p=0.0004). The percentage of CTPs meeting the 2 mm criteria in FW 
MVCT data sets was significantly less than the percentage of CTPs meeting the 2 mm criteria in CTMR kV 
data sets (66% vs. 79%, p=0.001). 
Table 3-2: Surrogate bladder CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Bladder Structure  
    Number of CTPs that differ by: Percent of CTPs that differ by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] [>10mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] [>10mm] 
CTMR kV 188 53 2 0 77.4% 21.8% 0.8% 0.0% 
  MV 158 78 7 0 65.0% 32.1% 2.9% 0.0% 
FSDs kV 196 45 2 0 80.7% 18.5% 0.8% 0.0% 
  MV 158 72 13 0 65.0% 29.6% 5.3% 0.0% 
FW kV 184 50 6 2 75.7% 20.6% 2.5% 0.8% 
  MV 161 72 9 1 66.3% 29.6% 3.7% 0.4% 
 
Table 3-3 summarizes the statistical characteristics of the CTP-diff results for the surrogate 
bladder structure for all six data sets. The mean CTP-diff for all samples sets was within the 2 mm 
criterion. As determined by a paired t-test, the mean CTP-diff for the FSDs MVCT was significantly 
greater than the mean CTP-diff for the CTMR kVCT (1.0 mm vs. 0.7 mm, p=0.005). The mean CTP-diff for 
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the FW MVCT was not significantly different than the mean CTP-diff for the CTMR kVCT (0.7 mm vs. 0.7 
mm, p=0.8). This suggests that surrogate bladder organ segmentation performed on MVCT data sets 
containing shielded FSDs and FW applicators is equivalent or slightly less accurate than organ 
segmentation perform on kVCT data sets of the unshielded CTMR applicator. This will be discussed 
further in subsection 3.3.1.4  
Table 3-3: Summary of surrogate bladder CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Bladder Structure 
*distances in mm 
 
n Mean σ 95% CI Range 
CTMR kV 243 0.7 1.7 0.5-0.9 12.7 
  MV 243 1.1 1.9 0.9-1.4 12.2 
FSDs kV 243 0.6 1.5 0.4-0.8 10.4 
  MV 243 1.0 2.2 0.7-1.3 13.7 
FW kV 243 0.6 2.4 0.3-0.8 25.6 
  MV 
243 0.8 2.3 0.4-1.0 15.6 
 
3.3.1.2 Results and Analysis for Rectum Segmentation 
For 2D organ segmentation analyses of the surrogate rectum, fewer CTP measurements met the 
±2mm criteria on MVCT data sets than on kVCT data sets. As reported in Table 3-4, kVCT data sets of the 
CTMR, FSDs and FW applicators resulted in 85%, 81% and 79% of points meeting the ±2 mm criteria, 
respectively; on MVCT data sets, these numbers decreased to 75%, 78% and 73%, respectively. A two-
proportion t-test determined that the percentage of CTPs meeting the 2 mm criteria in FSDs MVCT data 
sets was significantly less than the percentage of CTPs meeting the 2 mm criteria in CTMR kV data sets 
(85% vs. 78%, p=0.02). The percentage of CTPs meeting the 2 mm criteria in FW MVCT data sets was 
significantly less than the percentage of CTPs meeting the 2 mm criteria in CTMR kV data sets (85% vs. 
73%, p=0.0006).  
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Table 3-4: Surrogate rectum CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Rectum Structures  
    Number of points that differ by: Percent of points that differ by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 210 31 2 0 86.4% 12.8% 0.8% 0.0% 
  MV 183 49 8 3 75.3% 20.2% 3.3% 1.2% 
FSDs kV 193 41 8 1 79.4% 16.9% 3.3% 0.4% 
  MV 193 44 6 0 79.4% 18.1% 2.5% 0.0% 
FW kV 188 35 19 1 77.4% 14.4% 7.8% 0.4% 
  MV 181 60 2 0 74.5% 24.7% 0.8% 0.0% 
 
Table 3-5 summarizes the statistical characteristics of the CTP-diff results for the surrogate 
rectum structure for all six data sets. The mean CTP-diff for all samples sets was within the 2 mm 
criteria. As determined by the paired t-test the mean CTP-diff for the FSDs MVCT was significantly 
greater than the mean CTP-diff for the CTMR kVCT (1.2 mm vs. 0.7 mm, p=1.7E-09). The mean CTP-diff 
for the FW MVCT was significantly greater than the mean CTP-diff for the CTMR kVCT (1.0 mm vs. 0.7 
mm, p=0.02). This suggests that surrogate rectum organ segmentation performed on MVCT data sets 
acquired of the shielded FSDs and FW applicators is less accurate than organ segmentation perform on 
kVCT data sets of the unshielded CTMR applicator. This will be discussed further in subsection 3.3.1.4  
Table 3-5: Summary of surrogate rectum CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Rectum Structure  
 
 n Mean σ 95% CI Range 
CTMR kV 243 0.6 1.4 0.5-0.8 10.3 
  MV 243 1.3 2.1 1.0-1.6 15.4 
FSDs kV 243 0.5 2.0 0.3-0.8 16.9 
  MV 243 1.2 1.6 1.0-1.5 11.7 
FW kV 243 0.5 2.5 0.3-0.9 18.8 
  MV 243 1.0 1.5 0.8-1.2 9.9 
 
3.3.1.3 Results and Analyses for Bladder and Rectum Artifact Regions 
The results of the 2D organ segmentation analyses lean towards the conclusion that MVCT 
yields poorer quality and less-accurately segmented image sets than kVCT (see Section 1.4). These 
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results, however, were based off of CTP’s in all regions of segmenting, two-thirds of which was non-
artifact region. To more directly assess the influence of MVCT’s leser metal artifacts on segmentation 
performance, results were analyzed exclusively for the artifact region of the T&O applicators (Section 
2.1.2.3-artifact region definition). Results are separated by structure due to variations in surrogate 
structure construction and placement relative to T&O applicators. 
For 2D organ segmentation analyses of the surrogate bladder artifact regions, fewer CTP 
measurements met the ±2 mm criteria on MVCT data sets than on kVCT data sets. As reported in Table 
3-6, kVCT data sets of the CTMR, FSDs and FW applicators had 81%, 78% and 68% of CTPs meeting the 
±2 mm criteria, respectively; on MVCT data sets, these percentages decreased to 67%, 73% and 65%, 
respectively. A two-proportion t-test determined that the percentage of CTPs meeting the 2 mm criteria 
in FSDs MVCT data sets was significantly less than the percentage of CTPs meeting the 2 mm criteria in 
CTMR kV data sets (78% vs. 85%, p=0.2). The percentage of CTPs meeting the 2 mm criteria in FW MVCT 
data sets was significantly less than the percentage of CTPs meeting the 2 mm criteria in CTMR kV data 
sets (73% vs. 85%, p=0.02). 
Table 3-6: Surrogate bladder artifact region CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Bladder Artifact Region 
    Number of points that differ by: Percent of points that differ by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 51 12 0 0 81% 19% 0% 0% 
  MV 41 21 1 0 65% 33% 2% 0% 
FSDs kV 49 14 0 0 78% 22% 0% 0% 
  MV 47 16 0 0 75% 25% 0% 0% 
FW kV 42 17 4 0 67% 27% 6% 0% 
  MV 42 21 0 0 67% 33% 0% 0% 
Table 3-7 summarizes the statistical characteristics of the CTP-diff results for the surrogate 
bladder artifact region for all six data sets. The mean CTP-diff for all samples sets was within the ±2 mm 
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criteria. As determined by the paired t-test the mean CTP-diff for the FSDs MVCT was not significantly 
different than the mean CTP-diff for the CTMR kVCT (-0.1 mm vs. 0.2 mm, p=0.6). The mean CTP-diff for 
the FW MVCT was not significantly different than the mean CTP-diff for the CTMR kVCT (0.1 mm vs. 0.2 
mm, p=0.3). This suggests that surrogate bladder organ segmentation performed within the artifact 
region on MVCT data sets acquired of the shielded FSDs and FW applicators is as accurate as organ 
segmentation performed on kVCT data sets of the unshielded CTMR applicator. This will be discussed 
further in subsection 3.3.1.4  
Table 3-7: Summary of surrogate bladder artifact region CTP-diff results by applicator and imaging 
modality. 
CTP-diff Results: Surrogate Bladder Artifact Region  
*distances in mm 
 
 n Mean σ 95% CI Range 
CTMR kV 63 0.2 1.6 -0.2-0.6 8.6 
  MV 63 0.9 1.8 0.3-1.2 10.2 
FSDs kV 63 -0.2 1.7 -0.5-0.3 7.5 
  MV 63 0.2 1.9 -0.4-0.5 9.2 
FW kV 63 -0.8 2.4 -1.3- -0.1 12.2 
  MV 63 0.1 2.2 -0.7-0.4 8.6 
 
For 2D organ segmentation analyses of the surrogate rectum artifact regions, fewer CTP 
measurements met the ±2 mm criteria on MVCT data sets than on kVCT data sets for the CTMR 
applicator, while an increase was observed for the FSDs and FW applicators. As reported in Table 3-6, 
kVCT data sets of the CTMR, FSDs and FW applicators resulted in 77%, 60% and 58% of points meeting 
the ±2 mm criteria, respectively; whereas on MVCT data sets 65%, 73% and 73% met the ±2 mm criteria, 
respectively. A two-proportion t-test determined that the percentage of CTPs meeting the ±2 mm 
criteria in FSDs MVCT data sets was not significantly different than the percentage of CTPs meeting the 2 
mm criteria in CTMR kV data sets (73% vs. 77%, p=0.3). The percentage of CTPs meeting the 2 mm 
criteria in FW MVCT data sets was also not significantly different than the percentage of CTPs meeting 
the 2 mm criteria in CTMR kV data sets (73% vs. 77%, p=0.3). 
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Table 3-8: Surrogate rectum artifact region CTP-diff results by applicator and imaging modality. 
CTP-diff Results: Surrogate Rectum Artifact Region  
    Number of points that differ by: Percent of points that differ by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 65 14 2 0 80% 17% 2% 0% 
  MV 53 17 8 3 65% 21% 10% 4% 
FSDs kV 47 27 6 1 58% 33% 7% 1% 
  MV 60 15 6 0 74% 19% 7% 0% 
FW kV 44 19 17 1 54% 23% 21% 1% 
  MV 60 20 1 0 74% 25% 1% 0% 
 
Table 3-9 summarizes the statistical characteristics of the CTP-diff results for the surrogate 
rectum artifact region for all six data sets. The mean CTP-diff for all samples sets was within the ±2 mm 
criteria. As determined by the paired t-test the mean CTP-diff for the FSDs MVCT was not significantly 
different than the mean CTP-diff for the CTMR kVCT (0.1 mm vs. 0.2 mm, p=0.8). The mean CTP-diff for 
the FW MVCT was not significantly different than the mean CTP-diff for the CTMR kVCT (0.05 mm vs. 0.2 
mm, p=0.6). This suggests that surrogate rectum organ segmentation performed within the artifact 
region on MVCT data sets acquired of the shielded FSDs and FW applicators is as accurate as organ 
segmentation performed on kVCT data sets of the unshielded CTMR applicator. This will be discussed 
further in subsection 3.3.1.4 
Table 3-9: Summary of surrogate rectum artifact region CTP-diff results by applicator and imaging 
modality. 
CTP-diff Results: Surrogate Rectum Artifact Region  
*distances in mm 
 
 n Mean σ 95% CI Range 
CTMR kV 81 0.7 1.8 0.3-1.1 10.3 
  MV 81 1.8 3.0 1.2-2.5 15.4 
FSDs kV 81 0.6 3.1 -0.1-1.2 16.9 
  MV 81 1.5 2.3 1.0-2.0 11.3 
FW kV 81 0.3 3.9 -0.6-1.1 18.8 
  MV 81 1.2 1.7 0.8-1.5 8.0 
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When analyzing the CT artifact region, it was observed that, as distance increases within a CT 
slice from high Z objects, the metal artifact visually decreases (see Figure 3-5). To determine the impact, 
if any, this might have, the rectum artifact region was separated into two parts—the anterior region and 
posterior region. The anterior region contains CTP measurements for angles 0, 40, 80, 120, and 160 
degrees. The posterior region contains angles 200, 240, 280, and 320. Bladder results were not broken 
down by anterior and posterior results due to the bladder orientation relative to the artifact region, 
leading to few angles in each slice actually being found in the artifact region (see Figure 3-6). Rectum 
anterior and posterior artifact region results are found in Table 3-10. 
 
Figure 3-5: Axial CT slice of the FW shielded ovoids demonstrating the anterior and posterior artifact 
regions as well as the decrease in metal artifact with distance from the high Z objects.  
For 2D organ segmentation analyses of the surrogate rectum anterior artifact regions, fewer CTP 
measurements met the ±2 mm criteria on MVCT data sets than on kVCT data sets for the CTMR 
applicator, while more CTPs met the criteria for the FSDs and FW applicators. As reported in Table 3-10, 
kVCT data sets of the CTMR, FSDs and FW applicators resulted in 71%, 47% and 40% of points meeting 
the ±2 mm criteria, respectively; on MVCT data sets 64%, 73% and 73% met the ±2 mm criteria, 
respectively. A two-proportion t-test determined that the percentage of CTPs meeting the 2 mm criteria 
in FSDs MVCT data sets was not significantly different than the percentage of CTPs meeting the ±2 mm 
 
 
Anterior 
Posterior 
Region 
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criteria in CTMR kV data sets (73% vs. 71%, p=0.6). The percentage of CTPs meeting the ±2 mm criteria 
in FW MVCT data sets was also not significantly different than the percentage of CTPs meeting the ±2 
mm criteria in CTMR kV data sets (73% vs. 71%, p=0.6).  
 
Figure 3-6: Sagittal CT slice of the FW applicator demonstrating the location of the artifact region 
relative to measurements made within the sagittal slice. Note that only 2 of 9 CTP measures are 
included within the artifact region negating the values of an anterior/posterior-type artifact region 
analysis. 
Table 3-10: Surrogate rectum anterior and posterior artifact region CTP-diff results by applicator and 
imaging modality. 
CTP-diff Results: Surrogate Rectum Anterior & Posterior Artifact Region  
    Number of points that differ by: Percent of points that differ by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR-kV 
  
ant. 33 11 1 0 73% 24% 2% 0% 
post. 32 3 1 0 89% 8% 3% 0% 
CTMR-MV 
  
ant. 29 8 6 2 64% 18% 13% 4% 
post. 24 9 2 1 67% 25% 6% 3% 
FSDs-kV 
  
ant. 20 19 5 1 44% 42% 11% 2% 
post. 27 8 1 0 75% 22% 3% 0% 
FSDs-MV 
  
ant. 33 7 5 0 73% 16% 11% 0% 
post. 27 8 1 0 75% 22% 3% 0% 
FW-kV 
  
ant. 16 15 14 0 36% 33% 31% 0% 
post. 28 4 3 1 78% 11% 8% 3% 
FW-MV 
  
ant. 34 11 0 0 76% 24% 0% 0% 
post. 26 9 1 0 72% 25% 3% 0% 
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 Table 3-11 summarizes the sample characteristics of the CTP measures for the surrogate rectum 
artifact region for all six data sets. The mean CTP-diff for all samples sets was within the ±2 mm criteria. 
As determined by the paired t-test the mean CTP-diff for the FSDs MVCT was significantly different than 
the mean CTP-diff for the CTMR kVCT (1.7 mm vs. 0.8 mm, p=0.02). The mean CTP-diff for the FW MVCT 
was not significantly different than the mean CTP-diff for the CTMR kVCT (1.2 mm vs. 0.8 mm, p=0.5). 
This suggests that surrogate rectum organ segmentation performed within the anterior artifact region 
on MVCT data sets acquired of the shielded FSDs and FW applicators is as accurate as organ 
segmentation performed on kVCT data sets of the unshielded CTMR applicator. This will be discussed 
further in subsection 3.3.1.4 
Table 3-11: Summary of surrogate rectum anterior artifact region CTP-diff results by applicator and 
imaging modality 
CTP-diff Results: Surrogate Rectum Anterior Artifact Region 
*distances in mm 
 
 n Mean σ 95% CI Range 
CTMR kV 45 0.8 1.9 0.2-1.3 10.2 
  MV 45 1.8 3.4 0.8-2.8 15.4 
FSDs kV 45 0.5 3.8 -0.6-1.6 16.9 
  MV 45 1.7 2.6 1.0-2.5 11.1 
FW kV 45 0.2 4.6 -1.1-1.6 18.1 
  MV 45 1.2 1.5 0.8-1.7 6.4 
 
For 2D organ segmentation analyses of the surrogate rectum posterior artifact regions fewer 
CTP measurements met the ±2 mm criteria on MVCT data sets than on kVCT data. As reported in Table 
3-10, kVCT data sets of the CTMR, FSDs and FW applicators resulted in 83%, 78% and 81% of points 
meeting the ±2 mm criteria, respectively; on MVCT data sets 67%, 72% and 72% met the ±2 mm criteria, 
respectively. A two-proportion t-test determined that the percentage of CTPs meeting the ±2 mm 
criteria in FSDs MVCT data sets was not significantly different than the percentage of CTPs meeting the 2 
mm criteria in CTMR kV data sets (72% vs. 83%, p=0.1). The percentage of CTPs meeting the 2 mm 
criteria in FW MVCT data sets was also not significantly different than the percentage of CTPs meeting 
 54 
 
the 2 mm criteria in CTMR kV data sets (72% vs. 83%, p=0.1). This suggests that MVCT data sets of the 
shielded FSDs and FW applicators result in organ segmentation as accurate as kVCT data sets of the 
unshielded CTMR applicator in the posterior artifact region but may be trending towards significant 
differences. 
Table 3-12 summarizes the sample characteristics of the CTP measures for the surrogate rectum 
artifact region for all six data sets. The mean CTP-diff for all samples sets was within the ±2 mm criteria. 
As determined by the paired t-test the mean CTP-diff for the FSDs MVCT was not significantly different 
than the mean CTP-diff for the CTMR kVCT (1.3 mm vs. 0.7 mm, p=0.1). The mean CTP-diff for the FW 
MVCT was not significantly different than the mean CTP-diff for the CTMR kVCT (1.0 mm vs. 0.7 mm, 
p=0.9). This suggests that surrogate rectum organ segmentation performed within the posterior artifact 
region on MVCT data sets acquired of the shielded FSDs and FW applicators is as accurate as organ 
segmentation performed on kVCT data sets of the unshielded CTMR applicator. This will be discussed 
further in subsection 3.3.1.4 
Table 3-12: Summary of surrogate rectum posterior artifact region CTP-diff results by applicator and 
imaging modality 
CTP-diff Results: Surrogate Rectum Posterior Artifact Region 
*distances in mm 
 
 n Mean σ 95% CI Range 
CTMR kV 36 0.7 1.6 0.2-1.2 9.5 
  MV 36 1.9 2.6 1.0-2.8 12.8 
FSDs kV 36 0.6 1.8 0.1-1.2 8.6 
  MV 36 1.3 1.9 0.6-1.9 9.2 
FW kV 36 0.3 3.0 -0.7-1.3 16.7 
  MV 36 1.1 2.0 0.4-1.7 8.0 
 
3.3.1.4 CTP Results Discussion 
Data sets imaged with MVCT had higher mean CTP-diff values compared with the same sets 
imaged with kVCT. However, MVCT results within the artifact region for the shielded FSDs and FW 
applicators were consistently comparable to those achieved with the artifact-free CTMR compatible 
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applicator. All t-test results for the anterior rectal region indicate that there is no significant difference 
between CTMR kVCT organ segmentation and FW or FSDs MVCT organ segmentation in this region. This 
is valuable as the anterior rectal area is the region receiving the highest dose due to ICBT (inverse-
square falloff). The option to utilize shielded T&O ICBT applicators without sacrificing the ability to 
accurately segment the rectum is significant. Further studies could explore the ability of MVCT to 
mitigate metal artifact in the regions of the bladder closest to the ovoids.  
Also of significance is the fact that,  while the percentage of CTP-diffs meeting the ±2 mm 
hypothesis criteria decreased when utilizing MVCT (most cases), the percentage of CTP-diffs within ±2 
mm for the shielded applicators was consistently comparable to that of the CTMR MVCT data sets. 
Previous studies have concluded that TomoTherapy’s MVCT scanner is capable of yielding CT data sets 
with sufficient contrast and quality to facilitate segmentation of a number of soft tissues in the absence 
of metal artifact (Ruchala, et al., 1999) (Meeks, et al., 2005) (Korol, et al., 2010). Thus, in conjunction 
with the findings of these studies, the results of this study would indicate that MVCT data sets of the 
FSDs and FW applicators exhibit sufficient artifact reduction to facilitate patient organ segmentation 
when high Z objects are in close proximity (<20 mm). Clinical implementation of this methodology 
deserves further consideration. 
Though statistical testing indicated a significant difference between CTMR kVCT and FW MVCT 
CTP-diff results for the surrogate rectum structure, the mean values and standard deviations differed by 
only 0.3 mm and 0.1 mm, respectively.  These results are well within the mechanical uncertainty of the 
treatment delivery system (±1 mm). A means of determining the practical significance of results rather 
than statistical significance would yield different conclusions in some instances. 
3.3.2 Volume Comparison Results 
Three-dimensional organ segmentation analyses were based off a comparison of participants’ 
TPS reconstructed volume with the control volume measured via water displacement (VOL-diff). As the 
 56 
 
positioning of the surrogate bladder and rectum structures differed from one another as well as 
variations in physical characteristics (shape, wall thickness, etc.), results for bladder and rectum 
structures are analyzed separately. Results for all image sets containing T&O applicators are contained 
in Table 3-13 through Table 3-16.   
3.3.2.1 Volume Comparison: Bladder Results 
The overall organ segmentation results for the bladder structure are found in Table 3-13. Among 
all three applicators, reconstructed volume accuracy decreased on MVCT data sets. A two-proportion t-
test determined that the percent of VOL-diff measures meeting the 15 cc criteria on FSDs MVCT data 
sets was significantly less than the percent of VOL-diff measures meeting the 15 cc criteria on CTMR 
kVCT data sets (22% vs78%, p=0.01). The percent of VOL-diff measures meeting the 15 cc criteria on FW 
MVCT data sets was trending towards significantly less than the percent of VOL-diff measures meeting 
the 15 cc criteria for CTMR kVCT data sets (44% vs. 78%,p=0.07).  
Table 3-13: Organ segmentation results for segmented volumes: absolute volume results for the bladder 
structure. 
VOL-diff Results: Reconstructed Bladder 
    Number that differ by: Percent that differ by: 
    [0-15cc] 
[>15-
20cc] 
[>20-
25cc] [>25cc] [0-15cc] 
[>15-
20cc] 
[>20-
25cc] [>25cc] 
CTMR kV 7 1 0 1 78% 11% 0% 11% 
  MV 3 1 1 4 33% 11% 11% 44% 
FSDs kV 6 2 1 0 67% 22% 11% 0% 
  MV 2 3 2 2 22% 33% 22% 22% 
FW kV 7 2 0 0 78% 22% 0% 0% 
  MV 3 2 3 1 33% 22% 33% 11% 
 
Table 3-14 presents the sample characteristics of the reconstructed surrogate bladder volume 
for all six data sets. Among all the data sets, the mean reconstructed volumes averaged from 8.1 cc to 
20.9 cc from the control surrogate bladder volume. A paired t-test found that mean values of VOL-diff 
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on FSDs MVCT data sets were not significantly more different from control volumes than mean values of 
VOL-diff on CTMR kVCT data sets (18.9 cc vs. 11.1 cc, p=0.002). Mean values of VOL-diff on FW MVCT 
data sets were significantly more different from control volumes than mean values of VOL-diff on CTMR 
kVCT data sets (17.0 cc vs. 11.1 cc, p=0.3). This suggests that participants were able to produce similar 
quality of organ segmentation for FW MVCT and CTMR kVCT data sets where the quality worsened for 
FSDs kVCT data sets. It was also observed the for all MVCT data sets, the 95% confidence interval and 
range both grew, indicating MVCT yields poorer results than kVCT. 
Table 3-14: Volume Comparison bladder results.  
VOL-diff Results: Reconstructed Bladder (*volumes in  cc) 
 
n Mean σ 95% CI Range 
CTMR  kV 9 11.0 9.4 4.5 - 17.5 33.9 
  MV 9 21.6 11.0 14.0 - 29.2 33.3 
FSDs kV 9 9.4 8.7 3.4 - 15.5 25.7 
  MV 9 19.7 13.3 10.5 - 28.9 42.5 
FW kV 9 8.3 6.2 4.0 - 12.6 18.9 
  MV 9 18.0 11.4 10.1 - 25.9 41.0 
 
3.3.2.2 Volume Comparison: Rectum Results 
Overall organ segmentation results for the rectum structures are shown in Table 3-15. The 
percent of VOL-diff measures meeting the 15 cc criteria was 89% for all applicators for both imaging 
modalities. This yields a p-value of 0.5 using a two-proportion t-test. Applying the same two-proportion 
t-test to a ±10 cc criteria shows that the percent of VOL-diff measures meeting the 10 cc criteria on FSDs 
MVCT are not significantly different than the percent of VOL-diff measures meeting the 10 cc criteria on 
CTMR kVCT (67% vs. 78%, p=0.3). The percent of VOL-diff measures meeting the 10 cc criteria on FW 
MVCT are not significantly different than the percent of VOL-diff measures meeting the 10 cc criteria on 
CTMR kVCT, however, they may be trending towards being significantly less accurate than CTMR kVCT 
VOL-diffs (56% vs. 78%, p=0.15).  
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Table 3-15: Organ segmentation results for segmented volumes: absolute volume results for rectum 
structures. 
VOL-diff Results: Reconstructed Rectums 
  Number that differ by: Percent that differ by: 
    [0-15cc] 
[>15-
20cc] 
[>20-
25cc] [>25cc] [0-15cc] 
[>15-
20cc] 
[>20-
25cc] [>25cc] 
CTMR kV 8 0 1 0 89% 0% 11% 0% 
  MV 8 0 1 0 89% 0% 11% 0% 
FSDs kV 7 2 0 0 78% 22% 0% 0% 
  MV 8 1 0 0 89% 11% 0% 0% 
FW kV 8 1 0 0 89% 11% 0% 0% 
  MV 8 0 1 0 89% 0% 11% 0% 
 
Table 3-16 summarizes the sample characteristics for all six sample groups for VOL-diff 
measurements. The average VOL-diff for all sample sets ranged from -6.8 cc to 18.9 cc. A paired t-test 
found that the mean VOL-diff on FSDs MVCT data sets were significantly less than the mean VOL-diff on 
CTMR kVCT data sets (-1.2 cc vs. -6.8 cc, p=0.003). The mean VOL-diff on FW MVCT data sets was not 
significantly different than the mean VOL-diff on CTMR kVCT data sets (-1.3 cc vs. -6.8 cc, p=0.2). 
Removal of an outlier from the FW MVCT data (VOL-diff=21.6 cc) changes the FW MVCT mean VOL-diff 
to -4.1 cc with p=0.3. This suggests that participants were able to segment the rectum structure on FW 
MVCT data sets with similar accuracy as that achieved for CTMR kVCT data sets. It was also observed 
that for the shielded FSDs and FW applicators, MVCT imaging improved the 95% confidence interval 
however the range of participant VOL-diffs increased. 
Table 3-16: Volume Comparison bladder results.  
VOL-diff Results: Reconstructed Rectum (*volumes in cc) 
 
n Mean σ 95% CI Range 
CTMR  kV 9 -6.8 9.0 -13 - -0.6 32.1 
  MV 9 -0.3 10.6 -7.7 - 7.0 35.0 
FSDs kV 9 -8.4 8.7 -14.4 - -2.4 27.6 
  MV 9 -1.9 9.0 -8.2 - 4.3 29.0 
FW kV 9 -8.7 5.8 -12.8 - -4.7 21.1 
  MV 9 -1.3 10.7 -8.7 - 6.2 33.1 
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3.3.2.3 Volume Comparison Discussion 
Overall, the MVCT data sets containing the FSDs and FW applicators lead toward opposing 
conclusions regarding shielded applicators. Although the FSDs applicator shields exhibit less artifact than 
the FW applicator, results indicated participants were actually able to generate more accurate surrogate 
structure organ segmentation for the MVCT data sets containing the FW applicator. The observations of 
this portion of the study are limited to less than ten degrees of freedom, meaning results possibly 
exceed the limitations of the statistical tests utilized in this study. It would be of benefit to repeat this 
volume comparison portion of the study with either a larger number of participants (>20) or more CT 
data sets on which participants could perform organ segmentation. 
In all but the CTMR kV surrogate bladder and rectum data sets, a greater percentage of VOL-
diffs fell within the 15 cc criteria for surrogate rectum segmentation than for surrogate bladder 
segmentation, regardless of imaging energy or type of applicator (c.f Table 3-17). In other words, the 
participant reconstructed rectum volumes were closer to control volumes than participant-
reconstructed bladder volumes, suggesting that the surrogate bladder was more difficult to segment 
than the surrogate rectum structures. This could be due to structure wall shape and thickness: bladder 
walls were thinner in which case they suffered from poorer MVCT imaging contrast. Although the 
bladder and rectum structures varied from one another, it is still worth analyzing, as typical patient 
anatomies vary, resulting in varying responses to different imaging modalities. 
Table 3-17: VOL-diff comparison of bladder and rectum 
VOL-diff Results: Bladder versus Rectum (*volumes in cc)   
    Mean 
 
Max 
 
Min ±15cc Criteria 
    Blad. Rec. Blad. Rec. Blad. Rec. Blad. Rec. 
CTMR  kV 11.3 9.7 32.4 23.9 1.5 1.1 77.8% 88.9% 
  MV 21.6 9.7 37.1 23.5 3.8 2.7 33.3% 88.9% 
FSDs kV 10.0 9.5 23.2 19.6 1.0 3.2 77.8% 77.8% 
  MV 19.7 5.7 44.8 18.4 2.3 0.1 33.3% 88.9% 
FW kV 8.3 10.1 19.7 18.1 0.8 3.0 66.7% 88.9% 
  MV 18.3 8.6 39.8 21.6 1.2 0.3 22.2% 88.9% 
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For all MVCT data sets, the surrogate rectum had smaller mean VOL-diffs and more VOL-diffs 
meeting the 15 cc criteria than the surrogate bladder structures (see Table 3-17). Rectum results suggest 
participants were able to segment this structure with more accuracy than the bladder structure on kVCT 
and MVCT data sets. These surrogate rectum results are consistent with other studies demonstrating 
the viability of TomoTherapy’s MV scanner for organ segmentation (Ruchala, et al., 1999) (Meeks, et al., 
2005). While previous studies have not incorporated shielded HDR tandem and ovoid applicators, they 
have utilized unshielded CT/MR compatible applicators for which MV scans yielded sufficient contrast to 
segment the bladder, rectum and small bowel (Korol, et al., 2010). Results by Wagner et al. also indicate 
that MVCT scans of the shielded Fletcher-Suit-Delclos applicator yield acceptable CT data sets for 3D, 
MVCT-based treatment planning. This suggests that the surrogate rectum structures more closely 
approximated an actual rectum than the surrogate bladder approximated an actual bladder. However, 
additional studies with larger sample sizes would be needed to draw these conclusions. 
Another indication of physical differences between surrogate bladder and rectum structures is 
whether a structure volume was over- or underestimated. The over- and underestimations were 
recorded for both the kV and MV energies (see Table 3-18). These results show for kV image sets that 
the participants tended to overestimate bladder structures (=89%) and to underestimate rectum 
structure (=89%). For MV image sets the majority of participants continued to overestimate the 
surrogate bladder volume (=93%) while the over- and underestimations were more evenly distributed 
for the surrogate rectum structure (41% and 59%). 
Table 3-18: Comparison of over-and underestimations between kV and MV imaging modalities for 
surrogate bladder and rectum structures. 
VOL-diff Results: Over- vs. Underestimation 
    Bladder % of Volumes Rectum % of Volumes 
kV Under 2 7.4% 24 88.9% 
 
Over 25 92.6% 3 11.1% 
MV Under 1 3.7% 16 59.3% 
 
Over 26 96.3% 11 40.7% 
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3.3.3 Catheter Reconstruction Results 
3.3.3.1 Investigator Catheter Reconstruction via Oncentra’s Applicator Modeling Plugin 
A part of this study was to validate the use of Nucletron’s AMp for catheter reconstruction. To 
accomplish this purpose the results of the AMp will be reported with and tested statistically against 
participant’s catheter reconstruction results in the following section. Basic analyses are included in this 
section. 
As shown in Table 3-19, all but three AMp-defined distal dwell positions yielded marker-to-dwell 
differences (MD-diffs) within the ±2 mm hypothesis criteria. The mean deviation from the control values 
for all applicators was 1.0 mm ± 0.7 mm with a maximum deviation of 2.3mm. Of the 36 AMp-defined 
dwell positions, 50% were within ±1 mm of the control values which is within the mechanical tolerance 
of the treatment delivery system (afterloader, applicators, etc.). Of the three points differing by more 
than 2mm from control values, 1 was on kVCT data sets and 2 were on MVCT data sets.  
Table 3-19: Applicator Modeling plugin results for Nucletron’s CT/MR compatible applicator and 
shielded Fletcher-Williamson applicator. Results in green, yellow and red indicate values that are less 
than 1.0 mm from the control values, less than or equal to 2.0 mm from the control value and greater 
than 2.0 mm from the control values, respectively. The “Rectum-#” label refers to the bladder/rectum 
arrangement utilized for the given CT data set. The uncertainty in kV and MV images are ±1.3 mm and 
±1.6 mm, respectively 
Applicator Modeling Plugin: Raw Results 
*distances in mm R. Ovoid L. Ovoid Tandem 
CTMR kV 
Rectum 1 1.1 -0.3 0.7 
Rectum 2 1.4 0.5 0.0 
Rectum 3 1.4 -0.7 -0.1 
CTMR MV 
Rectum 1 -0.1 -1.3 0.0 
Rectum 2 1.3 -0.4 -1.7 
Rectum 3 0.2 -1.6 0.3 
FW kV 
Rectum 1 1.3 0.1 -1.1 
Rectum 2 2.3 -1.0 -1.6 
Rectum 3 1.3 -0.6 -1.0 
FW MV 
Rectum 1 0.9 -2.2 -2.3 
Rectum 2 0.9 -1.2 0.1 
Rectum 3 1.9 -1.4 -1.5 
 62 
 
3.3.3.2 Participant Catheter Reconstruction MD-diff Results 
As shown in Table 3-20, the percentage of MD-diffs that were within the 2 mm criteria for the 
CTMR, FSDs and FW applicator kVCT data sets were 96%, 85% and 52%, respectively. The percentage of 
MD-diffs that were within the 2 mm criteria for MVCT data sets were 93%, 96% and 93%. All CTMR-AMp 
kVCT and MVCT dwells were within the 2 mm criteria whereas the FW-AMp kVCT and MVCT data sets 
resulted in 78% and 83% of dwells being within the 2 mm criteria, respectively. A two-proportion t-test 
showed that the percentage of MD-diffs meeting the 2 mm criteria for FSDs MVCT data sets was not 
significantly different from the percentage of MD-diffs meeting the 2 mm criteria for CTMR kVCT data 
sets (96% vs. 96%, p=0.4). The percentage of MD-diffs meeting the 2 mm criteria for FW MVCT data sets 
was not significantly different from CTMR kVCT data sets (93% vs. 96%, p=0.3). This suggests that, for all 
distal dwell positions of the shielded FSDs and FW applicators, MVCT data sets provide sufficient 
visibility to accurately place distal source dwells within the TPS.  
Table 3-20: MD-diff results for all applicators for all catheter tubes combined. AMp MD-diff results were 
included as an alternate method of catheter reconstruction. 
MD-diff Results: All Catheter Tubes Combined  
    Number of points differing by: Percent of points differing by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 26 1 0 0 96% 4% 0% 0% 
  MV 26 1 0 0 96% 4% 0% 0% 
FSDs kV 23 4 0 0 85% 15% 0% 0% 
  MV 26 1 0 0 96% 4% 0% 0% 
FW kV 14 11 2 0 52% 41% 7% 0% 
  MV 25 2 0 0 93% 7% 0% 0% 
CTMR-
AMp 
kV 9 0 0 0 100% 0% 0% 0% 
MV 9 0 0 0 100% 0% 0% 0% 
FW-
AMp 
kV 8 1 0 0 89% 11% 0% 0% 
MV 7 2 0 0 78% 22% 0% 0% 
Table 3-21 summarizes the sample characteristics of the MD-diff measures for all catheters for 
all six data sets plus four AMp data sets. The mean MD-diff for all image sets was within the 2 mm 
criteria. As determined by an unpaired t-test, the mean MD-diff for the FSDs MVCT data sets was 
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significantly better than the mean MD-diff for the CTMR kVCT data sets (0.5 mm vs. 1.0 mm, p=0.05). 
The mean MD-diff for the FW MVCT was significantly better than the mean MD-diff for the CTMR kVCT 
(-0.3 mm vs. 1.0 mm, p=0.00003). For the CTMR kVCT and MVCT data sets, the mean AMp MD-diffs 
varied significantly for kV and insignificantly for MV from mean participant-generated MD-diffs (kV: 0.4 
mm vs. 1.0 mm, p=0.04; MV: -0.4 mm vs. 0.3 mm, p=0.07). For FW kVCT and MCT data sets, the mean 
AMp MD-diffs varied insignificantly from mean participant-generated MD-diffs (kV: 0.0 mm vs. -1.1 
mm,p=0.24; MV: -1.0 mm vs. -0.3 mm, p=0.6). 
Table 3-21: MD-diff results for all catheter tubes combined.  
MD-diff Results: All Catheter Tubes Combined  
*distances in mm n Mean σ 95% CI Range 
CTMR kV 27 0.9 0.6 0.7-1.2 2.9 
 
MV 27 0.2 0.9 -0.1-0.5 3.4 
FSDs kV 27 0.1 1.4 -0.4-0.7 5.6 
 
MV 27 0.3 1.0 -0.1-0.7 3.8 
FW kV 27 -0.5 2.7 -1.5- 0.5 9.8 
 
MV 27 -0.4 1.3 -0.9-0.1 5.9 
CTMR-AMp kV 9 0.4 0.8 -0.1-1.0 2.1 
 
MV 9 -0.4 1.0 -1-0.3 3 
FW-AMp kV 9 0.0 1.4 -1.0-0.9 3.9 
 
MV 9 -1.0 1.5 -2.0-0.5 4.2 
 
3.3.3.3 Ovoid Catheter Tubes 
As shown in Table 3-22, the percentage of MD-diffs that were within the 2 mm criteria for the 
CTMR, FSDs and FW applicator kVCT data sets were 94%, 83% and 28%, respectively. The percentage of 
MD-diffs that were within the 2 mm criteria for MVCT data sets were 89%, 94% and 94%. All CTMR-AMp 
kVCT and MVCT dwells were within the 2 mm criteria whereas the FW-AMp kVCT and MVCT data sets 
resulted in 83% of dwells being within the 2 mm criteria, respectively. A two-proportion t-test showed 
that the percentage of MD-diffs meeting the 2 mm criteria for FSDs MVCT data sets was not significantly 
different from the percentage of MD-diffs meeting the 2 mm criteria for CTMR kVCT data sets (94% vs. 
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94%, p=0.4). The percentage of MD-diffs meeting the 2 mm criteria for FW MVCT data sets was not 
significantly different from CTMR kVCT data sets (94% vs. 94%, p=0.3).  
Table 3-22: MD-diff results for all applicators for ovoid catheter tubes.  
MD-diff Results: Ovoid Catheter Tubes  
    Number of points differing by: Percent of points differing by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 17 1 0 0 94% 6% 0% 0% 
  MV 17 1 0 0 94% 6% 0% 0% 
FSDs kV 15 3 0 0 83% 17% 0% 0% 
  MV 17 1 0 0 94% 6% 0% 0% 
FW kV 5 11 2 0 28% 61% 11% 0% 
  MV 17 1 0 0 94% 6% 0% 0% 
CTMR-
AMp 
kV 6 0 0 0 100% 0% 0% 0% 
MV 6 0 0 0 100% 0% 0% 0% 
FW-
AMp 
kV 5 1 0 0 83% 17% 0% 0% 
MV 5 1 0 0 83% 17% 0% 0% 
 Table 3-23 summarizes the sample characteristics of the MD-diff measures for ovoid catheters 
for all six data sets plus four AMp data sets. The mean MD-diff for all sample sets was within the 2 mm 
criteria. As determined by an unpaired t-test, the mean MD-diff for the FSDs MVCT was not significantly 
better than the mean MD-diff for the CTMR kVCT (0.7 mm vs. 1.0 mm, p=0.3). The mean MD-diff for the 
FW MVCT was significantly better than the mean MD-diff for the CTMR kVCT (-0.3 mm vs. 1.0 mm, 
p=0.00003). For the CTMR kVCT and MVCT data sets, the mean AMp MD-diffs varied insignificantly from 
mean participant-generated MD-diffs (kV: 0.6 mm vs. 1.0 mm, p=0.2; MV: -0.3 mm vs. 0.4 mm, p=0.2). 
For FW kVCT and MCT data sets, the mean AMp MD-diffs varied insignificantly from mean participant-
generated MD-diffs (kV: -0.6 mm vs. -1.4 mm, p=0.1; MV: -0.3 mm vs. -0.3 mm, p=0.8). This suggests 
that, for distal ovoid dwell positions of the shielded FSDs and FW applicators, MVCT data sets provide 
sufficient visibility to accurately place distal source dwells within the TPS. 
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Table 3-23: MD-diff results for ovoid catheter tubes.  
MD-diff Results: Ovoid Catheter Tubes  
*distances in mm n Mean σ 95% CI Range 
CTMR kV 18 1.0 0.7 0.6-1.3 2.9 
 
MV 18 0.2 1.0 -0.3-0.6 3.4 
FSDs kV 18 0.3 1.3 -0.3-1.0 5.6 
 
MV 18 0.5 0.9 0.1-0.9 3.0 
FW kV 18 -0.6 3.1 -2.0 -0.9 9.8 
 
MV 18 -0.5 1.0 -1.0-0.0 3.9 
CTMR-AMp kV 6 0.6 0.9 -.2-1.3 2.1 
 
MV 6 -0.3 1.1 -1.2-0.6 3 
FW-AMp kV 6 0.6 1.3 -0.6-1.7 3.3 
 
MV 6 -0.2 1.6 -1.6-1.2 4.1 
 
3.3.3.4 Tandem Catheter Tubes 
As shown in Table 3-24, the percentages of MD-diffs that were within the 2 mm criteria for the 
CTMR, FSDs and FW applicator kVCT data sets were 100%, 78% and 100%, respectively. The percentage 
of MD-diffs that were within the 2 mm criteria for MVCT data sets were 100%, 100% and 89%. All AMp-
defined dwells were within the 2 mm criteria except for the FW MVCT which had 67% of dwells within 
the 2 mm criteria. A two-proportion t-test showed that the percentage of MD-diffs meeting the 2 mm 
criteria for FSDs MVCT data sets was not significantly different from the percentage of MD-diffs meeting 
the 2 mm criteria for CTMR kVCT data sets (94% vs. 94%, p=0.4). The percentage of MD-diffs meeting 
the 2 mm criteria for FW MVCT data sets was not significantly different from CTMR kVCT data sets (94% 
vs. 94%, p=0.3).  
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Table 3-24: MD-diff results for tandem catheter tubes. Applicator modeling plugin results were included 
as an alternate method of catheter reconstruction. 
Catheter Reconstruction Results: Tandem Catheter Tubes  
    Number of points differing by: Percent of points differing by: 
    
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
[0-
2mm] 
[>2-
5mm] 
[>5-
10mm] 
[>10-
15mm] 
CTMR kV 9 0 0 0 100% 0% 0% 0% 
  MV 9 0 0 0 100% 0% 0% 0% 
FSDs kV 8 1 0 0 89% 11% 0% 0% 
  MV 9 0 0 0 100% 0% 0% 0% 
FW kV 9 0 0 0 100% 0% 0% 0% 
  MV 8 1 0 0 89% 11% 0% 0% 
CTMR-
AMp 
kV 3 0 0 0 100% 0% 0% 0% 
MV 3 0 0 0 100% 0% 0% 0% 
FW-
AMp 
kV 3 0 0 0 100% 0% 0% 0% 
MV 2 1 0 0 67% 33% 0% 0% 
 Table 3-25 summarizes the sample characteristics of the MD-diff measures for tandem catheters 
for all six data sets plus four AMp data sets. The mean MD-diff for all sample sets was within the 2 mm 
criteria. As determined by an unpaired t-test, the mean MD-diff for the FSDs MVCT was not significantly 
better than the mean MD-diff for the CTMR kVCT (0.1 mm vs. 0.9 mm, p=0.08). The mean MD-diff for 
the FW MVCT was not significantly different than the mean MD-diff for the CTMR kVCT (-0.2 mm vs. -0.9 
mm, p=0.1). No statistical tests were applied to AMp-defined tandem catheter dwells as the sample size 
was too small. This suggests that, for distal tandem dwell positions of the shielded FSDs and FW 
applicators, MVCT data sets provide sufficient visibility to accurately place distal source dwells within 
the TPS. 
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Table 3-25: MD-diff results for tandem catheter tubes. 
MD-diff Results: Tandem Catheter Tubes  
*distances in mm n Mean σ 95% CI Range 
CTMR kV 9 0.9 0.4 0.7-1.2 1.1 
 
MV 9 0.3 0.6 -0.1-0.7 2.0 
FSDs kV 9 -0.3 1.7 -1.4-0.9 4.5 
 
MV 9 0.1 1.3 0.8-1.0 3.4 
FW kV 9 -0.4 1.7 -1.5-0.8 4.4 
 
MV 9 -0.2 1.9 -1.5-1.1 5.9 
CTMR-AMp kV 3 0.2 0.9 -0.4-0.8 0.8 
 
MV 3 -0.5 1.1 -2.0-1.0 2 
FW-AMp kV 3 -1.2 1.3 -1.7- -0.8 0.6 
 
MV 3 -1.2 1.6 -2.9-0.5 2.4 
3.3.3.5 Catheter Reconstruction Results Discussion 
A summary of catheter reconstruction results is given in Table 3-26. For all MVCT data sets, 
participant-defined MD-diff results either remained the same as or improved upon kVCT results, with 
the exception of one outlier for the FW MVCT tandem distal dwell location (=-2.3). Utilization of CT/MR 
compatible applicators with kVCT imaging is current clinical practice at many institutions. This suggests 
that MVCT imaging of shielded applicators could possibly be implemented as clinical practice with no 
reduction in quality compared to CT/MR compatible applicators with kVCT.. 
Table 3-26: Summary of MD-diff results for all catheter tubes, tandem tubes and ovoid tubes. 
Summary of MD-diff Measures Meeting ±2 mm 
Criteria 
    All Tandem Ovoids 
CTMR kV 96% 100% 94% 
  MV 93% 100% 89% 
FSDs kV 85% 89% 83% 
  MV 96% 100% 94% 
FW kV 52% 100% 28% 
  MV 93% 89% 94% 
CTMR-AMp kV 100% 100% 100% 
  MV 100% 100% 100% 
FW-AMp kV 89% 100% 83% 
  MV 78% 67% 83% 
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Table 3-26 shows the advantage of MVCT when utilizing shielded T&O applicators. Both shielded 
T&O applicators saw an improvement in terms of the number of MD-diff measures within 2 mm. Most 
noticeable is the improvement within the ovoid region where 28% of MD-diff measures on kVCT were 
within 2 mm of the control, which improved to 94% of MD-diff measures on MVCT being within 2 mm, a 
change of +66%. 
Though no clinics are currently utilizing the AMp to facilitate catheter reconstruction for shielded 
applicators, these results indicate that further consideration should be given for clinical implementation 
of the AMp. It appears from these results that a combination of the AMp with MV imaging would allow 
for accurate catheter reconstruction of the distal dwell location. Limitations of these results include 
small sample sizes and only one participant performing organ segmentation. 
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Chapter 4  Conclusions 
4.1 Summary of Results 
This study demonstrated that MVCT is a feasible alternative for acquiring clinically viable CT data 
sets of shielded T&O-type applicators, specifically Nucletron’s tungsten-shielded Fletcher-Williamson 
applicator and Varian’s stainless steel-shielded Fletcher-Suit-Delclos-style applicator. Results indicate 
that MVCT data sets acquired of the shielded FSDs and FW T&O applicators consistently display 
sufficient image quality to allow for accurate organ segmentation. The ability to accurately segment 
OARs in the artifact region is critical for correct DVH analysis, providing the best opportunity for early 
and late sequelae prevention. Catheter reconstruction quality for MVCT data sets of the shielded FSDs 
and FW applicators was comparable to the catheter reconstruction performed for kVCT data sets of the 
unshielded, artifact-free CTMR applicator. Overall, TomoTherapy’s Hi Art II MVCT scanner yielded image 
sets displaying sufficient image quality to facilitate accurate and acceptable organ segmentation and 
catheter reconstruction. Utilization of Nucletron’s AMp yielded catheter reconstruction quality 
comparable to that achieved by participants for kVCT and MVCT data sets. 
4.2 Response to Hypothesis 
In response to the hypothesis, neither kVCT nor MVCT yielded image sets of sufficient quality for 
all physicists to meet the hypothesis metrics for the criterion used in this study. While the criterion may 
not be realistic for day-to-day clinical standards, they did provide a sufficient metric to compare kVCT 
imaging of the CTMR applicator with MVCT imaging of the FW and FSDs applicators. MVCT imaging of 
shielded FW and FSDs applicators was sufficiently comparably to the current, clinical standard that 
further consideration need be given to include MVCT as proper procedure for the imaging of cervical 
cancer patients treated using shielded tandem and ovoid applicators. 
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4.3 Future Work 
For both 2D and 3D organ segmentation methods, the bladder consistently had fewer CTP-diffs 
and reconstructed volumes meeting the hypothesis criteria. A new method of developing surrogate 
bladder structures should be explored to allow consistency of results throughout the experiment.. This 
could be done by first making a rigid structure around which the bladder could mold rather than around 
an inflated balloon which is prone to stretching the hot aquaplast. Another possible solution could be to 
purchase or develop a rigid pelvic phantom designed specifically for the T&O applicators being explored, 
possibly utilizing technology offered commercially. 
A number of parameters in this study, such as slice thickness, could be better controlled to 
mitigate errors arising from differences in kV and MV image acquisition. Though the SFOV would not 
physically change much, it could potentially reduce any bias towards either kVCT or MVCT imaging. Also, 
matched slice thicknesses would potentially reduce TPS volume reconstruction errors due to 
interpolating over larger volumes on MVCT data sets than kVCT data sets. 
Regarding catheter reconstruction, the method used in this study was only capable of validating 
the most distal dwell position of each applicator tube. Another strategy could be investigated, allowing 
for the accuracy of all dwell locations to be validated. A possible idea would be to rigidly attach two 
fiducial markers in line with each other and in the same sagittal plane as the catheter tube dwell 
positions. This would facilitate distance and angle measures between the fiducial markers and each of 
the catheter’s dwell locations. The clinical commissioning procedure would, in theory, work for 
determining control values for a study of this nature. 
The use of Nucletron’s AMp for catheter reconstruction in this study approached the accuracy of 
the participant-defined catheter reconstruction. This catheter reconstruction was solely performed by 
the investigator. To validate the AMp for clinical use, the next step should be to increase the sample size 
as well as the number of medical physicists participating in the study.  
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Appendix A: Surrogate Structures-Contrast Agent vs. Aquaplast 
The use of contrast agent was explored as an aid in organ segmentation for MVCT scans. ICRU 
report 38 specifies the use of a bladder Foley catheter filled with 7 ml of contrast to aid in the 
localization of ICRU-defined bladder point. The percentage of actual contrast to saline is up to individual 
clinics to decide what suits them best. At MBPCC, a 7% solution of Omnipaque 300 mgI/ml mixed with a 
normal saline is typically used. This was tested with the MVCT scanner and determined 
undistinguishable when compared with surrounding water for most center and width values. The 
amount of contrast was increased to 10%. Visual inspection of the 10% contrast scans yielded what were 
thought to be acceptable results however a comparison of contours generated from the kVCT and MVCT 
scans for the CTMR applicator (no artifact present) showed that the MVCT structure had a volume 15.1% 
smaller than that of the kVCT. It was concluded that 10% contrast also provided insufficient contrast. 
Higher contrast amounts were explored however it was observed that, as contrast levels increased, 
streaking artifacts were introduced into the kVCT scans due to the high effective atomic number of 
iodinated contrast (54). At a 50% contrast agent to saline mixture, the rectum structure contrast was 
acceptable on MVCT scans and also lacked streaking artifact making this a desirable setup if one is solely 
using MVCT. Due to the streaking artifact issues along with the bladder and rectum structure rigidity 
issues, an alternative was sought to deformed condoms filled with contrast agent and thus, aquaplast 
became the material of choice. It is still possible that clinically acceptable results may be achieved with 
the use of a high percentage contrast to saline mixture however accurate comparisons between kVCT 
and MVCT are not feasible due to streaking artifact. Meeks et al determined that MVCT provides 
sufficient contrast to contour the bladder and rectum therefore it would be feasible to conduct a future 
experiment using high percentages of contrast agent in a Foley balloon catheter for MVCT treatment 
planning scans. (Meeks, et al., 2005) 
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The use of air, a negative contrast agent, was also explored. A positive contrast agent has a 
higher attenuation coefficient than surround materials whereas a negative contrast agent as a lower 
attenuation coefficient than surrounding tissues. Iodinated contrast is an example of a positive contrast 
agent and air is an example of a negative contrast agent. Negative contrast agents can be used 
effectively on kVCT and MVCT scans. Korol et al. used air as a Foley catheter contrast agent for MVCT 
treatment planning scans of cervical cancer patients with bilateral hip prostheses treated with a Varian 
CT/MR compatible tandem and ovoid applicator. (Korol, et al., 2010)  Air is also commonly used in GI 
radiographs for procedures such as Barium-air enemas. Reconstruction algorithms can compensate for 
air heterogeneities resulting in no artifact from contrast agents. I observed that for both kVCT and 
MVCT, distinguishing between air and soft tissue is a trivial matter. Several drawbacks prevented the use 
of air. First, is that a Foley catheter is no longer used to calculate dose to the ICRU-defined bladder 
point; rather, dose is calculated to the hottest 2CC of bladder tissue using DVH analysis. Second, there 
are no current, clinical methods for filling the bladder and rectum organs with air so it is clinically 
irrelevant. Third, it has already been shown that MVCT scans provide sufficient contrast to delineate the 
bladder, rectum and sigmoid colon in the absence of metal artifact. (Meeks, et al., 2005) This means that 
if MVCT can reduce the shielded T&O applicator induced metal artifact, then there is the possibility that 
adequate contrast will be present in the CT scan to segment the bladder, rectum and sigmoid colon.  
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Appendix B: Participation Instructions 
Purpose of research: 
The purpose of this research is to compare the quality of organ segmentation and catheter 
reconstruction for HDR cervical brachytherapy administered using 3 different tandem and ovoid (T&O) 
applicators: Nucletron’s shielded CT/MR compatible, Nucletron’s shielded Fletcher-Williamson, and 
Varian’s shielded Fletcher-Suit-Delclos-style. The quality of plans will be determined by organ 
segmentation and catheter reconstruction accuracy. A water phantom, containing only a bladder 
surrogate, a rectum surrogate and HDR T&O applicator is used to facilitate these measurements. KVCT 
and MVCT imaging modalities have been used to acquire the image sets you will use for treatment 
planning.   
 
Participant’s Responsibility: 
For the 7 image sets, you are asked to segment the bladder and rectum structures in the pelvic water 
phantom. To minimize confusion there are only four constituents to the phantom: a bladder surrogate, a 
rectum surrogate, water and one of 3 HDR T&O applicators. The bladder is the anterior structure; the 
rectum is the posterior structure. You will see fiducial markers on the bladder and rectum surrogates. 
Any time these markers appear, do your best to ignore them.  
You are also asked to perform catheter reconstruction for the tandem and ovoids in image sets where 
an applicator is visible.  
Several guidelines are given for TPS setup, Organ Segmentation, and Catheter reconstruction. Please 
follow the specified guidelines. For all other TPS settings, follow your clinical protocol.  
*Please provide a copy of your clinical protocol for HDR cervical brachytherapy. 
Order of Events: 
1. For the image sets, follow the numerical order for organ segmentation and catheter 
reconstruction. DO NOT VIEW THE NEXT IMAGE SET UNTIL ORGAN SEGMENTATION AND 
CATHETER RECONSTRUCTION IS COMPLETE. Doing so could compromise the integrity of your 
results. 
 
2. While performing organ segmentation and catheter reconstruction, fill out the corresponding 
image set instructions/information sheet. 
 
3. Once completed, export the image sets with the plan and structure information. Please place 
the image sets in folders with the same number but add the label completed. For example, you 
receive a folder labeled: 1. When you are finished, you create a new folder labeled: 1-
completed. 
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Oncentra Masterplan Settings: 
1. Change Image Smoothing to Lanczos window: 
 
Tools menu  Options  General  Image Smoothing 
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2. Verify ROI voxel size is 2 mm 
 
ROI menu  Manage ROI Catalog…  ROI Catalog (choose ROI name i.e. Bladder)  
edit  deselect Automatic Voxel Size (if already selected)  Change voxel size to 2 mm 
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Organ Segmentation Instructions: 
 
 
1. This is an example of what you will see-yellow is the bladder, green is the rectum.  
 
a. Segment to the outer edge of the tissue wall 
 
b. Ignore fiducial markers. They lie directly on the surface of the structures so assume the 
tissue continues directly inside the markers. 
 
c. When image artifact is present, do the best guesswork you can.  
 
d. Record Window/Level presets or values that were used 
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Because you are contouring a phantom, you need to be aware of two things: 
1. The bladder immobilization arm can inhibit segmentation. In the image series below you can see 
where it begins to come off the bladder. Slice numbers will be given were this approximation 
should be made (see the instructions for each image set). Using your best approximation, follow 
the example in the images below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Unlike a true rectum, the surrogate rectums have defined start and end points. An example of a 
starting point is shown below. Please contour all parts of the rectum visible in each CT slice.  
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Catheter Reconstruction: 
If source position markers are visible, plan off those. Source position markers will not be visible for the 
shielded T&O applicators in which case you are expected to follow your current, clinical protocol for 
catheter reconstruction of shielded T&O applicators (e.g. at Mary Bird Perkins Cancer Center and MD 
Anderson, the first dwell position is chosen by placing the center of the source in the center of the tube 7 
mm from the ovoid tip) 
 
Within Oncentra, please use the following settings 
for catheter reconstruction: 
1. Under preferences, choose “No Sequencing” 
2. Under Catheters, choose 3 for the number of 
catheters 
3. Under Applicator Properties, choose: 
a. 5.0 mm source step 
b. Start at Tip End 
 
 
 
 
 
 
 
 
 
 
*Also, be aware when performing catheter 
reconstruction for the applicator(s) with source 
position markers visible that a fiducial marker has 
been placed on the tandem and it should not be 
confused with the source position markers for 
catheter reconstruction. See image below. 
 
 
 
Fiducial Marker 
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Export Instructions (for those at institutions other than Mary Bird Perkins): 
After performing organ segmentation and catheter reconstruction, you will need to export your plan 
information.  
1. Be sure to save the current plan (under File tab). 
 
2. Click the Export tab: 
 
 
 
 
 
 
 
 
 
 
3. This will then give you the option of what you want to export. At this point, you just need to 
choose the “RT Plan”. This will contain all the organ segmentation and catheter reconstruction 
information. 
 
 
4. Next, click export on the bottom of the window. 
 
5. Now, you will want to go to the location listed in the “Directory” spot above. In this case it is: 
D:\OTP_DATA\DICOM\ExportTemp\. From here, you can just copy all the files into a folder and 
label it in the style mentioned above (i.e. image set 1 is labeled 1-Completed).  
 
6. Lastly, organize all of your image sets, zip them (conserve space and save time), and upload 
them to the amazon cloud server.  
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Appendix C: Participant’s Raw Results 
The results for the participants of this study are reported in following subsections. An analysis 
and discussion of these results is given in Section 3.3.1. For all raw results, values highlighted in red 
differed by more than the hypothesized metric values. In the case of two-dimensional organ 
segmentation analysis, values highlighted in yellow signify values that met the hypothesis metric of ±2 
mm but differed by more than 1 mm from the control value. For catheter reconstruction accuracy, 
values highlighted in yellow signify value that met the hypothesis metric of ±2  mm however were 
outside the mechanical tolerance of the treatment delivery system (±1 mm).  
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Table C-1: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values  
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 sup 10.7 10.1 13.4 19.1 19.7 20.9 23.6 24 17.9 0.9 1 0.5 1.2 0.1 0.4 0.7 0.2 1.3 
 
mid 30.6 26.6 18.9 16.6 21.4 22.9 16.1 16.3 22.9 1.8 2.7 0.4 1.9 0.6 1.1 0.1 2 1.5 
 
inf 18.3 18.4 16.7 16.5 15.3 17.1 16.8 17.9 18.1 0 0.7 0.6 0.2 0.9 1.6 0.7 0.1 0.1 
CTMR MV 3 sup 13.6 13.1 12.8 14.1 19.3 25 26.9 19.6 16.2 0.8 1 0.4 0.3 0.5 0.6 2.2 1 0.5 
 
mid 13.1 21 24.3 16.3 17.4 17.5 17.6 14.8 12.5 0.4 0.2 0.7 4.8 6.8 2.1 0.8 1.3 0.1 
 
inf 16.6 16.1 16.5 17.4 20.6 20.5 19.9 21.2 20.3 0.8 1.1 0.4 0.7 0.2 1.1 1.4 0.4 0.8 
FW kV 3 sup 14.1 13 12.7 15 21.4 24.8 25.8 19.6 16.5 1.3 0.9 0.3 0.6 1.6 0.4 1.1 1 0.2 
 
mid 13.3 18.8 21.2 18.6 15.4 15.9 17.5 14.8 12.1 0.6 2.4 2.4 7.1 4.8 0.5 0.9 1.3 0.3 
 
inf 16.6 15.4 16.2 17.2 20.7 20.7 18.6 20.3 19.8 0.8 0.4 0.1 0.5 0.3 1.3 0.1 0.5 0.3 
FW MV 1 sup 18.2 13.8 14.5 15.8 23.2 17.6 15.1 13.3 18.2 2.3 0.2 1.3 0 3.3 1.5 0.6 2.3 1.7 
 
mid 11.5 16.9 23.9 17.9 16.4 16.8 19.3 18.9 15.1 4.3 2 0.1 1.7 2.1 2 0.9 3.5 5.4 
 
inf 23.5 13 14 19.1 14.3 14.1 19.3 23.2 26 3.2 1 1.6 1.9 1.2 1.5 0.5 1.1 0.3 
FSDs kV 1 sup 15.5 13.1 12.6 15.5 20.4 16.9 17.6 15.5 17.1 0.4 0.5 0.6 0.3 0.5 0.8 1.9 0.1 0.6 
 
mid 13.7 18.9 18.3 17.1 15.2 16.8 19.9 15.9 15.3 6.5 4 5.7 0.9 0.9 2 1.5 0.5 5.6 
 
inf 21.2 12.5 13.3 16.7 13.8 12.8 17.9 22.7 25.7 0.9 0.5 0.9 0.5 0.7 0.2 0.9 1.6 0 
FSDs MV 2 sup 11.5 10.7 14.6 19.1 21.2 21.8 23.4 24.1 16.3 1.7 1.6 1.7 1.2 1.6 0.5 0.5 0.3 0.3 
  mid 28.5 24.1 18.4 18.6 21.5 21.6 17.5 15.9 21.2 0.3 0.2 0.1 0.1 0.5 0.2 1.3 1.6 0.2 
  inf 17.4 19.4 16.5 16.5 15.5 17.8 18.1 19.2 18.2 0.9 0.3 0.4 0.2 1.1 2.3 2 1.4 0 
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Table C-2: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values 
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 rlat 15.2 17.9 19.1 20.6 19.1 18.2 24 21.7 15.8 0.9 0.6 0.5 4.4 3.1 1.3 0.3 0.8 0.4 
 
mid 29.2 32.6 37.2 28.2 24.9 24.8 26.7 32.1 33 1.8 2.8 1.5 0.4 0.3 0.3 0.9 0.9 0.8 
 
llat 16 13.8 14.6 18.5 19.3 18.4 18.6 15.5 15.4 0.4 0.1 1.3 0.6 1.2 2.3 2.8 0.1 1.7 
CTMR MV 3 rlat 16.4 19.5 19.9 19.7 19.4 21.2 25.9 22.3 15.1 2.1 1 0.3 3.5 3.4 4.3 1.6 0.2 0.3 
 
mid 31.9 35.3 38.4 27.9 25.1 24 28.7 32.4 35.6 4.5 5.5 0.3 0.7 0.1 0.5 1.1 0.6 1.8 
 
llat 17.1 13.7 13.6 18.3 20.3 19.1 19.1 18.1 15.7 0.7 0 0.3 0.4 2.2 3 3.3 2.5 2 
FW kV 3 rlat 14.8 18.4 17.7 17.9 17.9 20.5 24.1 19.8 15.5 0.5 0.1 1.9 1.7 1.9 3.6 0.2 2.7 0.1 
 
mid 28.3 32.1 38.9 28 25.4 24.1 26.2 31.8 35.3 0.9 2.3 0.2 0.6 0.2 0.4 1.4 1.2 1.5 
 
llat 16.8 14.3 14.6 18 18.5 17 17.7 17.1 15.1 0.4 0.6 1.3 0.1 0.4 0.9 1.9 1.5 1.4 
FW MV 1 rlat 17.3 17 19.7 20.5 19.7 17.6 21.4 21.1 17.1 3 1.5 0.1 4.3 3.7 0.7 2.9 1.4 1.7 
 
mid 28.1 32.2 39.6 30.1 26.9 25.1 26.7 31.1 36.5 0.7 2.4 0.9 1.5 1.7 0.6 0.9 1.9 2.7 
 
llat 16.1 14 14.7 14.9 18.4 19.4 18.3 14.1 14.8 0.3 0.3 1.4 3 0.3 3.3 2.5 1.5 1.1 
FSDs kV 1 rlat 16 19.6 20.1 19.3 16 18.6 21.9 21.7 15.5 1.7 1.1 0.5 3.1 0 1.7 2.4 0.8 0.1 
 
mid 29 32.6 38.5 29.2 24.9 22.3 27.1 32.5 33.9 1.6 2.8 0.2 0.6 0.3 2.2 0.5 0.5 0.1 
 
llat 16.4 14.5 13.7 18.1 18.4 17.4 17.2 15.5 15.4 0 0.8 0.4 0.2 0.3 1.3 1.4 0.1 1.7 
FSDs MV 2 rlat 17.3 17.3 20.6 20 19.4 18.1 22.4 21.7 15.7 3 1.2 1 3.8 3.4 1.2 1.9 0.8 0.3 
 
mid 28.9 31.9 39.2 28.8 24.5 22.3 28.7 27.8 33.6 1.5 2.1 0.5 0.2 0.7 2.2 1.1 5.2 0.2 
  llat 16.5 13.4 14.7 18.4 18 16.4 18.5 15.9 15.7 0.1 0.3 1.4 0.5 0.1 0.3 2.7 0.3 2 
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Table C-3: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
 
 
 
 
 
 
 
 
 
 
 
Table C-4: Results from catheter reconstruction for the procedurally defined, distal-most dwell position. 
“Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 2 R. Ovoid -13.5 24.3 -90.4 -11.8 9.5 -73.6 22.5 1.0 
  L. Ovoid 12.7 23.3 -90.4 12.9 10.0 -77.2 18.7 2.0 
  Tandem -0.5 72.5 -71.2 1.1 51.0 -74.9 21.9 1.2 
CTMR MV 3 R. Ovoid -13.3 29.6 -96.8 -12.8 10.9 -81.2 24.4 0.9 
  L. Ovoid 12.6 29.6 -95.1 12.1 12.5 -82.0 21.5 0.8 
  Tandem -3.7 75.8 -72.2 -1.5 53.6 -77.1 22.8 0.2 
FSDs kV 1 R. Ovoid -17.6 26.0 -78.6 -14.7 5.1 -65.3 24.9 0.2 
  L. Ovoid 11.7 24.9 -79.5 11.1 6.1 -66.6 22.8 1.6 
  Tandem 0.0 85.3 -47.5 -1.7 64.9 -52.2 21.0 2.7 
FSDs MV 2 R. Ovoid -15.4 22.9 -101.9 -13.4 3.0 -86.9 25.0 0.1 
  L. Ovoid 13.4 23.6 -101.5 12.9 4.2 -87.1 24.2 0.3 
  Tandem 0.2 84.3 -73.6 -1.3 62.9 -78.4 22.0 1.7 
FW kV 3 R. Ovoid -9.4 30.1 -85.6 -12.2 9.4 -69.4 26.4 4.8 
  L. Ovoid 10.0 30.9 -84.9 13.7 10.2 -69.2 26.2 4.4 
  Tandem 1.2 88.9 -52.3 0.4 66.0 -56.0 23.2 0.4 
FW MV 1 R. Ovoid -13.9 21.0 -93.4 -12.9 2.3 -82.1 21.9 0.2 
  L. Ovoid 14.3 21.4 -94.5 12.8 1.7 -82.4 23.2 1.3 
  Tandem -0.4 74.0 -76.4 -1.0 49.3 -78.7 24.8 1.2 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 2 271.4 24.4 124.3 1.1 
CTMR MV 3 290.5 43.5 172.9 11.4 
FSDs kV 1 271.2 24.2 153.1 7.3 
FSDs MV 2 278.6 31.6 123.2 2.2 
FW kV 3 273.2 26.2 166.3 18.1 
FW MV 1 283.8 36.8 160.6 0.3 
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Table C-5: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values  
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 sup 9.5 9.1 12.1 17.3 20.5 22.3 22.6 23.4 15.6 0.3 0 0.8 0.6 0.9 1 0.3 0.4 1 
 
mid 30.1 24.4 16.9 16 20.4 20.4 14.5 14.7 20.7 1.3 0.5 1.6 2.5 1.6 1.4 1.7 0.4 0.7 
 
inf 18.6 19.5 16.7 16.2 16.7 17.5 17.5 18.5 17.1 0.3 0.4 0.6 0.5 2.3 2 1.4 0.7 1.1 
CTMR MV 3 sup 13.6 13.6 13.4 15 20.5 26.1 27.4 20.3 18.6 0.8 1.5 1 0.6 0.7 1.7 2.7 1.7 1.9 
 
mid 10.6 21 23.8 13.7 16.1 18.1 19.1 18.1 14.8 2.1 0.2 0.2 2.2 5.5 2.7 0.7 2 2.4 
 
inf 16.7 16.5 17.7 18.9 21.8 20.2 20.7 20.5 19.1 0.9 1.5 1.6 2.2 1.4 0.8 2.2 0.3 0.4 
FW kV 3 sup 14.1 12.9 13.1 15 20.6 26.2 25.3 19.9 15.9 1.3 0.8 0.7 0.6 0.8 1.8 0.6 1.3 0.8 
 
mid 12.6 17.6 24.8 18.1 14.4 12.8 13.9 16.1 12.3 0.1 3.6 1.2 6.6 3.8 2.6 4.5 0 0.1 
 
inf 16.9 15.5 16.7 18 21.5 20.7 19.6 21.7 21 1.1 0.5 0.6 1.3 1.1 1.3 1.1 0.9 1.5 
FW MV 1 sup 15.3 15.8 15.1 16.7 19.7 18.2 15 13.1 17.5 0.6 2.2 1.9 0.9 0.2 2.1 0.7 2.5 1 
 
mid 10.9 14.2 23.5 17.3 16.2 17.3 19.9 18.8 14.1 3.7 0.7 0.5 1.1 1.9 2.5 1.5 3.4 4.4 
 
inf 22.2 13.4 13.3 19.8 13.8 14 18.2 21.5 23.6 1.9 1.4 0.9 2.6 0.7 1.4 0.6 2.8 2.1 
FSDs kV 1 sup 14.9 13.4 14 15.8 22.1 18.5 10.9 9.6 13.8 1 0.2 0.8 0 2.2 2.4 4.8 6 2.7 
 
mid 11 17.8 22 17.8 15.1 16.3 21.4 15.4 12.1 3.8 2.9 2 1.6 0.8 1.5 3 0 2.4 
 
inf 21.2 13.2 13.7 17.9 13.3 13.7 19 22.2 26.5 0.9 1.2 1.3 0.7 0.2 1.1 0.2 2.1 0.8 
FSDs MV 2 sup 9.6 9.2 13.4 16.8 20.5 20.7 23.2 23.9 16.2 0.2 0.1 0.5 1.1 0.9 0.6 0.3 0.1 0.4 
  mid 30 23.5 20.1 20.2 21.1 23.4 15.3 14.1 20.5 1.2 0.4 1.6 1.7 0.9 1.6 0.9 0.2 0.9 
  inf 18.8 18.3 15.4 15.8 16.6 18.8 19.1 18.6 19.1 0.5 0.8 0.7 0.9 2.2 3.3 3 0.8 0.9 
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Table C-6: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
 
 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values 
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 rlat 14.5 17.1 18.7 20.1 19.3 18.9 22.7 20.3 14.7 0.2 1.4 0.9 3.9 3.3 2 1.6 2.2 0.7 
 
mid 29.5 32.1 37.4 28.3 24.6 23.8 26.3 31.7 33.6 2.1 2.3 1.3 0.3 0.6 0.7 1.3 1.3 0.2 
 
llat 16.8 15.2 13.6 19.7 19.6 18.7 18.9 16.4 14.5 0.4 1.5 0.3 1.8 1.5 2.6 3.1 0.8 0.8 
CTMR MV 3 rlat 16.3 17 16.7 19.5 21.4 20.2 23.1 23.7 15.1 2 1.5 2.9 3.3 5.4 3.3 1.2 1.2 0.3 
 
mid 33.2 34.2 38.8 28.6 24.8 22.4 28.2 30.9 34.8 5.8 4.4 0.1 0 0.4 2.1 0.6 2.1 1 
 
llat 16.8 13.4 13.6 18.2 19.8 18.9 17.9 17.6 17.3 0.4 0.3 0.3 0.3 1.7 2.8 2.1 2 3.6 
FW kV 3 rlat 14.4 18.2 18.8 19.4 17.7 22.8 17.7 17.1 15.5 0.1 0.3 0.8 3.2 1.7 5.9 6.6 5.4 0.1 
 
mid 30 33.3 37.8 28.1 24.6 22.1 26.3 33 30.6 2.6 3.5 0.9 0.5 0.6 2.4 1.3 0 3.2 
 
llat 17.2 14.1 14.3 19.6 18.5 16.8 17.5 16.7 17.1 0.8 0.4 1 1.7 0.4 0.7 1.7 1.1 3.4 
FW MV 1 rlat 16 16.3 20.9 21 19.5 27.4 24.5 19.1 14.5 1.7 2.2 1.3 4.8 3.5 10.5 0.2 3.4 0.9 
 
mid 30.6 33.7 38 28.3 24.6 22.6 28.4 29.1 33.5 3.2 3.9 0.7 0.3 0.6 1.9 0.8 3.9 0.3 
 
llat 16.8 15.5 15.3 19.7 19.6 18.2 18.6 16.2 14.7 0.4 1.8 2 1.8 1.5 2.1 2.8 0.6 1 
FSDs kV 1 rlat 15.2 19 19.4 18.2 18.2 20.9 22.9 21 16.2 0.9 0.5 0.2 2 2.2 4 1.4 1.5 0.8 
 
mid 30 32.2 38.6 28.2 24.1 23.1 27 32 35 2.6 2.4 0.1 0.4 1.1 1.4 0.6 1 1.2 
 
llat 16.6 14 13.7 19.2 18.3 17.7 17.8 16.2 15 0.2 0.3 0.4 1.3 0.2 1.6 2 0.6 1.3 
FSDs MV 2 rlat 14.3 18 17.7 19.8 18.8 20.2 23.6 21.2 16.5 0 0.5 1.9 3.6 2.8 3.3 0.7 1.3 1.1 
 
mid 31.4 35.4 39.4 29.9 26 22.2 27.5 32.6 33.1 4 5.6 0.7 1.3 0.8 2.3 0.1 0.4 0.7 
 
llat 16.6 14.1 15.6 17.6 17.5 17.5 18.9 16.2 19.3 0.2 0.4 2.3 0.3 0.6 1.4 3.1 0.6 5.6 
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Table C-7: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 2 273.2 26.2 116.2 9.1 
CTMR MV 3 290.5 43.5 176.7 7.7 
FSDs kV 1 278.4 31.4 152.3 8.1 
FSDs MV 2 283.7 36.7 125.2 0.1 
FW kV 3 268.6 21.6 170.6 13.8 
FW MV 1 281.6 34.6 153.9 6.5 
 
Table C-8: Results from catheter reconstruction for the procedurally defined, distal-most dwell position. 
“Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results       
    Dwell Coordinates Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 2 R. Ovoid -13.8 23.8 -90.3 -11.8 9.5 -73.6 22.1 1.4 
 
L. Ovoid 13.0 22.9 -92.0 12.9 10.0 -77.2 19.6 1.1 
 
Tandem -0.4 71.6 -70.9 1.1 51.0 -74.9 21.0 2.0 
CTMR MV 3 R. Ovoid -13.7 29.6 -96.3 -12.8 10.9 -81.2 24.1 0.6 
 
L. Ovoid 13.3 28.1 -95.4 12.1 12.5 -82.0 20.6 0.1 
 
Tandem -3.9 76.2 -72.2 -1.5 53.6 -77.1 23.2 0.2 
FSDs kV 1 R. Ovoid -14.6 27.1 -82.6 -14.7 5.1 -65.3 28.0 2.9 
 
L. Ovoid 7.7 26.6 -82.8 11.1 6.1 -66.6 26.3 1.9 
 
Tandem -0.1 87.5 -46.4 -1.7 64.9 -52.2 23.4 0.3 
FSDs MV 2 R. Ovoid -13.6 22.5 -102.5 -13.4 3.0 -86.9 25.0 0.1 
 
L. Ovoid 12.4 22.8 -101.7 12.9 4.2 -87.1 23.7 0.8 
 
Tandem -0.3 86.5 -72.9 -1.3 62.9 -78.4 24.3 0.6 
FW kV 3 R. Ovoid -10.9 25.5 -86.9 -12.2 9.4 -69.4 23.8 2.2 
 
L. Ovoid 16.3 32.2 -85.7 13.7 10.2 -69.2 27.6 5.7 
 
Tandem 1.3 89.4 -51.4 0.4 66.0 -56.0 23.9 0.3 
FW MV 1 R. Ovoid -13.6 19.8 -96.3 -12.9 2.3 -82.1 22.5 0.9 
 
L. Ovoid 13.2 21.1 -97.2 12.8 1.7 -82.4 24.4 2.5 
  Tandem 0.1 73.0 -76.7 -1.0 49.3 -78.7 23.8 0.2 
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Table C-9: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values        
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 sup 12.3 11.5 14.6 19.2 20.6 22.7 24.9 25.2 19.7 2.5 2.4 1.7 1.3 1 1.4 2 1.4 3.1 
  mid 31.9 25.3 18.4 16.9 21.1 22.7 16.8 16.7 23.2 3.1 1.4 0.1 1.6 0.9 0.9 0.6 2.4 1.8 
  inf 18.2 19.3 18 15.3 16.7 17.2 19.7 20.1 20.3 0.1 0.2 1.9 1.4 2.3 1.7 3.6 2.3 2.1 
CTMR MV 3 sup 15 13.6 13.8 16 21.6 26.3 27.8 20.9 19.6 2.2 1.5 1.4 1.6 1.8 1.9 3.1 2.3 2.9 
  mid 16.1 21.5 24.2 24 18.9 18.6 21.3 17.9 14.4 3.4 0.3 0.6 12.5 8.3 3.2 2.9 1.8 2 
  inf 17.1 15.3 16.8 18.7 22.1 22.7 20.3 23.7 20.5 1.3 0.3 0.7 2 1.7 3.3 1.8 2.9 1 
FW kV 3 sup 15.8 13.9 15.2 21.6 26.3 26.4 27 20.8 18.5 3 1.8 2.8 7.2 6.5 2 2.3 2.2 1.8 
  mid 14.9 19.5 20.3 14.5 17.1 14.8 19.9 15.8 13.1 2.2 1.7 3.3 3 6.5 0.6 1.5 0.3 0.7 
  inf 17.5 15.4 17.3 17.8 22.6 22.1 20.3 22.5 21.3 1.7 0.4 1.2 1.1 2.2 2.7 1.8 1.7 1.8 
FW MV 1 sup 18.1 15.3 15.6 18.9 22.5 18.3 18.1 16.4 20.4 2.2 1.7 2.4 3.1 2.6 2.2 2.4 0.8 3.9 
  mid 11.4 19.8 23.6 18.1 17.4 19 21.8 19.8 13.1 4.2 4.9 0.4 1.9 3.1 4.2 3.4 4.4 3.4 
  inf 27.4 14.7 14.8 20.4 15.2 16.2 20.8 23.6 27.1 7.1 2.7 2.4 3.2 2.1 3.6 2 0.7 1.4 
FSDs kV 1 sup 16.6 14.2 15 16.3 20 21.6 17.9 16.6 18.4 0.7 0.6 1.8 0.5 0.1 5.5 2.2 1 1.9 
  mid 9.8 17.9 24 16.1 16 16.2 20.9 18.9 11.9 2.6 3 0 0.1 1.7 1.4 2.5 3.5 2.2 
  inf 23 13.5 15.2 19.3 13.9 14.4 19.7 23.6 25.9 2.7 1.5 2.8 2.1 0.8 1.8 0.9 0.7 0.2 
FSDs MV 2 sup 11.6 10 14.5 20.5 22.8 24 24.8 25.1 17.8 1.8 0.9 1.6 2.6 3.2 2.7 1.9 1.3 1.2 
  mid 30.2 23.7 17.9 18 20.8 23.4 17.5 18.2 24 1.4 0.2 0.6 0.5 1.2 1.6 1.3 3.9 2.6 
  inf 17.7 19.4 15.8 17.3 17.3 19 19.3 20.3 18.9 0.6 0.3 0.3 0.6 2.9 3.5 3.2 2.5 0.7 
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Table C-10: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values        
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
CTMR kV 2 rlat 15.4 20.3 19.9 20.7 20.1 19.3 26.9 22.9 15.5 1.1 1.8 0.3 4.5 4.1 2.4 2.6 0.4 0.1 
 
mid 29.2 33 37.8 29.1 25.5 26.6 27 31.6 34.4 1.8 3.2 0.9 0.5 0.3 2.1 0.6 1.4 0.6 
 
llat 16.3 16.3 20.3 20.1 18.4 18.7 18.5 17.5 17 0.1 2.6 7 2.2 0.3 2.6 2.7 1.9 3.3 
CTMR MV 3 rlat 14.3 19.3 20.6 18.7 20.5 20.8 23.4 22.9 14.4 0 0.8 1 2.5 4.5 3.9 0.9 0.4 1 
 
mid 30.2 32.6 38.6 29.9 24.2 24 28.9 32 34.8 2.8 2.8 0.1 1.3 1 0.5 1.3 1 1 
 
llat 18.9 15.7 14.6 21.7 20.5 18 19.5 17.8 15.6 2.5 2 1.3 3.8 2.4 1.9 3.7 2.2 1.9 
FW kV 3 rlat 16.1 18.7 19.7 19.9 17.9 32 22.1 21.1 15.6 1.8 0.2 0.1 3.7 1.9 15.1 2.2 1.4 0.2 
 
mid 28.1 32.7 39.3 28.5 24.5 24 26.9 32.6 34.7 0.7 2.9 0.6 0.1 0.7 0.5 0.7 0.4 0.9 
 
llat 17.7 15.6 15.1 20 19.4 18.3 17.3 16.9 17.3 1.3 1.9 1.8 2.1 1.3 2.2 1.5 1.3 3.6 
FW MV 1 rlat 17.3 19.6 20.6 21.9 20.2 19.2 21.3 21.8 15.5 3 1.1 1 5.7 4.2 2.3 3 0.7 0.1 
 
mid 30.3 33.6 42 31.8 24.3 23.3 28.4 33.6 34.6 2.9 3.8 3.3 3.2 0.9 1.2 0.8 0.6 0.8 
 
llat 16.6 14.2 15.7 18.4 19.7 19.4 19.3 17.6 17.1 0.2 0.5 2.4 0.5 1.6 3.3 3.5 2 3.4 
FSDs kV 1 rlat 16.5 20.1 19.6 19.5 18.1 20.1 24.9 21.9 16 2.2 1.6 0 3.3 2.1 3.2 0.6 0.6 0.6 
 
mid 29.4 33.2 38.4 28.9 24.3 23.2 27.8 33.1 34.5 2 3.4 0.3 0.3 0.9 1.3 0.2 0.1 0.7 
 
llat 17.6 15 16.3 19.8 19.3 18.1 17.6 17.2 16.4 1.2 1.3 3 1.9 1.2 2 1.8 1.6 2.7 
FSDs MV 2 rlat 15.8 19.8 20.8 21.3 21.4 21.8 23.7 23.5 14.8 1.5 1.3 1.2 5.1 5.4 4.9 0.6 1 0.6 
 
mid 29.2 35.1 41.5 30.1 25.4 22.3 28.5 33.2 34.4 1.8 5.3 2.8 1.5 0.2 2.2 0.9 0.2 0.6 
  llat 17.3 15.2 16.5 20 19.7 19 19.5 18 17.1 0.9 1.5 3.2 2.1 1.6 2.9 3.7 2.4 3.4 
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Table C-11: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 2 295.9 48.9 133.5 8.2 
CTMR MV 3 297.8 50.8 192.2 7.9 
FSDs kV 1 286.7 39.7 168.3 8.0 
FSDs MV 2 308.3 61.3 135.9 10.6 
FW kV 3 283.2 36.2 187.3 3.0 
FW MV 1 303.3 56.3 181.9 21.6 
 
Table C-12: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 2 R. Ovoid -12.8 24.1 -90.6 -11.8 9.5 -73.6 22.4 1.0 
 
L. Ovoid 13.1 23.4 -92.0 12.9 10.0 -77.2 20.0 0.7 
 
Tandem -0.2 72.4 -71.1 1.1 51.0 -74.9 21.8 1.3 
CTMR MV 3 R. Ovoid -13.5 28.3 -96.6 -12.8 10.9 -81.2 23.2 0.2 
 
L. Ovoid 12.8 27.9 -95.7 12.1 12.5 -82.0 20.6 0.1 
 
Tandem -4.1 75.4 -71.9 -1.5 53.6 -77.1 22.6 0.5 
FSDs kV 1 R. Ovoid -17.3 25.5 -79.9 -14.7 5.1 -65.3 25.2 0.1 
 
L. Ovoid 11.9 24.9 -80.3 11.1 6.1 -66.6 23.3 1.2 
 
Tandem 0.3 87.3 -46.5 -1.7 64.9 -52.2 23.2 0.5 
FSDs MV 2 R. Ovoid -15.8 21.9 -101.1 -13.4 3.0 -86.9 23.8 1.3 
 
L. Ovoid 14.1 22.3 -100.4 12.9 4.2 -87.1 22.5 1.9 
 
Tandem -0.3 84.7 -73.3 -1.3 62.9 -78.4 22.4 1.3 
FW kV 3 R. Ovoid -13.0 27.1 -78.1 -12.2 9.4 -69.4 19.7 1.9 
 
L. Ovoid 16.1 27.2 -79.0 13.7 10.2 -69.2 19.8 2.1 
 
Tandem 0.9 89.1 -51.4 0.4 66.0 -56.0 23.6 0.0 
FW MV 1 R. Ovoid -13.5 19.0 -93.3 -12.9 2.3 -82.1 20.1 1.5 
 
L. Ovoid 14.9 19.6 -95.4 12.8 1.7 -82.4 22.2 0.3 
 
Tandem -0.2 76.8 -75.3 -1.0 49.3 -78.7 27.7 4.2 
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Table C-13: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values        
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 10.7 10.1 13.4 19.1 19.7 20.9 23.6 24 17.9 0.9 1 0.5 1.2 0.1 0.4 0.7 0.2 1.3 
 
mid 30.6 26.6 18.9 16.6 21.4 22.9 16.1 16.3 22.9 1.8 2.7 0.4 1.9 0.6 1.1 0.1 2 1.5 
 
llat 18.3 18.4 16.7 16.5 15.3 17.1 16.8 17.9 18.1 0 0.7 0.6 0.2 0.9 1.6 0.7 0.1 0.1 
FW MV 3 rlat 13.6 13.1 12.8 14.1 19.3 25 26.9 19.6 16.2 0.8 1 0.4 0.3 0.5 0.6 2.2 1 0.5 
 
mid 13.1 21 24.3 16.3 17.4 17.5 17.6 14.8 12.5 0.4 0.2 0.7 4.8 6.8 2.1 0.8 1.3 0.1 
 
llat 16.6 16.1 16.5 17.4 20.6 20.5 19.9 21.2 20.3 0.8 1.1 0.4 0.7 0.2 1.1 1.4 0.4 0.8 
FSDs kV 3 rlat 14.1 13 12.7 15 21.4 24.8 25.8 19.6 16.5 1.3 0.9 0.3 0.6 1.6 0.4 1.1 1 0.2 
 
mid 13.3 18.8 21.2 18.6 15.4 15.9 17.5 14.8 12.1 0.6 2.4 2.4 7.1 4.8 0.5 0.9 1.3 0.3 
 
llat 16.6 15.4 16.2 17.2 20.7 20.7 18.6 20.3 19.8 0.8 0.4 0.1 0.5 0.3 1.3 0.1 0.5 0.3 
FSDs MV 1 rlat 18.2 13.8 14.5 15.8 23.2 17.6 15.1 13.3 18.2 2.3 0.2 1.3 0 3.3 1.5 0.6 2.3 1.7 
 
mid 11.5 16.9 23.9 17.9 16.4 16.8 19.3 18.9 15.1 4.3 2 0.1 1.7 2.1 2 0.9 3.5 5.4 
 
llat 23.5 13 14 19.1 14.3 14.1 19.3 23.2 26 3.2 1 1.6 1.9 1.2 1.5 0.5 1.1 0.3 
CTMR kV 1 rlat 15.5 13.1 12.6 15.5 20.4 16.9 17.6 15.5 17.1 0.4 0.5 0.6 0.3 0.5 0.8 1.9 0.1 0.6 
 
mid 13.7 18.9 18.3 17.1 15.2 16.8 19.9 15.9 15.3 6.5 4 5.7 0.9 0.9 2 1.5 0.5 5.6 
 
llat 21.2 12.5 13.3 16.7 13.8 12.8 17.9 22.7 25.7 0.9 0.5 0.9 0.5 0.7 0.2 0.9 1.6 0 
CTMR MV 2 rlat 11.5 10.7 14.6 19.1 21.2 21.8 23.4 24.1 16.3 1.7 1.6 1.7 1.2 1.6 0.5 0.5 0.3 0.3 
 
mid 28.5 24.1 18.4 18.6 21.5 21.6 17.5 15.9 21.2 0.3 0.2 0.1 0.1 0.5 0.2 1.3 1.6 0.2 
  llat 17.4 19.4 16.5 16.5 15.5 17.8 18.1 19.2 18.2 0.9 0.3 0.4 0.2 1.1 2.3 2 1.4 0 
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Table C-14: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 15.2 17.9 19.1 20.6 19.1 18.2 24 21.7 15.8 0.9 0.6 0.5 4.4 3.1 1.3 0.3 0.8 0.4 
 
mid 29.2 32.6 37.2 28.2 24.9 24.8 26.7 32.1 33 1.8 2.8 1.5 0.4 0.3 0.3 0.9 0.9 0.8 
 
llat 16 13.8 14.6 18.5 19.3 18.4 18.6 15.5 15.4 0.4 0.1 1.3 0.6 1.2 2.3 2.8 0.1 1.7 
FW MV 3 rlat 16.4 19.5 19.9 19.7 19.4 21.2 25.9 22.3 15.1 2.1 1 0.3 3.5 3.4 4.3 1.6 0.2 0.3 
 
mid 31.9 35.3 38.4 27.9 25.1 24 28.7 32.4 35.6 4.5 5.5 0.3 0.7 0.1 0.5 1.1 0.6 1.8 
 
llat 17.1 13.7 13.6 18.3 20.3 19.1 19.1 18.1 15.7 0.7 0 0.3 0.4 2.2 3 3.3 2.5 2 
FSDs kV 3 rlat 14.8 18.4 17.7 17.9 17.9 20.5 24.1 19.8 15.5 0.5 0.1 1.9 1.7 1.9 3.6 0.2 2.7 0.1 
 
mid 28.3 32.1 38.9 28 25.4 24.1 26.2 31.8 35.3 0.9 2.3 0.2 0.6 0.2 0.4 1.4 1.2 1.5 
 
llat 16.8 14.3 14.6 18 18.5 17 17.7 17.1 15.1 0.4 0.6 1.3 0.1 0.4 0.9 1.9 1.5 1.4 
FSDs MV 1 rlat 17.3 17 19.7 20.5 19.7 17.6 21.4 21.1 17.1 3 1.5 0.1 4.3 3.7 0.7 2.9 1.4 1.7 
 
mid 28.1 32.2 39.6 30.1 26.9 25.1 26.7 31.1 36.5 0.7 2.4 0.9 1.5 1.7 0.6 0.9 1.9 2.7 
 
llat 16.1 14 14.7 14.9 18.4 19.4 18.3 14.1 14.8 0.3 0.3 1.4 3 0.3 3.3 2.5 1.5 1.1 
CTMR kV 1 rlat 16 19.6 20.1 19.3 16 18.6 21.9 21.7 15.5 1.7 1.1 0.5 3.1 0 1.7 2.4 0.8 0.1 
 
mid 29 32.6 38.5 29.2 24.9 22.3 27.1 32.5 33.9 1.6 2.8 0.2 0.6 0.3 2.2 0.5 0.5 0.1 
 
llat 16.4 14.5 13.7 18.1 18.4 17.4 17.2 15.5 15.4 0 0.8 0.4 0.2 0.3 1.3 1.4 0.1 1.7 
CTMR MV 2 rlat 17.3 17.3 20.6 20 19.4 18.1 22.4 21.7 15.7 3 1.2 1 3.8 3.4 1.2 1.9 0.8 0.3 
 
mid 28.9 31.9 39.2 28.8 24.5 22.3 28.7 27.8 33.6 1.5 2.1 0.5 0.2 0.7 2.2 1.1 5.2 0.2 
 
llat 16.5 13.4 14.7 18.4 18 16.4 18.5 15.9 15.7 0.1 0.3 1.4 0.5 0.1 0.3 2.7 0.3 2 
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Table C-15: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 1 271.4 24.4 124.3 1.1 
CTMR MV 2 290.5 43.5 172.9 11.4 
FSDs kV 3 271.2 24.2 153.1 7.3 
FSDs MV 1 278.6 31.6 123.2 2.2 
FW kV 2 273.2 26.2 166.3 18.1 
FW MV 3 283.8 36.8 160.6 0.3 
 
Table C-16: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 1 R. Ovoid -13.5 24.3 -90.4 -11.8 9.5 -73.6 22.5 1.0 
  L. Ovoid 12.7 23.3 -90.4 12.9 10.0 -77.2 18.7 2.0 
  Tandem -0.5 72.5 -71.2 1.1 51.0 -74.9 21.9 1.2 
CTMR MV 2 R. Ovoid -13.3 29.6 -96.8 -12.8 10.9 -81.2 24.4 0.9 
  L. Ovoid 12.6 29.6 -95.1 12.1 12.5 -82.0 21.5 0.8 
  Tandem -3.7 75.8 -72.2 -1.5 53.6 -77.1 22.8 0.2 
FSDs kV 3 R. Ovoid -17.6 26.0 -78.6 -14.7 5.1 -65.3 24.9 0.2 
  L. Ovoid 11.7 24.9 -79.5 11.1 6.1 -66.6 22.8 1.6 
  Tandem 0.0 85.3 -47.5 -1.7 64.9 -52.2 21.0 2.7 
FSDs MV 1 R. Ovoid -15.4 22.9 -101.9 -13.4 3.0 -86.9 25.0 0.1 
  L. Ovoid 13.4 23.6 -101.5 12.9 4.2 -87.1 24.2 0.3 
  Tandem 0.2 84.3 -73.6 -1.3 62.9 -78.4 22.0 1.7 
FW kV 2 R. Ovoid -9.4 30.1 -85.6 -12.2 9.4 -69.4 26.4 4.8 
  L. Ovoid 10.0 30.9 -84.9 13.7 10.2 -69.2 26.2 4.4 
  Tandem 1.2 88.9 -52.3 0.4 66.0 -56.0 23.2 0.4 
FW MV 3 R. Ovoid -13.9 21.0 -93.4 -12.9 2.3 -82.1 21.9 0.2 
  L. Ovoid 14.3 21.4 -94.5 12.8 1.7 -82.4 23.2 1.3 
  Tandem -0.4 74.0 -76.4 -1.0 49.3 -78.7 24.8 1.2 
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Table C-17: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values       
 
angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 10.6 9.9 12.5 18.7 20.1 21.9 23.9 23.8 15.8 0.8 0.8 0.4 0.8 0.5 0.6 1 0 0.8 
 
mid 26.8 23 20.2 21.2 23.4 20.8 15.1 13.6 21.4 2 0.9 1.7 2.7 1.4 1 1.1 0.7 0 
 
llat 17.8 18 16.2 16.4 16.7 16 18.3 17.2 17.2 0.5 1.1 0.1 0.3 2.3 0.5 2.2 0.6 1 
FW MV 3 rlat 12.3 10.8 11.9 14.3 19.9 24.5 25 17.1 16.5 0.5 1.3 0.5 0.1 0.1 0.1 0.3 1.5 0.2 
 
mid 11.2 21.8 25.9 13.4 13.8 15.8 18.5 16 11.2 1.5 0.6 2.3 1.9 3.2 0.4 0.1 0.1 1.2 
 
llat 16.3 14.3 16.2 18 20.8 21.9 21.8 21 20 0.5 0.7 0.1 1.3 0.4 2.5 3.3 0.2 0.5 
FSDs kV 3 rlat 12.9 11.3 11.7 13.2 20.8 24.7 26.5 19 17.9 0.1 0.8 0.7 1.2 1 0.3 1.8 0.4 1.2 
 
mid 14 21.1 24.8 20.8 15.5 15.2 18.6 14.7 13 1.3 0.1 1.2 9.3 4.9 0.2 0.2 1.4 0.6 
 
llat 16 15.5 16.1 17.9 21.1 20.9 20.2 21.8 20.2 0.2 0.5 0 1.2 0.7 1.5 1.7 1 0.7 
FSDs MV 1 rlat 16.1 13.8 14.7 17.6 22.1 18.5 18.1 16.1 19.2 0.2 0.2 1.5 1.8 2.2 2.4 2.4 0.5 2.7 
 
mid 15.7 22 23.7 17.5 15.6 16.8 18.2 18.4 17.5 8.5 7.1 0.3 1.3 1.3 2 0.2 3 7.8 
 
llat 21.8 14.3 15.4 18 14.3 14.7 20.5 23.6 26.4 1.5 2.3 3 0.8 1.2 2.1 1.7 0.7 0.7 
CTMR kV 1 rlat 16.9 13.6 12.6 16.2 20.7 18.3 18 16.8 16.1 1 0 0.6 0.4 0.8 2.2 2.3 1.2 0.4 
 
mid 14.9 18.3 23.1 16.8 16.3 15.6 20.9 14.9 17.5 7.7 3.4 0.9 0.6 2 0.8 2.5 0.5 7.8 
 
llat 20.4 12.4 12.8 17.5 13.4 14.1 18.6 22.5 24.3 0.1 0.4 0.4 0.3 0.3 1.5 0.2 1.8 1.4 
CTMR MV 2 rlat 11 9.3 12.5 19.1 21.7 22.6 24.6 24.6 17.7 1.2 0.2 0.4 1.2 2.1 1.3 1.7 0.8 1.1 
 
mid 29.5 24.5 16.5 17.5 23.4 22.4 16.9 15.7 22.6 0.7 0.6 2 1 1.4 0.6 0.7 1.4 1.2 
  llat 18.4 18.4 15.8 17.1 15.4 16.7 18.5 17 16.9 0.1 0.7 0.3 0.4 1 1.2 2.4 0.8 1.3 
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Table C-18: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 15.4 19.6 19.9 19.5 18.7 17.6 25.1 18.2 15.5 1.1 1.1 0.3 3.3 2.7 0.7 0.8 4.3 0.1 
 
mid 28.8 31.1 37.9 28.7 24.9 23.2 28.9 33.9 33.3 1.4 1.3 0.8 0.1 0.3 1.3 1.3 0.9 0.5 
 
llat 16.9 14 13.6 17.8 19.3 17.4 18.2 14.6 14.2 0.5 0.3 0.3 0.1 1.2 1.3 2.4 1 0.5 
FW MV 3 rlat 14.8 17.4 19.1 16.1 18.7 22.3 20.2 21.5 15.9 0.5 1.1 0.5 0.1 2.7 5.4 4.1 1 0.5 
 
mid 29.2 31.9 38.4 29.6 23.7 21.3 27.6 33.6 32 1.8 2.1 0.3 1 1.5 3.2 0 0.6 1.8 
 
llat 16.5 13.1 13.1 17.8 18.6 17 18.3 16.4 14 0.1 0.6 0.2 0.1 0.5 0.9 2.5 0.8 0.3 
FSDs kV 3 rlat 14.4 17.3 19.4 18.7 18.8 17.3 23.4 20.4 16.4 0.1 1.2 0.2 2.5 2.8 0.4 0.9 2.1 1 
 
mid 28.9 31.3 38.4 28.5 23.6 22.2 28.1 34.6 32.9 1.5 1.5 0.3 0.1 1.6 2.3 0.5 1.6 0.9 
 
llat 16.5 13.6 13.8 17.6 18.4 16.7 15.1 16.1 15 0.1 0.1 0.5 0.3 0.3 0.6 0.7 0.5 1.3 
FSDs MV 1 rlat 14.7 19.3 18.1 20.3 20.1 20.9 20.8 20.2 17.4 0.4 0.8 1.5 4.1 4.1 4 3.5 2.3 2 
 
mid 29.6 34.1 40 28.2 25.1 25.3 27.2 31 32.9 2.2 4.3 1.3 0.4 0.1 0.8 0.4 2 0.9 
 
llat 16.9 15.1 14.6 18.3 17.6 16.7 17.7 17.1 17.2 0.5 1.4 1.3 0.4 0.5 0.6 1.9 1.5 3.5 
CTMR kV 1 rlat 14.5 18.4 19.3 20.3 16.5 19.2 24.1 21.6 15.2 0.2 0.1 0.3 4.1 0.5 2.3 0.2 0.9 0.2 
 
mid 29.2 31.6 36.9 27.7 24.4 24.2 26.9 33 34.4 1.8 1.8 1.8 0.9 0.8 0.3 0.7 0 0.6 
 
llat 17.2 15.3 14.6 19.1 17.8 15.8 17.2 16.3 15.3 0.8 1.6 1.3 1.2 0.3 0.3 1.4 0.7 1.6 
CTMR MV 2 rlat 16.4 19.6 17.9 19.9 21.9 16.8 23.3 22.1 17 2.1 1.1 1.7 3.7 5.9 0.1 1 0.4 1.6 
 
mid 30 33.2 39.4 30.5 26 25.4 28.5 33.6 34.5 2.6 3.4 0.7 1.9 0.8 0.9 0.9 0.6 0.7 
  llat 15.6 14.9 12.6 17.7 17.4 16.2 18.7 20.6 16.7 0.8 1.2 0.7 0.2 0.7 0.1 2.9 5 3 
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Table C-19: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 1 272.3 25.3 157.6 2.7 
CTMR MV 2 280.7 33.7 123.2 2.1 
FSDs kV 3 264.5 17.5 170.5 13.8 
FSDs MV 1 279.8 32.8 165.5 5.2 
FW kV 2 270.2 23.2 117.8 7.5 
FW MV 3 276.4 29.4 173.9 10.4 
 
Table C-20: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 1 R. Ovoid -11.4 24.5 -84.1 -10.4 8.7 -68.5 22.2 1.2 
 
L. Ovoid 14.4 24.5 -84.7 15.0 9.8 -69.8 20.9 0.2 
 
Tandem -0.4 71.7 -61.0 1.6 50.3 -65.9 22.0 1.0 
CTMR MV 2 R. Ovoid -12.9 24.7 -101.6 -12.3 9.9 -86.5 21.2 2.3 
 
L. Ovoid 12.8 24.3 -102.2 13.1 10.9 -88.8 19.0 1.8 
 
Tandem -1.5 73.0 -82.0 0.5 50.5 -84.9 22.8 0.3 
FSDs kV 3 R. Ovoid -13.5 31.7 -79.6 -11.7 11.7 -66.0 24.3 0.9 
 
L. Ovoid 15.3 31.4 -79.6 13.0 12.0 -66.2 23.7 0.8 
 
Tandem 0.1 93.0 -52.7 0.2 69.9 -58.5 23.8 0.1 
FSDs MV 1 R. Ovoid -16.7 23.2 -91.9 -12.6 4.2 -78.7 23.5 1.6 
 
L. Ovoid 13.2 23.7 -93.2 12.3 5.0 -79.4 23.3 1.2 
 
Tandem 1.9 86.9 -65.6 0.5 64.3 -70.6 23.2 0.5 
FW kV 2 R. Ovoid -11.0 30.2 -94.3 -14.0 10.2 -76.9 26.7 5.0 
 
L. Ovoid 8.6 29.2 -92.4 11.6 10.2 -76.8 24.8 2.9 
 
Tandem -1.4 79.3 -68.2 -2.2 56.3 -71.7 23.3 0.3 
FW MV 3 R. Ovoid -14.8 33.2 -94.8 -13.4 15.0 -83.0 21.7 0.1 
 
L. Ovoid 14.7 33.6 -93.9 12.2 14.8 -82.8 22.0 0.1 
 
Tandem -1.0 93.6 -63.6 -1.4 69.9 -68.6 24.2 0.7 
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Table C-21: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values  
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 11.2 10.4 14.5 18.5 20.2 21.2 22.7 23.8 17.1 1.4 1.3 1.6 0.6 0.6 0.1 0.2 0 0.5 
 
mid 29.8 18.1 11.4 11.2 16.3 19.6 16.2 15.8 23.4 1 5.8 7.1 7.3 5.7 2.2 0 1.5 2 
 
llat 19.1 20 17.2 15.8 14.7 17 17.4 16.9 19.9 0.8 0.9 1.1 0.9 0.3 1.5 1.3 0.9 1.7 
FW MV 3 rlat 13.9 12.6 11.9 14.1 20.4 24 26.3 18.4 15.2 1.1 0.5 0.5 0.3 0.6 0.4 1.6 0.2 1.5 
 
mid 13.1 20.9 24.5 13.8 11.4 13.7 17.6 16.5 13.6 0.4 0.3 0.9 2.3 0.8 1.7 0.8 0.4 1.2 
 
llat 17.2 15.8 15.8 17.1 20.8 20 18.6 22.9 19.8 1.4 0.8 0.3 0.4 0.4 0.6 0.1 2.1 0.3 
FSDs kV 3 rlat 13.9 11.6 12.6 13.1 19.3 24 26 19.2 17.6 1.1 0.5 0.2 1.3 0.5 0.4 1.3 0.6 0.9 
 
mid 15.1 19.7 19 14.3 11.9 12.4 18 16.5 13.8 2.4 1.5 4.6 2.8 1.3 3 0.4 0.4 1.4 
 
llat 16.6 15.7 16.2 17.1 19.2 20.6 20 21.8 20.8 0.8 0.7 0.1 0.4 1.2 1.2 1.5 1 1.3 
FSDs MV 1 rlat 16.1 14.9 14 16.2 21.6 18.2 18.4 17.1 17 0.2 1.3 0.8 0.4 1.7 2.1 2.7 1.5 0.5 
 
mid 9.7 19 23.8 17.4 15.1 16.9 17.8 16 10.9 2.5 4.1 0.2 1.2 0.8 2.1 0.6 0.6 1.2 
 
llat 22.7 13.9 15 19 14.5 14 20 23.3 26.4 2.4 1.9 2.6 1.8 1.4 1.4 1.2 1 0.7 
CTMR kV 1 rlat 16.3 12.9 14.7 16.8 20.5 17.6 18 17.3 17.9 0.4 0.7 1.5 1 0.6 1.5 2.3 1.7 1.4 
 
mid 10 17.2 23.3 15.5 15.2 15.5 18.6 17.9 10.5 2.8 2.3 0.7 0.7 0.9 0.7 0.2 2.5 0.8 
 
llat 20.6 12.6 12.9 19 12.8 14.4 18.9 22.2 24.3 0.3 0.6 0.5 1.8 0.3 1.8 0.1 2.1 1.4 
CTMR MV 
2 rlat 10.9 10.9 14.6 18.7 20.4 21.3 23 23 17.2 1.1 1.8 1.7 0.8 0.8 0 0.1 0.8 0.6 
 
mid 27.3 24.4 15.6 16 22.4 25.4 17.3 14.4 22.6 1.5 0.5 2.9 2.5 0.4 3.6 1.1 0.1 1.2 
  llat 18.4 16.9 16.3 17.3 15.3 14.9 17.2 15.2 16.7 0.1 2.2 0.2 0.6 0.9 0.6 1.1 2.6 1.5 
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Table C-22: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FW kV 2 rlat 14.7 19.7 20.3 19.2 18.2 20 25.2 19.7 15.4 0.4 1.2 0.7 3 2.2 3.1 0.9 2.8 0 
  mid 27.5 33.3 28.2 29.3 24.7 23.5 27 33.9 33 0.1 3.5 10.5 0.7 0.5 1 0.6 0.9 0.8 
  llat 16.9 14.6 13.7 18.6 19.8 17.7 17.7 17.9 15.9 0.5 0.9 0.4 0.7 1.7 1.6 1.9 2.3 2.2 
FW MV 3 rlat 15.1 17.5 20.1 19.4 21.2 21.3 23.7 21.4 16.1 0.8 1 0.5 3.2 5.2 4.4 0.6 1.1 0.7 
  mid 30 33.4 40 28.4 24.3 21.6 27.5 28.7 35.7 2.6 3.6 1.3 0.2 0.9 2.9 0.1 4.3 1.9 
  llat 19.4 15.7 14.2 16.7 19.9 15.4 18.1 17.8 15.3 3 2 0.9 1.2 1.8 0.7 2.3 2.2 1.6 
FSDs kV 3 rlat 15.2 18.8 20.3 18.4 17.8 19.4 23 21.8 15.8 0.9 0.3 0.7 2.2 1.8 2.5 1.3 0.7 0.4 
  mid 29.5 31.3 38.2 29.4 24.8 24.3 26.6 34 36.5 2.1 1.5 0.5 0.8 0.4 0.2 1 1 2.7 
  llat 17.8 14.2 13.1 18.2 19.6 17.5 17.8 16.8 15.8 1.4 0.5 0.2 0.3 1.5 1.4 2 1.2 2.1 
FSDs MV 1 rlat 14.8 19.3 20.1 20.7 18.6 21.4 26.1 23.1 16 0.5 0.8 0.5 4.5 2.6 4.5 1.8 0.6 0.6 
  mid 29.3 33.7 38.1 31.2 25.9 23.2 27.3 29 34.4 1.9 3.9 0.6 2.6 0.7 1.3 0.3 4 0.6 
  llat 16.4 16.3 15.4 19.5 20.4 17 17.8 16.8 18.5 0 2.6 2.1 1.6 2.3 0.9 2 1.2 4.8 
CTMR kV 1 rlat 14.6 17.3 19.1 19.7 20.1 20.4 22.6 21.5 15.2 0.3 1.2 0.5 3.5 4.1 3.5 1.7 1 0.2 
  mid 28.5 32.1 37.2 28.5 24.2 25.3 27.3 32.8 35.5 1.1 2.3 1.5 0.1 1 0.8 0.3 0.2 1.7 
  llat 16.3 14.3 14.5 17.7 18.7 16.5 17.1 16.8 16.6 0.1 0.6 1.2 0.2 0.6 0.4 1.3 1.2 2.9 
CTMR MV 2 rlat 17.4 18.9 19.6 18.5 18.4 21.3 23.9 22.4 18.8 3.1 0.4 0 2.3 2.4 4.4 0.4 0.1 3.4 
  mid 27.3 32.4 37.3 31.3 23.2 21.5 28.7 27.6 36.2 0.1 2.6 1.4 2.7 2 3 1.1 5.4 2.4 
  llat 17.1 15.2 14.3 18 19 16.3 18 18.4 14.8 0.7 1.5 1 0.1 0.9 0.2 2.2 2.8 1.1 
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Table C-23: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 1 274.9 27.9 151.9 8.4 
CTMR MV 2 276.4 29.4 120.3 5.0 
FSDs kV 3 279.5 32.5 164.7 19.6 
FSDs MV 1 282.3 35.3 161.3 1.0 
FW kV 2 279.4 32.4 118.6 6.7 
FW MV 3 282.4 35.4 172.8 11.5 
 
Table C-24: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 1 R. Ovoid -10.2 23.9 -84.4 -10.4 8.7 -68.5 22.0 1.5 
 
L. Ovoid 13.8 23.5 -84.8 15.0 9.8 -69.8 20.4 0.4 
 
Tandem 1.7 71.7 -60.8 1.6 50.3 -65.9 22.0 1.0 
CTMR MV 2 R. Ovoid -12.6 24.6 -102.9 -12.3 9.9 -86.5 22.0 1.4 
 
L. Ovoid 13.7 24.6 -103.0 13.1 10.9 -88.8 19.7 1.0 
 
Tandem -1.1 73.7 -80.8 0.5 50.5 -84.9 23.6 0.6 
FSDs kV 3 R. Ovoid -13.8 36.0 -79.0 -11.7 11.7 -66.0 27.6 2.5 
 
L. Ovoid 15.1 36.0 -78.7 13.0 12.0 -66.2 27.1 2.7 
 
Tandem 0.2 94.6 -51.5 0.2 69.9 -58.5 25.7 2.0 
FSDs MV 1 R. Ovoid -15.7 28.0 -88.9 -12.6 4.2 -78.7 26.1 1.0 
 
L. Ovoid 13.6 28.4 -89.2 12.3 5.0 -79.4 25.4 1.0 
 
Tandem 1.3 87.5 -65.2 0.5 64.3 -70.6 23.8 0.1 
FW kV 2 R. Ovoid -15.3 30.6 -89.2 -14.0 10.2 -76.9 23.9 2.2 
 
L. Ovoid 14.0 29.0 -90.1 11.6 10.2 -76.8 23.2 1.3 
 
Tandem -0.6 80.2 -68.3 -2.2 56.3 -71.7 24.2 0.6 
FW MV 3 R. Ovoid -14.5 34.2 -88.1 -13.4 15.0 -83.0 19.9 1.8 
 
L. Ovoid 15.4 34.7 -87.2 12.2 14.8 -82.8 20.6 1.2 
  Tandem -1.4 93.9 -63.9 -1.4 69.9 -68.6 24.5 0.9 
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Table C-25: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 sup 9.9 9.6 13.3 19.1 20.2 21.3 22.7 23.6 15.3 0.1 0.5 0.4 1.2 0.6 0 0.2 0.2 1.3 
 
mid 24.8 17.8 15 16.8 21.1 21.5 15.6 14.2 20.6 4 6.1 3.5 1.7 0.9 0.3 0.6 0.1 0.8 
 
inf 18.1 18.7 17.4 17.4 16.7 16.7 16.7 17.7 18.2 0.2 0.4 1.3 0.7 2.3 1.2 0.6 0.1 0 
FSDs MV 3 sup 12.8 13.2 13.1 14.7 19.4 24.2 25.5 19.3 14.9 0 1.1 0.7 0.3 0.4 0.2 0.8 0.7 1.8 
 
mid 13.1 20.7 24.8 13.3 16 17.7 17.2 14.7 13.5 0.4 0.5 1.2 1.8 5.4 2.3 1.2 1.4 1.1 
 
inf 16.1 16.6 17.4 17.8 20.6 17.8 17.2 21 19.1 0.3 1.6 1.3 1.1 0.2 1.6 1.3 0.2 0.4 
CTMR kV 3 sup 12.5 11.7 11.7 13.2 19 24.7 25.5 18.5 15.6 0.3 0.4 0.7 1.2 0.8 0.3 0.8 0.1 1.1 
 
mid 12 20.6 23.1 12.2 12.7 14.9 17.5 16 12 0.7 0.6 0.5 0.7 2.1 0.5 0.9 0.1 0.4 
 
inf 15.5 14.9 16.4 17.2 21.3 20.2 18.7 21.3 18.5 0.3 0.1 0.3 0.5 0.9 0.8 0.2 0.5 1 
CTMR MV 1 sup 16.6 15.5 15.3 17.6 19.5 17.4 17.4 16.8 16.9 0.7 1.9 2.1 1.8 0.4 1.3 1.7 1.2 0.4 
 
mid 14.2 19.8 23.7 15.7 14.4 14.6 20.4 17.9 15.1 7 4.9 0.3 0.5 0.1 0.2 2 2.5 5.4 
 
inf 22.4 14.5 14.3 19.1 11.9 14.1 17.8 21.4 25.8 2.1 2.5 1.9 1.9 1.2 1.5 1 2.9 0.1 
FW kV 1 sup 16.1 13.1 13.6 16.6 20.7 16.3 12.2 14.5 16.5 0.2 0.5 0.4 0.8 0.8 0.2 3.5 1.1 0 
 
mid 15.4 21.2 21.7 14.7 14.3 15 18.4 16.6 14.8 8.2 6.3 2.3 1.5 0 0.2 0 1.2 5.1 
 
inf 20 11.9 12.7 17.2 13.1 13.9 18.2 22.4 25.2 0.3 0.1 0.3 0 0 1.3 0.6 1.9 0.5 
FW MV 2 sup 11.4 11.9 15.1 19 21.4 22.7 24.1 24.8 16.5 1.6 2.8 2.2 1.1 1.8 1.4 1.2 1 0.1 
  mid 29 24.2 18.2 18.9 24.4 20.6 13.6 13.3 20.1 0.2 0.3 0.3 0.4 2.4 1.2 2.6 1 1.3 
  inf 17.3 18.6 16.6 16.9 16.5 16.7 17.5 17.5 16.8 1 0.5 0.5 0.2 2.1 1.2 1.4 0.3 1.4 
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Table C-26: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 rlat 14.3 16.2 19.2 17.7 16.3 19.3 20.5 19 15.1 0 2.3 0.4 1.5 0.3 2.4 3.8 3.5 0.3 
 
mid 26.8 34.8 37.1 29 24.1 23.2 26.7 34.8 33.7 0.6 5 1.6 0.4 1.1 1.3 0.9 1.8 0.1 
 
llat 17.3 13.9 13.4 18.8 17.9 16.6 17.4 16.4 15.4 0.9 0.2 0.1 0.9 0.2 0.5 1.6 0.8 1.7 
FSDs MV 3 rlat 15.3 18.1 21.6 18.3 16.1 18.6 22.6 21.3 15.2 1 0.4 2 2.1 0.1 1.7 1.7 1.2 0.2 
 
mid 27.4 31.4 40 28.4 23.2 19.5 27.2 29.7 34.9 0 1.6 1.3 0.2 2 5 0.4 3.3 1.1 
 
llat 17.2 13.8 13.2 18.5 19.2 17.3 16.7 16.5 16.3 0.8 0.1 0.1 0.6 1.1 1.2 0.9 0.9 2.6 
CTMR kV 3 rlat 15.2 17.6 19.3 16.7 16.1 18.1 21.7 22.1 15.3 0.9 0.9 0.3 0.5 0.1 1.2 2.6 0.4 0.1 
 
mid 28.8 31.8 37.5 27.1 24.9 25.1 26.7 32.4 32.9 1.4 2 1.2 1.5 0.3 0.6 0.9 0.6 0.9 
 
llat 15.8 13.6 12.9 18.4 19.1 17.7 17.3 14.7 15 0.6 0.1 0.4 0.5 1 1.6 1.5 0.9 1.3 
CTMR MV 1 rlat 15.4 17.5 19.3 19.2 15.2 18 23.8 22 15.8 1.1 1 0.3 3 0.8 1.1 0.5 0.5 0.4 
 
mid 30.6 34.1 38.3 29.7 23.9 24.9 27.9 32.1 34.7 3.2 4.3 0.4 1.1 1.3 0.4 0.3 0.9 0.9 
 
llat 15.3 12.9 14.1 17.7 20.9 19.5 19.4 16.2 15.4 1.1 0.8 0.8 0.2 2.8 3.4 3.6 0.6 1.7 
FW kV 1 rlat 15.5 18.8 19.8 17.5 16.8 18.3 19.4 18.7 14.6 1.2 0.3 0.2 1.3 0.8 1.4 4.9 3.8 0.8 
 
mid 29 32.6 38.7 28.7 24 21.9 26.3 31.9 31.4 1.6 2.8 0 0.1 1.2 2.6 1.3 1.1 2.4 
 
llat 17 14.9 14.4 18.1 17.8 16 17.4 17 15.8 0.6 1.2 1.1 0.2 0.3 0.1 1.6 1.4 2.1 
FW MV 2 rlat 13.7 14.7 17.2 15.8 16.2 16.9 21 21.2 15.4 0.6 3.8 2.4 0.4 0.2 0 3.3 1.3 0 
 
mid 27.3 34 39 28.3 22.4 21.2 26.5 32.1 33.7 0.1 4.2 0.3 0.3 2.8 3.3 1.1 0.9 0.1 
  llat 16.1 12.9 12.7 17.6 18.6 18 17.4 18.2 15.6 0.3 0.8 0.6 0.3 0.5 1.9 1.6 2.6 1.9 
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Table C-27: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 3 262.0 15.0 160.4 23.9 
CTMR MV 1 275.2 28.2 163.0 2.7 
FSDs kV 2 261.0 14.0 114.2 11.1 
FSDs MV 3 267.2 20.2 165.9 18.4 
FW kV 1 265.0 18.0 149.7 10.6 
FW MV 2 262.3 15.3 121.5 3.8 
 
Table C-28: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 3 R. Ovoid -11.0 23.1 -83.1 -11.4 8.7 -67.8 21.0 2.5 
 
L. Ovoid 14.6 23.6 -82.8 14.0 9.8 -68.2 20.1 0.6 
 
Tandem -1.3 71.5 -60.3 0.9 49.9 -65.0 22.2 0.8 
CTMR MV 1 R. Ovoid -14.8 26.9 -93.9 -13.3 11.7 -78.5 21.7 1.8 
 
L. Ovoid 11.8 26.6 -96.6 12.0 12.9 -81.5 20.4 0.3 
 
Tandem -2.4 76.3 -74.6 -0.5 53.7 -78.5 23.0 0.0 
FSDs kV 2 R. Ovoid -16.7 27.9 -89.1 -13.3 9.9 -72.8 24.5 0.6 
 
L. Ovoid 12.9 29.1 -87.7 11.1 10.4 -73.0 23.9 0.6 
 
Tandem -0.3 92.2 -58.7 -1.1 70.3 -62.6 22.3 1.4 
FSDs MV 3 R. Ovoid -16.4 31.3 -92.0 -14.2 12.5 -79.4 22.7 2.4 
 
L. Ovoid 13.2 31.7 -91.1 11.1 12.8 -78.9 22.6 1.8 
 
Tandem -4.0 92.9 -64.4 -3.7 70.1 -70.1 23.5 0.2 
FW kV 1 R. Ovoid -14.0 23.0 -78.5 -13.1 5.6 -68.8 19.9 3.8 
 
L. Ovoid 12.5 23.0 -76.3 12.4 5.3 -69.7 18.9 3.0 
 
Tandem 0.1 75.3 -62.0 -0.5 52.2 -64.7 23.3 0.3 
FW MV 2 R. Ovoid -15.9 22.7 -101.2 -13.6 4.7 -88.6 22.1 0.4 
  L. Ovoid 14.0 22.6 -102.4 11.6 5.4 -89.9 21.4 0.5 
  Tandem -1.3 75.4 -85.4 -1.6 52.8 -86.7 22.6 0.9 
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Table C-29: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 sup 11.2 9.9 12.9 17.9 20.5 21.8 24.6 23.4 15.5 1.4 0.8 0 0 0.9 0.5 1.7 0.4 1.1 
 
mid 24.6 19.4 14.3 15.6 17.6 19.2 15.3 15.5 20.9 4.2 4.5 4.2 2.9 4.4 2.6 0.9 1.2 0.5 
 
inf 18.2 20 14.4 16.8 16.2 15.3 17.3 18 19.2 0.1 0.9 1.7 0.1 1.8 0.2 1.2 0.2 1 
FSDs MV 3 sup 14.6 13.8 13.2 15.7 20.2 25.1 27.8 20.2 17 1.8 1.7 0.8 1.3 0.4 0.7 3.1 1.6 0.3 
 
mid 14.1 21.7 24.6 21.4 19.5 20 18.3 17 13.3 1.4 0.5 1 9.9 8.9 4.6 0.1 0.9 0.9 
 
inf 18.7 15.4 17.2 18.7 21.2 20.3 20.2 21.4 20.3 2.9 0.4 1.1 2 0.8 0.9 1.7 0.6 0.8 
CTMR kV 3 sup 12.9 11.7 12 13.9 20.9 25.2 26.7 20 16.7 0.1 0.4 0.4 0.5 1.1 0.8 2 1.4 0 
 
mid 11.9 20.9 24.4 14.7 12.5 15.6 19.3 16.1 13.3 0.8 0.3 0.8 3.2 1.9 0.2 0.9 0 0.9 
 
inf 16.2 15.5 17.3 17.9 21.2 20.6 20.2 19.9 18.7 0.4 0.5 1.2 1.2 0.8 1.2 1.7 0.9 0.8 
CTMR MV 1 sup 18.2 15.5 16 18.5 21 20.7 18.9 17.5 18.2 2.3 1.9 2.8 2.7 1.1 4.6 3.2 1.9 1.7 
 
mid 17.3 22.2 24.1 17.3 14.6 14.6 19.7 20.3 21.2 10.1 7.3 0.1 1.1 0.3 0.2 1.3 4.9 11.5 
 
inf 24.3 16.2 15.9 19.6 15 14.4 20.1 22.5 29 4 4.2 3.5 2.4 1.9 1.8 1.3 1.8 3.3 
FW kV 1 sup 15.8 13.9 12.4 16.7 20.9 16.4 12.8 12 15.2 0.1 0.3 0.8 0.9 1 0.3 2.9 3.6 1.3 
 
mid 16.6 21.5 15.8 13.9 13.5 14.3 18.8 15 18.2 9.4 6.6 8.2 2.3 0.8 0.5 0.4 0.4 8.5 
 
inf 21.4 12.3 12.6 16.7 13 13.4 18.5 23.9 26.3 1.1 0.3 0.2 0.5 0.1 0.8 0.3 0.4 0.6 
FW MV 2 sup 12.3 11.3 15.3 20 22 22 24.2 25.7 18.6 2.5 2.2 2.4 2.1 2.4 0.7 1.3 1.9 2 
 
mid 28.7 24.4 20.2 19.5 21.8 20.9 16.3 15.7 20.9 0.1 0.5 1.7 1 0.2 0.9 0.1 1.4 0.5 
  inf 19.1 19.3 18.8 18.1 16.5 18.5 17.7 18.1 18.7 0.8 0.2 2.7 1.4 2.1 3 1.6 0.3 0.5 
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Table C-30: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 rlat 15.9 18.8 20.4 20.4 20.1 20 22.8 21.4 15.4 1.6 0.3 0.8 4.2 4.1 3.1 1.5 1.1 0 
 
mid 28.3 32.1 37.1 28.8 25.4 23.8 28.1 35.5 32.9 0.9 2.3 1.6 0.2 0.2 0.7 0.5 2.5 0.9 
 
llat 17.7 14.4 13.8 17.5 18.4 17 17.7 18.1 15.4 1.3 0.7 0.5 0.4 0.3 0.9 1.9 2.5 1.7 
FSDs MV 3 rlat 15 19.6 22.7 21.7 23.7 20.7 27.3 23.2 16.3 0.7 1.1 3.1 5.5 7.7 3.8 3 0.7 0.9 
 
mid 29.7 23.8 40.7 33.4 25.6 23.2 27.3 31.7 34 2.3 6 2 4.8 0.4 1.3 0.3 1.3 0.2 
 
llat 17.9 16.2 14.4 17.6 18.5 18.1 19.7 21.1 19.1 1.5 2.5 1.1 0.3 0.4 2 3.9 5.5 5.4 
CTMR kV 3 rlat 16.7 18.6 19.7 20 18.3 20.3 21.6 22.9 16 2.4 0.1 0.1 3.8 2.3 3.4 2.7 0.4 0.6 
 
mid 29.4 32.3 37.9 28.1 24.1 23.7 27.7 34 34.2 2 2.5 0.8 0.5 1.1 0.8 0.1 1 0.4 
 
llat 17.8 14.4 17.4 14 13.2 19.8 19.5 17.4 18.2 1.4 0.7 4.1 3.9 4.9 3.7 3.7 1.8 4.5 
CTMR MV 1 rlat 17.3 18.4 21.9 23 20.6 18.1 23.4 23.2 15.8 3 0.1 2.3 6.8 4.6 1.2 0.9 0.7 0.4 
 
mid 28.5 33.6 39.6 29.8 24 22.5 28.2 34.8 34.1 1.1 3.8 0.9 1.2 1.2 2 0.6 1.8 0.3 
 
llat 16.6 13.9 13.3 19.4 20.3 18.3 20.4 17.4 16.3 0.2 0.2 0 1.5 2.2 2.2 4.6 1.8 2.6 
FW kV 1 rlat 16.3 19.3 19.8 20.6 19.4 18 22.6 21 15.5 2 0.8 0.2 4.4 3.4 1.1 1.7 1.5 0.1 
 
mid 28.7 32.7 38.4 29.1 24.1 23.7 27.2 31.9 25 1.3 2.9 0.3 0.5 1.1 0.8 0.4 1.1 8.8 
 
llat 17.5 14.5 13.2 16.6 17.2 16.5 17.5 17.4 16.2 1.1 0.8 0.1 1.3 0.9 0.4 1.7 1.8 2.5 
FW MV 2 rlat 15.3 18.5 20.9 22.2 24 20 21.5 21.7 16.7 1 0 1.3 6 8 3.1 2.8 0.8 1.3 
  mid 26.2 32.6 39 29.6 24.8 22.6 27.6 27.9 32.3 1.2 2.8 0.3 1 0.4 1.9 0 5.1 1.5 
  llat 17 12.6 13.7 18.4 22 18.8 20 16.1 17.9 0.6 1.1 0.4 0.5 3.9 2.7 4.2 0.5 4.2 
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Table C-31: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 3 280.2 33.2 176.9 7.4 
CTMR MV 1 300.6 53.6 183.9 23.5 
FSDs kV 2 280.5 33.5 122.1 3.2 
FSDs MV 3 296.4 49.4 186.2 1.9 
FW kV 1 264.3 17.3 151.9 8.5 
FW MV 2 287.1 40.1 133.5 8.1 
 
Table C-32: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates   Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 3 R. Ovoid -11.2 24.4 -84.0 -11.4 8.7 -67.8 22.6 0.9 
 
L. Ovoid 14.6 24.1 -82.9 14.0 9.8 -68.2 20.5 0.2 
 
Tandem -1.4 72.0 -60.5 0.9 49.9 -65.0 22.7 0.4 
CTMR MV 1 R. Ovoid -14.8 29.0 -95.8 -13.3 11.7 -78.5 24.5 1.0 
 
L. Ovoid 11.5 28.0 -96.4 12.0 12.9 -81.5 21.2 0.5 
 
Tandem -2.5 76.9 -75.1 -0.5 53.7 -78.5 23.5 0.5 
FSDs kV 2 R. Ovoid -16.2 29.1 -90.8 -13.3 9.9 -72.8 26.5 1.4 
 
L. Ovoid 12.8 29.3 -88.3 11.1 10.4 -73.0 24.4 0.1 
 
Tandem 0.1 93.3 -58.3 -1.1 70.3 -62.6 23.4 0.3 
FSDs MV 3 R. Ovoid -16.6 33.4 -93.2 -14.2 12.5 -79.4 25.2 0.0 
 
L. Ovoid 13.3 34.3 -91.6 11.1 12.8 -78.9 25.1 0.6 
 
Tandem -3.5 93.2 -63.9 -3.7 70.1 -70.1 23.9 0.2 
FW kV 1 R. Ovoid -14.0 24.2 -80.3 -13.1 5.6 -68.8 21.9 0.2 
 
L. Ovoid 13.3 24.2 -82.3 12.4 5.3 -69.7 22.7 0.9 
 
Tandem 0.7 75.2 -62.2 -0.5 52.2 -64.7 23.2 0.4 
FW MV 2 R. Ovoid -14.4 22.9 -101.5 -13.6 4.7 -88.6 22.3 0.7 
  L. Ovoid 14.9 21.5 -102.1 11.6 5.4 -89.9 20.5 1.4 
  Tandem -0.6 75.6 -85.2 -1.6 52.8 -86.7 22.9 0.7 
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Table C-33: Results from two-dimensional CTP organ segmentation measurements for surrogate rectum structures. Color coding for columns 
displaying differences from control values is as follows: No coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “sup”, “mid”, 
and “inf” refer to locations relative to the artifact region. Sup=superior, inf=inferior and mid=middle. 
CTP: Rectum Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 sup 10.7 10.1 13.4 19.1 19.7 20.9 23.6 24 17.9 0.9 1 0.5 1.2 0.1 0.4 0.7 0.2 1.3 
 
mid 30.6 26.6 18.9 16.6 21.4 22.9 16.1 16.3 22.9 1.8 2.7 0.4 1.9 0.6 1.1 0.1 2 1.5 
 
inf 18.3 18.4 16.7 16.5 15.3 17.1 16.8 17.9 18.1 0 0.7 0.6 0.2 0.9 1.6 0.7 0.1 0.1 
FSDs MV 3 sup 13.6 13.1 12.8 14.1 19.3 25 26.9 19.6 16.2 0.8 1 0.4 0.3 0.5 0.6 2.2 1 0.5 
 
mid 13.1 21 24.3 16.3 17.4 17.5 17.6 14.8 12.5 0.4 0.2 0.7 4.8 6.8 2.1 0.8 1.3 0.1 
 
inf 16.6 16.1 16.5 17.4 20.6 20.5 19.9 21.2 20.3 0.8 1.1 0.4 0.7 0.2 1.1 1.4 0.4 0.8 
CTMR kV 3 sup 14.1 13 12.7 15 21.4 24.8 25.8 19.6 16.5 1.3 0.9 0.3 0.6 1.6 0.4 1.1 1 0.2 
 
mid 13.3 18.8 21.2 18.6 15.4 15.9 17.5 14.8 12.1 0.6 2.4 2.4 7.1 4.8 0.5 0.9 1.3 0.3 
 
inf 16.6 15.4 16.2 17.2 20.7 20.7 18.6 20.3 19.8 0.8 0.4 0.1 0.5 0.3 1.3 0.1 0.5 0.3 
CTMR MV 1 sup 18.2 13.8 14.5 15.8 23.2 17.6 15.1 13.3 18.2 2.3 0.2 1.3 0 3.3 1.5 0.6 2.3 1.7 
 
mid 11.5 16.9 23.9 17.9 16.4 16.8 19.3 18.9 15.1 4.3 2 0.1 1.7 2.1 2 0.9 3.5 5.4 
 
inf 23.5 13 14 19.1 14.3 14.1 19.3 23.2 26 3.2 1 1.6 1.9 1.2 1.5 0.5 1.1 0.3 
FW kV 1 sup 15.5 13.1 12.6 15.5 20.4 16.9 17.6 15.5 17.1 0.4 0.5 0.6 0.3 0.5 0.8 1.9 0.1 0.6 
 
mid 13.7 18.9 18.3 17.1 15.2 16.8 19.9 15.9 15.3 6.5 4 5.7 0.9 0.9 2 1.5 0.5 5.6 
 
inf 21.2 12.5 13.3 16.7 13.8 12.8 17.9 22.7 25.7 0.9 0.5 0.9 0.5 0.7 0.2 0.9 1.6 0 
FW MV 2 sup 11.5 10.7 14.6 19.1 21.2 21.8 23.4 24.1 16.3 1.7 1.6 1.7 1.2 1.6 0.5 0.5 0.3 0.3 
 
mid 28.5 24.1 18.4 18.6 21.5 21.6 17.5 15.9 21.2 0.3 0.2 0.1 0.1 0.5 0.2 1.3 1.6 0.2 
  inf 17.4 19.4 16.5 16.5 15.5 17.8 18.1 19.2 18.2 0.9 0.3 0.4 0.2 1.1 2.3 2 1.4 0 
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Table C-34: Results from two-dimensional CTP organ segmentation measurements for surrogate bladder structures. Color coding for columns 
displaying differences from control values is as follows: no coloring signifies results within 1 mm of control values, yellow coloring signifies 
results differing from the control values by 1-2 mm, light red signifies results differing from control values by 2-5 mm and dark red signifies 
results differing from control values by more than 5 mm. Clear and yellow results met the hypothesis criteria of ±2 mm. The terms “rlat”, “mid” 
and “llat” refer to locations relative to the artifact region. Rlat=right lateral, llat= left lateral and mid=middle. 
CTP: Bladder Results                     
*distances in mm Measured values             Absolute difference from control values       
  angle: 0 40 80 120 160 200 240 280 320 0 40 80 120 160 200 240 280 320 
FSDs kV 2 rlat 15.2 17.9 19.1 20.6 19.1 18.2 24 21.7 15.8 0.9 0.6 0.5 4.4 3.1 1.3 0.3 0.8 0.4 
 
mid 29.2 32.6 37.2 28.2 24.9 24.8 26.7 32.1 33 1.8 2.8 1.5 0.4 0.3 0.3 0.9 0.9 0.8 
 
llat 16 13.8 14.6 18.5 19.3 18.4 18.6 15.5 15.4 0.4 0.1 1.3 0.6 1.2 2.3 2.8 0.1 1.7 
FSDs MV 3 rlat 16.4 19.5 19.9 19.7 19.4 21.2 25.9 22.3 15.1 2.1 1 0.3 3.5 3.4 4.3 1.6 0.2 0.3 
 
mid 31.9 35.3 38.4 27.9 25.1 24 28.7 32.4 35.6 4.5 5.5 0.3 0.7 0.1 0.5 1.1 0.6 1.8 
 
llat 17.1 13.7 13.6 18.3 20.3 19.1 19.1 18.1 15.7 0.7 0 0.3 0.4 2.2 3 3.3 2.5 2 
CTMR kV 3 rlat 14.8 18.4 17.7 17.9 17.9 20.5 24.1 19.8 15.5 0.5 0.1 1.9 1.7 1.9 3.6 0.2 2.7 0.1 
 
mid 28.3 32.1 38.9 28 25.4 24.1 26.2 31.8 35.3 0.9 2.3 0.2 0.6 0.2 0.4 1.4 1.2 1.5 
 
llat 16.8 14.3 14.6 18 18.5 17 17.7 17.1 15.1 0.4 0.6 1.3 0.1 0.4 0.9 1.9 1.5 1.4 
CTMR MV 1 rlat 17.3 17 19.7 20.5 19.7 17.6 21.4 21.1 17.1 3 1.5 0.1 4.3 3.7 0.7 2.9 1.4 1.7 
 
mid 28.1 32.2 39.6 30.1 26.9 25.1 26.7 31.1 36.5 0.7 2.4 0.9 1.5 1.7 0.6 0.9 1.9 2.7 
 
llat 16.1 14 14.7 14.9 18.4 19.4 18.3 14.1 14.8 0.3 0.3 1.4 3 0.3 3.3 2.5 1.5 1.1 
FW kV 1 rlat 16 19.6 20.1 19.3 16 18.6 21.9 21.7 15.5 1.7 1.1 0.5 3.1 0 1.7 2.4 0.8 0.1 
 
mid 29 32.6 38.5 29.2 24.9 22.3 27.1 32.5 33.9 1.6 2.8 0.2 0.6 0.3 2.2 0.5 0.5 0.1 
 
llat 16.4 14.5 13.7 18.1 18.4 17.4 17.2 15.5 15.4 0 0.8 0.4 0.2 0.3 1.3 1.4 0.1 1.7 
FW MV 2 rlat 17.3 17.3 20.6 20 19.4 18.1 22.4 21.7 15.7 3 1.2 1 3.8 3.4 1.2 1.9 0.8 0.3 
  mid 28.9 31.9 39.2 28.8 24.5 22.3 28.7 27.8 33.6 1.5 2.1 0.5 0.2 0.7 2.2 1.1 5.2 0.2 
  llat 16.5 13.4 14.7 18.4 18 16.4 18.5 15.9 15.7 0.1 0.3 1.4 0.5 0.1 0.3 2.7 0.3 2 
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Table C-35: Results from three-dimensional reconstructed volume organ segmentation measurements. 
Color coding for columns displaying differences from control values is as follows:  no coloring means the 
volume recorded was within the predetermined systematic error, red means the volume recorded 
exceeded the systematic error. The systematic error for the bladder, rectum 1, rectum 2 and rectum 3 
was ±17.7cc, ±21.0cc, ±16.1cc and ±29.6cc, respectively. Values within 15cc of control values met the 
hypothesis criteria of ±15cc. 
Volume Comparison Results 
*volume in cc Bladder Difference Rectum Difference 
CTMR kV 3 262.0 15.0 160.4 23.9 
CTMR MV 1 275.2 28.2 163.0 2.7 
FSDs kV 2 261.0 14.0 114.2 11.1 
FSDs MV 3 267.2 20.2 165.9 18.4 
FW kV 1 265.0 18.0 149.7 10.6 
FW MV 2 262.3 15.3 121.5 3.8 
 
Table C-36: Results from catheter reconstruction for the procedurally defined, distal-most dwell 
position. “Distance” refers to the distance between the distal-most catheter tube dwell position and the 
applicator reference marker. The difference between TPS generated values and control values is in the 
“” column. Color coding for the column displaying differences is as follows: no coloring signifies values 
within ±1 mm of control values, yellow signifies values between ±1-2 mm of control values (within 
hypothesis criteria of ±2 mm) and red signifies values differing by more than ±2 mm. 
Catheter reconstruction results         
    Dwell Coordinates Fiducial Marker Coordinates   
*distances in mm x y z x y z Distance 
CTMR kV 3 R. Ovoid -11.0 23.1 -83.1 -11.4 8.7 -67.8 21.0 2.5 
 
L. Ovoid 14.6 23.6 -82.8 14.0 9.8 -68.2 20.1 0.6 
 
Tandem -1.3 71.5 -60.3 0.9 49.9 -65.0 22.2 0.8 
CTMR MV 1 R. Ovoid -14.8 26.9 -93.9 -13.3 11.7 -78.5 21.7 1.8 
 
L. Ovoid 11.8 26.6 -96.6 12.0 12.9 -81.5 20.4 0.3 
 
Tandem -2.4 76.3 -74.6 -0.5 53.7 -78.5 23.0 0.0 
FSDs kV 2 R. Ovoid -16.7 27.9 -89.1 -13.3 9.9 -72.8 24.5 0.6 
 
L. Ovoid 12.9 29.1 -87.7 11.1 10.4 -73.0 23.9 0.6 
 
Tandem -0.3 92.2 -58.7 -1.1 70.3 -62.6 22.3 1.4 
FSDs MV 3 R. Ovoid -16.4 31.3 -92.0 -14.2 12.5 -79.4 22.7 2.4 
 
L. Ovoid 13.2 31.7 -91.1 11.1 12.8 -78.9 22.6 1.8 
 
Tandem -4.0 92.9 -64.4 -3.7 70.1 -70.1 23.5 0.2 
FW kV 1 R. Ovoid -14.0 23.0 -78.5 -13.1 5.6 -68.8 19.9 3.8 
 
L. Ovoid 12.5 23.0 -76.3 12.4 5.3 -69.7 18.9 3.0 
 
Tandem 0.1 75.3 -62.0 -0.5 52.2 -64.7 23.3 0.3 
FW MV 2 R. Ovoid -15.9 22.7 -101.2 -13.6 4.7 -88.6 22.1 0.4 
  L. Ovoid 14.0 22.6 -102.4 11.6 5.4 -89.9 21.4 0.5 
  Tandem -1.3 75.4 -85.4 -1.6 52.8 -86.7 22.6 0.9 
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